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Abstract 
The koala (Phascolarctos cinereus) is a native Australian arboreal marsupial and the 
only surviving member of the family, Phascolarctidae. While it is acknowledged that 
habitat destruction is the single most significant threat to the koala, disease, either on 
its own or aggravated by habitat pressures, is a major factor in increased morbidity 
and mortality, and reduced reproductive rates, all of which lead to wild populations 
of koalas under serious threat of irreversible decline or loss. The main aetiological 
agents of disease in the koala belong to the family Chlamydiaceae, obligate 
intracellular pathogens of both humans and animals. C. pneumoniae and C. pecorum 
have been detected in most wild koala populations screened, with C. pecorum found 
to be significantly more widespread and the more pathogenic of the two species. 
Ocular infections cause keratoconjunctivitis leading to blindness. Rhinitis and 
pneumonia are associated with respiratory infections. Urinary tract infections often 
manifest as cysts in the bladder leading to incontinence and loss of bladder function, 
resulting in continual urine soiling or ‘wet bottom’. Infections of the genital tract can 
cause severe inflammation and fibrosis resulting in cystitis and infertility. While 
antibiotics present a treatment option for chlamydial infections, they alone are not 
sufficient to cure the koalas affected from severe chlamydiosis and can also affect the 
intestinal microflora and health of the animals. Thus, an effective vaccine to prevent 
the adverse consequences of chlamydial infections in koalas is important for the 
management of declining koala populations. Hence, in an attempt to develop a 
prophylactic as well as therapeutic chlamydial vaccine in koalas, the present study 
(a) investigated the genetic diversity of C. pecorum strains in wild koala locations 
across Australia and the implications for a recombinant C. pecorum major outer 
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membrane based vaccine, (b) evaluated a C. pecorum multi-subunit vaccine in 
healthy as well as naturally infected koalas, (c) evaluated the antigenic specificity of 
a monovalent versus polyvalent MOMP based C. pecorum vaccine in healthy koalas, 
and (d) characterised the antibody responses induced by naturally infected koalas as 
well as Chlamydia-free animals before and after immunisation with a MOMP-based 
vaccine. 
A critical aspect for the development of vaccines against koala chlamydial infections 
is a thorough understanding of the prevalence and strain diversity of C. pecorum 
infections across wild populations. In this study (Chapter Three), we describe the 
largest survey (403 koalas from eight wild populations and three wildlife hospitals) 
examining the diversity of C. pecorum infections. 181 of the 403 koalas (45%) tested 
positive for C. pecorum by species-specific quantitative PCR with infection rates 
ranging from 20% to 61% in the eight wild populations sampled. The ompA gene, 
which encodes the chlamydial major outer membrane protein (MOMP), has been the 
major target of several chlamydial vaccines. Based on our analysis of the diversity of 
MOMP amino types in the infected koalas, we conclude that, (a) there exists 
significant diversity of C. pecorum strains in koalas, with 10 distinct, full length C. 
pecorum MOMP amino types identified in the 11 koala locations sampled, and (b) 
despite this diversity, there are predicted T and B cell epitopes in both conserved as 
well as variable domains of MOMP which suggest cross-amino type immune 
responses. 
A successful vaccine would provide a valuable management tool against the major 
threat caused by chlamydial infections in koalas. Vaccination, however has the 
potential to enhance pathology in animals exposed to natural infection prior to 
vaccination, a finding in early human and primate trials of whole cell vaccines to 
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prevent trachoma. In the present study (Chapter Four), we have shown that a multi-
subunit chlamydial vaccine can be safely administered to both healthy koalas as well 
as koalas that have a previous or current chlamydial infection. Vaccination did not 
worsen pre-existing lesions and similar levels of systemic (plasma) and mucosal 
(ocular) antibodies and lymphocyte proliferation were achieved in both healthy and 
diseased koalas following vaccination. Importantly, plasma from both groups was 
able to react against MOMP from genotypes other than the immunising genotype, 
suggesting that induction of immunity against multiple genotypes may be possible. 
Whilst there are obvious logistical problems associated with vaccination of wild 
koalas that need to be overcome, our results provide strong evidence that 
development of a chlamydial vaccine to protect this iconic marsupial is feasible.  
Potential problems with the use of MOMP-based vaccines relate to the wide range of 
genetic diversity in its four variable domains. In this study (Chapter Five), we 
evaluated the immune response of koalas vaccinated with a MOMP-based C. 
pecorum vaccine formulated with genetically and serologically diverse MOMPs. 
Animals immunised with individual MOMPs developed strong antibody and 
lymphocyte proliferation responses to both homologous as well as heterologous 
MOMP proteins. Importantly, we also showed that vaccine induced antibodies which 
effectively neutralised various heterologous strains of koala C. pecorum in an in vitro 
assay. Finally, we also demonstrated that the immune responses in monovalent as 
well as polyvalent MOMP vaccine groups were able to recognise whole chlamydial 
elementary bodies, illustrating the feasibility of developing an effective MOMP 
based C. pecorum vaccine that could protect against a range of strains.  
An important step towards developing a vaccine in koalas is to understand the host 
immune response to chlamydial infection. In this study (Chapter Six), we used the 
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Pepscan methodology to identify B cell epitopes across the MOMP of four C. 
pecorum strains/genotypes that are recognized following, (a) natural live infection, 
(b) recombinant MOMP vaccination and (c) natural live infection followed by 
recombinant MOMP vaccination. This investigation for the first time was successful 
in identifying B cell epitopes recognised by wild koalas naturally infected with two 
C. pecorum genotypes. Following vaccination of healthy and diseased koalas, we 
also identified vaccine-induced antibodies that recognised new epitopes in conserved 
as well as variable domains across the MOMPs of multiple strains of C. pecorum.  
Taken together, the findings in this study have demonstrated that it is feasible to 
develop a safe and effective recombinant MOMP-based vaccine in Chlamydia free as 
well as severely diseased koalas. Most importantly, this study is first of its kind to 
evaluate a MOMP based vaccine against multiple C. pecorum amino types/strains.  
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1.1 A DESCRIPTION OF THE SCIENTIFIC PROBLEM INVESTIGATED 
Chlamydia infection continues to be a major threat to the long-term survival of the 
koala. While it is acknowledged that habitat destruction is the single most significant 
threat to the koala [1], chlamydial disease [2], either on its own or aggravated by 
habitat pressures, is a major factor in increased morbidity and mortality, and reduced 
reproductive rates; all of which lead to sub-populations of koalas under serious threat 
of irreversible decline / loss [3]. Chlamydia infection directly threatens the long term 
survival of the koala in two main ways, (1) ocular infection of both male and female 
koalas can progress to conjunctival scarring and blindness (Figure 1A) which 
severely reduces the animal’s ability to feed and increases the risk of road accidents 
and dog attacks, and (2) female koalas commonly have urogenital infections which 
can progress to cystitis (Figure 1B) and infertility. This can significantly reduce the 
reproductive capacity of a population, and when combined with habitat pressures, 
can result in a serious decline of the population. The disease is visibly devastating 
and likely very painful for the animals.  
Figure 1: Signs of Chlamydiosis caused by C. pecorum infections in koalas which 
include (A) Keratoconjunctivitis, and (B) Urinary bladder infections leading to “wet 
bottom”. 
While chlamydial infection in koalas has been around for some time, the results are 
clearly getting worse. As an example of the magnitude of its importance, 32 - 40% of 
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the more than 1000 koalas presenting annually to koala care centres or hospitals in 
NSW (Friends of the Koala Care Centre in Lismore) and Queensland (Australia 
Zoo), respectively, have serious chlamydial disease and many of these cannot be 
rehabilitated [4]. Many, now semi-isolated wild populations are also at serious threat 
of extinction.  
Antibiotics are an obvious option for the treatment of chlamydial infections in 
koalas, however major challenges are that they require very high doses to clear 
chronic chlamydial infections [5, 6] and subsequently harm the unique gut microbial 
flora required to digest the eucalypt leaves that it feeds on (Osawa and Carrick, 
1990). Moreover, the use of antibiotics is not straightforward and often requires the 
animals to be housed and supplemental fed during their, often long (up to 45 days) of 
treatment. The more obvious alternative to combat this disease is to develop a 
chlamydial vaccine. Chlamydial vaccines are notoriously difficult and despite 
significant worldwide efforts to develop a human Chlamydia vaccine, there has been 
only modest progress. To develop a successful vaccine for koalas we have a 10-step 
plan, involving; (1) selection of suitable vaccine candidate antigens and evaluation in 
a small animal model for strong B cell and T cell derived protection, (2) development 
of reagents suitable for koala immunological assays, (3) evaluate the genetic 
diversity of Chlamydia strains in koalas from wild populations, (4) immunise 
Chlamydia negative koalas (in captivity) with a prototype vaccine to confirm vaccine 
safety and immunogenicity, (5) immunise Chlamydia positive koalas to confirm; (a) 
enhanced immune response from the vaccine, (b) no evidence of enhanced diseased 
pathology from the vaccine, (6) develop a boutique vaccine that will protect against 
the range of strains of Chlamydia seen in wild populations, (7) develop the vaccine 
for male koalas as well as female koalas, (8) vaccinate wild koala populations to 
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evaluate the vaccine under true field conditions and also to determine the degree of 
protection against a live infectious challenge and the benefit given to breeding 
female koalas, (9) develop single shot long acting adjuvants to enable us to vaccinate 
koalas just once, (10) make the vaccine available to groups for implementation in; (a) 
koala sanctuaries and zoos, (b) koala hospitals and care centres, (c) wild koalas 
undergoing longer-term monitoring programs. 
1.2 THE OVERALL OBJECTIVE OF THE STUDY 
The overall objective of the work described in this thesis is to contribute to the 
development of C. pecorum vaccine for koalas by addressing the above mentioned 
steps 3, 4, 5 and 6.   
1.3 THE SPECIFIC AIMS OF THE STUDY 
1. To investigate the epizootiology and genetic diversity of various C. 
pecorum infections in several wild koala populations across South East 
Queensland and its implications for developing a vaccine. (Chapter Three). 
2. To evaluate the immune responses in healthy as well as naturally infected 
wild koalas immunised with a multi-subunit vaccine (Chapter Four). 
3. To evaluate the immunogenicity of a monovalent versus polyvalent C. 
pecorum MOMP based vaccine (Chapter Five). 
4. To characterise the MOMP specific antibody responses in healthy as well 
as naturally infected animals, prior to and post vaccination (Chapter Six). 
1.4 AN ACCOUNT OF SCIENTIFIC PROGRESS LINKING THE 
SCIENTIFIC PAPERS 
The four papers presented as part of this thesis are directly linked to the topic 
“Development of a C. pecorum vaccine for koalas”.  
Chapter Three describes the screening of eleven wild koala locations across Australia 
for the purpose of (a) characterising the prevalence of C. pecorum infections, (b) 
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assign an ompA genotyping scheme to determine the genetic diversity of C. pecorum 
infections in these populations and to relate to other Australian populations, and (c) 
identify the new MOMP amino types across these populations and further 
implications for subsequent development of a MOMP based vaccine. The work 
presented in this chapter has been submitted to the journal “Veterinary 
Microbiology”. 
Chapter Four describes the evaluation of a C. pecorum MOMP vaccine in both 
healthy as well as naturally C. pecorum infected wild koalas. This is the first 
evaluation of a MOMP vaccine in koalas using a koala C. pecorum specific MOMP 
and NrdB protein. The work presented in this chapter has been published in the 
journal “Vaccine”. 
Chapter Five described in this thesis evaluates the immunogenicity of a monovalent 
vs. polyvalent MOMP based vaccine in healthy koalas. This study is the first of its 
kind to evaluate three different MOMP based vaccine formulations in koalas. The 
results in this chapter has been published in the journal “Vaccine”. 
Chapter Six of this thesis characterises the antibody responses specific to MOMP in 
healthy and naturally C. pecorum infected koalas, prior to and after vaccination. The 
results of this chapter has been submitted with revisions to the Journal “PLOS One”. 
This thesis has been written in the format of a series of manuscripts and chapters in 
accordance with the Queensland University of Technology’s “PhD Thesis by 
Published Papers” guidelines. Chapter Two is a review of the literature which 
demonstrates a thorough knowledge of the area and provides arguments to support 
this study. Chapters Three to Six have been submitted/accepted for publication in 
peer reviewed journals. Chapter Seven is a comprehensive discussion of the main 
findings of this study. 
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2.1 NOMENCLATURE AND TAXONOMY 
 
Chlamydia is a genus of coccoid, gram negative obligate intracellular bacteria that 
are pathogenic to humans and animals causing a wide spectrum of diseases in the 
eyes, respiratory tract and urogenital tract. The Greek word Chlamys means “a 
mantle or cape fastened around the shoulder”, worn by men in ancient Greece and 
refers to how the bacterial inclusions are draped around the nucleus of the host cell 
[1].  
The taxonomy of Chlamydia is a contentious issue which can be divided into two 
eras. The pre 1999 classification consisted of one Family Chlamydiaceae, one genus 
Chlamydia [2]. In this taxonomy, the genus Chlamydia contained four species, 
Chlamydia trachomatis [2] infecting humans, swine, mice and hamsters; C. psittaci 
[2] infecting mammals, birds, cats and guinea pigs; C. pneumoniae [3] infecting 
humans and other species, C. pecorum [4], infecting a wide range of mammals 
(cattle, sheep and goats (ruminants), koalas (marsupials), and swine). In 1999, a 
reclassification by Everett et al. [5] was proposed to rearrange the genus Chlamydia 
into two genera (Chlamydia and Chlamydophila) containing a total of nine species. 
The genus Chlamydophila was subdivided into six species; C. abortus, C. psittaci, C. 
felis, C. caviae, C. pecorum, and C. pneumoniae infecting mammals, birds, cats, 
guinea pig, mammals and humans respectively. The genus Chlamydia, on the other 
hand, consists of three species C. trachomatis, C. suis, C. muridarum infecting 
humans, swine and mice respectively. C. trachomatis has three biovars and 15 
serovars. These include Trachoma (A, B, Ba, and C), Urethritis (D-K) and 
Lymphogranuloma venereum LGV (L1, L2, and L3).  
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Table 1. Taxonomical classification of order Chlamydiales. 
Family I: 
Chlamydiaceae 
Family II: 
Parachlamydiaceae 
Family III: 
Simkaniaceae 
Family IV: 
Waddliaceae 
Family V: 
Criblamydiaceae 
Family VI: 
Piscichlamydiaceae 
Family VII: 
Rhabdochlamydiaceae 
Genus I: 
Chlamydia 
Genus I: 
Parachlamydia 
Genus I: 
Simkania 
Genus I: Waddlia 
Genus I: 
Criblamydia 
Genus I: 
Piscichlamydia 
Genus I: 
Rhabdochlamydia 
  C. trachomatis   P. acanthamoebae   S. negevensis   W. chrondrophila   C. sequanensis   P. salmonis   R. crassificans 
  C. psittaci 
Genus II: 
Protochlamydia 
Genus II: 
Fritschea 
  W. malaysiensis       R. porcellionis 
  C. pneumoniae    P. amoebophila   F. bemisiae         
  C. pecorum   P. naegleriophila   F. eriococci         
  C. muridarum 
Genus III: 
Neochlamydia 
          
  C. suis   N. hartmannellae           
  C. felis             
  C. abortus             
  C. caviae             
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This reclassification, however, was an emotional issue and an impressive number of 
eminent chlamydiologists were vehemently opposed to the reclassification. Their 
objections were summarised in a letter [6] to the International Journal of Systematic 
and Evolutionary Microbiology to which the authors of the 'new' classification 
replied [7].  While the presence of nine species within the Chlamydiaceae was not 
particularly controversial, the main criticisms were: (a) insufficient reason to divide 
Chlamydiaceae into 2 new genera, (b) too much emphasis on nucleic acid data and 
not much consideration of basic biological characteristics/markers, and (c) few 
objected to the genus name Chlamydophila which literally means “like Chlamydia”. 
Hence for the above reasons, a one genus (Chlamydia), nine species classification 
will be used in this document [8]. 
2.2 HOST SPECIFICTY AND DISEASE PATTERNS 
Each of the chlamydial species have a broad host tropism and disease patterns.  
C. trachomatis mainly infects humans and causes ocular, genital and lymph node 
infections. Ocular infections include conjunctivitis, inflammation of the lining of eye 
lids and eye, in both adults and babies. Genital infections include cervicitis (infection 
of the neck of womb or cervix), pelvic inflammatory disease (PID) (infection or 
inflammation of uterus and fallopian tubes) in women [9,10]. In men, C. trachomatis 
can cause urethritis (inflammation of urethra; [11]), epididymitis (infection of 
testicles; [12]) and prostatitis [13]. Lymph node infections include 
Lymphogranuloma venereum [14]. 
C. muridarum is the mouse pneumonitis biovar of C. trachomatis. It has the ability 
to produce experimental infections in mice similar to C. trachomatis infections in 
humans [15]. It infects both genital and respiratory epithelium in mice. 
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C. suis is a chlamydial species identified initially in healthy pigs. It is different to the 
other Chlamydiae causing infections in pigs, and its disease features resemble C. 
trachomatis [16]. Based on their divergence in host tropism and 16S rRNA gene 
sequences, they have been reclassified as Chlamydia suis [5]. In gnotobiotic pigs, C. 
suis strains cause asymptomatic intestinal infections in young weanling pigs, with 
intestinal lesions but no diarrhoea [17].  
C. psittaci causes infections in a wide range of domesticated and feral (wild) bird 
species. All the avian species are likely to be natural hosts for C. psittaci. Psittacosis 
in birds is systemic and symptoms include inflammation of the eyes, breathing 
problems and watery droppings. The infection is transmissible to humans with 
nonspecific symptoms like pneumonia, endocarditis and encephalitis [18]. 
C. pneumoniae causes infections in humans and an increasing range of animals 
including the koalas [19], iguanas, chameleons, frogs and turtles [20]. In humans it 
causes pharyngitis, bronchitis and atypical pneumonia [21,22]. 
C. felis causes feline chlamydiosis associated with pneumonia and conjunctivitis in 
cats [23]. 
C. abortus causes abortion and foetal loss in sheep, cattle and goats globally (ovine 
enzootic abortion or OEA). These isolates have produced abortion and mastitis in 
cattle. Along with these, the isolates excreted in sheep and cattle faeces have also 
caused abortion in both of those ruminant species [24]. 
C. caviae (Guinea Pig Inclusion Conjuctivitis) causes infections in guinea pigs 
mainly associated with keratoconjuctivitis [25]. It also infects the genital tract of 
guinea pigs similar to the C. trachomatis infections in humans. Hence it is used as an 
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experimental model in studying disease pathology of C. trachomatis genital 
infections [26]. 
C. pecorum was initially a strain of C. psittaci but as the genus expanded and 
substantial genetic differences emerged between the strains, this resulted in the 
formation of two different species, C. pneumoniae and C. pecorum [4]. It is 
associated with diseases in cattle [4], koalas [27] and pigs [28]. C. pecorum strains 
are associated with conjunctivitis, pneumonia, polyarthritis (stiff lamb disease), 
abortion, enteritis, encephalomyelitis and diarrhoea [29]. They may also cause 
metritis, salpingitis and infertility in cattle [30]. In koalas, infection with C. 
pecorum causes ocular and genito-urinary diseases [31]. 
2.3 CHLAMYDIAL DEVELOPMENTAL CYCLE 
 Species of Chlamydiales infect various hosts as metabolically inactive particles that 
differentiate further to carry out their developmental cycle. The developmental cycle 
consist of two stages, infectious and non-infectious. The infectious elementary body 
(EB) is a metabolically inactive particle with a rigid, disulfide cross-linked outer 
membrane which enables the EB to attach to and invade host cells [32-38]. During 
infection, EBs are internalised in membrane bound vacuoles named inclusions. The 
EB converts into a metabolically active reticulate body (RB), and later through 
binary fission, converts back to EB (secondary differentiation). The host cell then 
lyses, releasing EBs that infect neighbouring cells. Under stressful growth 
conditions, caused by immunological responses, antibiotics, or nutrient deprivation, 
the developmental cycle is disrupted, resulting in the appearance of large, aberrant 
RBs [39].  
The EB nucleoid is dense due to condensation of nuclear material by the proteins 
HctA and HctB [40,41]. EBs have scarce peptidoglycan present in their cell wall. 
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Structural rigidity is hypothesised to be due to the cross linked nature of the outer 
membrane complex. Inter and intramolecular cysteine bonds exist between the 
cysteine rich proteins of the outer envelope including OmpA, OmcB and OmcA [42]. 
Initial attachment occurs through electrostatic interactions of the bacteria with 
heparin sulfate containing glycosaminoglycans [37,38,43,44]. It is a reversible 
reaction and occurs by binding to the surface exposed OmpA protein [37]. The 
second step is an irreversible binding stage which was studied with the help of 
chemically mutagenised cell lines, however the receptor has not yet been identified 
[45]. Chlamydial EBs are comprised of substantial quantities of mRNA and 
ribosomes, despite their lack of metabolic activity. The bulk of EB mRNA encodes 
late gene products, a reflection of the transcriptome during the final stages of the RB 
to EB secondary differentiation [46].  
RB is the result of the internalisation of EBs following primary differentiation. RBs 
are larger in size than EBs with majority of the granular cytoplasm filled with nucleic 
acids and distinguishable from the highly condensed nucleic acid content of the EB. 
They are non-infectious and bounded by an inner and an outer-membrane resembling 
other gram negative organisms. The surface of RBs is covered with projections and 
rosettes (TTSS needle structures) which project from the bacterial surface along the 
inclusion membrane [47].  
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Figure 1. Chlamydial developmental cycle. Diagrammatic representation of 
developmental cycle of Chlamydia depicting major events. Figure adapted from 
Abdel Rahman, Y.M. and R.J. Belland, 2005 [48]. 
Upon internalisation, Chlamydia modifies the attributes of the nascent vacuole. 
Findings of Heinzen et al.  [49]; Scidmore et al. [50]; Van Ooij et al. [51]  
demonstrated that the chlamydial inclusion membrane is non-fusogenic with both 
endosomes and lysosomes. Conversely, they have interactions with vesicles 
containing sphingomyelin [52] and cholesterol of the Golgi complex [53]. These 
events take place in the early stage of the developmental cycle which is essential for 
productive replication of Chlamydia in the host cell but the molecular basis for these 
events is yet to be revealed.  
Cell division takes place during the RB stage. Genome sequencing indicates that 
Chlamydia lack an identifiable ftsZ ortholog, which encodes a protein centrally 
involved in bacterial cell division and found in all other sequenced eubacteria. 
Another surprising finding from the genomic analysis was the presence of genes 
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essential for the synthesis of peptidoglycan [54], particularly since attempts to 
identify peptidoglycan in RBs were previously unsuccessful [55]. However, 
penicillin and other β-lactams are inhibitory to chlamydial growth and probably 
target the penicillin binding proteins. This paradoxical situation has been referred to 
as the “chlamydial anomaly” [56].  
During RB re-differentiation to EB, termed “secondary differentiation”, 70 genes 
have been reported to be expressed after 24h post infection [57]. Two groups of 
genes, the late temporal group and the very late group were present at this stage and 
the latter consists of genes that show elevated expression levels between 24h and 36h 
post infection. The late cluster includes genes involved in chromosome condensation 
as well as chlamydial unique genes of unknown function. Very late temporal cluster 
genes consist of six genes encoding specific proteins of unknown function.  
2.4 CHLAMYDIAL ANTIGENS 
A range of chlamydial antigens have been evaluated in mice and non-human 
primates for their ability to elicit humoral and cellular immune responses and in 
vaccine development with both C. muridarum and C. trachomatis. Although the 
proteins of the outer membrane have received the most attention, the construction of 
complete genome libraries and expression of specific predicted proteins have 
identified a range of different chlamydial immunogenic proteins that potentially offer 
protective ability as vaccine antigens [58,59]. A few of the most commonly studied 
antigens are described in further detail below. 
2.4.1 Major Outer Membrane Protein 
The chlamydial protein that is present in the largest quantity in EBs and RBs is the 
MOMP, encoded by the gene ompA, formerly referred to as omp1 [60]. The MOMP 
is found in EBs in the ratio of 5 MOMP: 2 OmcA: 1 OmcB [61] and in contrast to 
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the cysteine-rich proteins, the MOMP is also present in RBs [32,62]. However, the 
MOMP structure is different in the two developmental forms, being disulfide cross-
linked in EBs and completely reduced in RBs [33,34,63-65]. DNA sequencing of the 
MOMP from various serovars of C. trachomatis demonstrated the presence of four 
variable domains (VDs) and five constant domains (CDs) (Figure 2) and [66-68]. 
The sequence variability of the VD shown in these studies has been considered to be 
a mechanism for the bacteria to evade immunological surveillance of the host. The 
variable regions tend to be surface exposed and the MOMP is immunodominant in 
all chlamydial strains examined, except C. pneumoniae [69,70]. An enormous 
research effort has been put into the MOMP as a candidate for a subunit chlamydial 
vaccine. Protection in animal models appears to be serovar specific, dependant on 
conformational epitopes, and short-lived [71-74]. 
The studies of Kuo and collaborators [75,76] also support a role for MOMP in the 
attachment process, but through an N-linked high-mannose type of oligosaccharide 
rather than the peptide portion of the MOMP. Whether or not the MOMP is a 
glycoprotein remains controversial. One unambiguous function of the MOMP is that 
of a porin, originally demonstrated using MOMP-enriched octylglucoside extracts of 
C.trachomatis in a liposome swelling assay [35]. This study have also found that the 
MOMP had to be reduced and maintained in a cross-linked state by modification of 
cysteine residues with iodoacetamide to maintain porin function, suggesting that only 
reduced MOMP functions as a porin. In contrast, Wyllie et al. [77] found that it was 
not necessary to alkylate sulfhydryl residues and that porin activity was not abolished 
by treatment of the MOMP with oxidising agents, suggesting that the MOMP may 
function even when cross-linked. 
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Several studies have proposed the topology of the MOMP using various secondary 
structure prediction algorithms [78-80]. In a model proposed by Rodriguez-Maranon 
et al. [79], MOMP was shown to have 16 antiparallel β-sheets forming a barrel-like 
structure consistent with that of other porins. The variable domains are located in 
four of the loops facing the cell exterior, and disulfide bridges located at the base of 
two variable domains have been mapped [81].  
 
Figure 2. Model of C. trachomatis MOMP structure. Residues in the 
transmembrane strands are boxed, with bold border to indicate side chains facing the 
bilayer. External loops (including constituent VS domains; VS1, VS2, VS3 and VS4) 
are labelled, and cysteine residues are shaded. (Figure adapted from Findlay et al. 
[78]) 
2.4.2 Pmps 
Sequence analysis of the C. trachomatis genome [54] identified an unknown family 
that has attracted the attention of various researchers. Nine polymorphic membrane 
proteins (Pmps) have been identified in C. trachomatis and 21 in C. pneumoniae 
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(representing 13.6% and 17.5% of the two genome Chlamydia-specific coding 
capacities respectively) emphasising the importance of this gene family in 
Chlamydia biology [82-84]. Initial clues about biological function were derived from 
bioinformatic analyses, analogies to similar gene families in other bacteria, and pre-
genomic characterisation of several members of gene family in C. abortus [85]. The 
family encodes high molecular weight proteins that are surface exposed and display 
shared repeated structural motifs that are the basics for their grouping in a family. 
Properties of the Pmp proteins, pmp genes and biological and immune functions are 
summarised below in Table 2.  
Table 2. Subtypes, properties and biological functions of Pmp proteins in various chlamydial species. 
Subtype Properties of the gene Properties of the protein Function 
A Single copy in all Chlamydia spp [86] 
Undetected by 
IFA/immunoproteomic 
analysis [87] 
- 
B 
Single copy in C. 
pneumoniae 
(pmpB/pn) [88], C. 
caviae (pmpB/ca) 
[89]  and C. abortus 
(pmpB/ab) [90] 
PmpB/pn detected by 
proteomic and 
immunoproteomic analysis 
PmpB/tr detected by 
proteomic analysis in 
serovars A,D and L2 [91] 
PmpB/pn stimulates 
IL-6 and MCP-1 
production by 
endothelial cells by 
activation of the 
NF-κB pathway 
[92] 
D 
Single copy in all 
Chlamydia spp. 
unlinked to other 
pmp genes [86] 
PmpD/pn detected by 
proteomic 
immunoproteomic and IFA 
analyses [87] 
PmpD detected in serovars 
A and D, not in L2 [91] 
PmpD/pn stimulates 
IL-6 and MCP-1 
production by 
endothelial cells by 
activation of the 
NF-κB pathway 
[92] 
E 
Two subtype variants 
in trachomatis 
(pmpE/tr and F/tr) 
[93] and muridarum 
(pmpE/mu and F/mu) 
[83]: expanded 
subfamilies in C. 
pneumoniae, C. 
caviae and C. 
abortus in the  
Late expressed PmpE/tr 
detected in the OM [87] 
PmpE-1,2/pn detected by 
immunoblot analysis and 
immunoproteomic analysis 
[91] pmpEGH cluster 
[89,90] 
- 
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Subtype Properties of the gene Properties of the protein Function 
G 
Two subtype variants 
in C. trachomatis 
(pmpG/mu and 
pmpI/tr) and C. 
muridarum 
(pmpG/mu and 
pmp/mu): expanded 
subfamilies in C. 
pneumoniae, C. 
caviae and C. 
abortus in two 
genomic clusters 
[83,89,90,94] 
PmpG-6/ab located at the 
OM surface in RBs and EBs 
[95] 
PmpG-3 and G-6/pn 
expressed in all EBs, PmpG-
4/pn differentially expressed 
in EBs [96] 
PmpG-2,6-9,11,13/pn 
detected by immunoblot 
analysis [97] 
PmpG-1,2,6-8,10,11,13/pn 
detected by proteomic, 
immunoproteomic  analysis 
[87] 
PmpG-6/pn 
recognized by 
CD4+T cells during 
murine C. 
pneumoniae 
infection [98] 
H 
Single copy in all 
Chlamydia spp. in 
the pmpEGH cluster 
[86] 
Late expressed PmpH/tr 
detected in the OM 
PmpH/pn detected by 
proteomic and immunoblot 
analysis [87] 
- 
 
The proteins encoded by pmp genes are unique to the Chlamydiaceae. Salient 
features of the Pmp proteins shared among species are the presence of multiple 
repeats of the GGAI (I, L, V) and FXXN signature motifs that are repeated [54,99]. 
Another feature of most Pmp proteins is the presence of a leader sequence, consistent 
with the surface localisation of these proteins. Trp residues in the carboxy terminal 
half and a carboxy terminal Phe residue are strongly suggestive of an outer 
membrane location.  
Evidence that Pmps stimulate both innate and immune defences is steadily 
accumulating. PmpB/pn, PmpD/pn and PmpG-6/pn stimulate CD4+T cells during 
murine infection with C. pneumoniae [98,100]. On the other hand, PmpB/pn and 
PmpD/pn also stimulate pro-inflammatory cytokine production through activation of 
the NF-κB pathway [92,101]. 
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2.4.3 Cysteine-Rich Proteins OmcA and OmcB 
The first proteins to be identified in EBs were two quantitatively major cysteine-rich 
envelope proteins [34,64,65] encoded by same bicistronic operon [102-105]. They 
were originally designated EnvA and EnvB in C. psittaci [61] and Omp3 and Omp2 
in C.trachomatis [103] and later renamed OmcA and OmcB because they are 
functional association with the outer membrane complex, as defined by insolubility 
in the weak anionic detergent sodium lauryl sarcosinate (Sarkosyl). The 
extraordinary cysteine-rich OmcA is a lipoprotein with a structure similar to murein 
lipoproteins found in gram-negative bacteria [106]. OmcB is post transcriptionally 
processed to two proteins of approximately 60 kDa.  
2.4.4 CPAF 
T lymphocytes recognise infected cells through MHC-peptide complexes that are 
presented on the surface of infected cells, hence many intracellular pathogens have 
evolved mechanisms to avoid detection by the acquired immune system by impairing 
MHC antigen presentation. While sequestered within the inclusion, Chlamydia 
interfere with antigen presentation by preventing cell surface expression of MHC 
class I and II molecules in infected cells. C. trachomatis and C. pneumoniae suppress 
the interferon γ activated MHC class I and II expression in infected host cells by 
secreting a lactacystin-sensitive chlamydial protease-like or proteasome-like activity 
factor, CPAF, across the inclusion membrane into cytosol of infected cells [107-
109]. CPAF is expressed by both C. trachomatis and C. pneumoniae and is the only 
chlamydial protein shown to be secreted into the host cytosol [110-112]. CPAF has 
been shown to be necessary and sufficient to induce degradation of host transcription 
factors RXF5 and upstream stimulation factor 1 (USF1) that are required for the 
expression of MHC class I and class II molecules. Chlamydiae target IFN-γ 
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signalling pathways required for MHC class I and II expression since expression of 
two other IFN-γ induced transcription factors, IFN regulatory factor (IRF-1) and 
intercellular adhesion molecule 1 (ICAM-1), were unaffected by chlamydial 
infection [108]. Additionally, CPAF has also been shown to cleave keratin, which 
may facilitate the breakdown of the cytoskeletal network to allow unrestricted 
growth of the inclusion [113]. Majority of the evidence for CPAF has been largely 
based on observed cleavage or degradation of specific host proteins during an 
infection, using the immunoblotting assay on the lysates of Chlamydia-infected cells 
[107,114]. However, a recent study has re-examined the previously reported 
proteolysis of CPAF substrates and found no detectable proteolysis when CPAF 
activity was inhibited during cell processing [115]. These findings suggest other 
mechanisms might be responsible for these Chlamydia-host interactions and raises 
concerns about all published roles of CPAF in chlamydial pathogenesis. 
2.4.5 Incs  
All Chlamydiae develop and multiply within a unique non-acidified vacuole termed 
the inclusion. This vacuole is embedded with a group of proteins (Inc proteins) that 
are unique to the chlamydial lineage. Inc proteins may also be important antigens in 
cell-mediated immune responses following chlamydial infection. Serology and 
molecular cloning approaches led to the identification of C. caviae IncA, IncB, and 
IncC. All of them have been shown to reside in the inclusion membrane through the 
use of fluorescence microscopic analysis with specific antibodies [116,117]. Four Inc 
proteins were discovered in C. trachomatis (IncD-G), which were localised in the 
inclusion membrane and produced early in the chlamydial infectious process [118].  
C. caviae IncA, IncB and IncC were initially identified through a serologic analysis 
of guinea pigs that had cleared serial infections by the pathogen. Bannantine et al. 
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[119,120] examined the serologic response to a collection of C. trachomatis Inc 
proteins following experimental or natural infection and revealed that several Inc 
proteins were recognised by antibodies in patient sera.  
2.4.6 NrdB 
Ribonucleotide reductase is an enzyme that catalyses the synthesis of the four 
deoxynucleoside triphosphates (dNTPs) with its activity being the rate limiting step 
of DNA synthesis. Ribonucleotide reductases are grouped into three major classes (I-
III) and share a common catalytic mechanism, involving activation of the 
ribonucleotide by abstraction of the 3’ hydrogen atom of the ribose by a transient 
radical of the enzyme. Sequencing of the C.trachomatis serovar D genome found that 
the chlamydial ribonucleotide reductase belonged to the class Ia family of enzymes 
[121]. Class I ribonucleotide reductases consist of two homodimeric proteins, R1 (α2) 
(nrdA in E.coli) and R2 (β2) (nrdB in E.coli). The small β chain contains an oxygen-
linked di-ferric centre and, in its active form, a stable free radical normally associated 
with tyrosine residue that is essential for reduction of ribonucleotides. The radical 
bearing tyrosine is conserved among more than 200 sequenced R2 subunits. The 
chlamydial ribonucleotide reductase is quite unusual in that it does not contain the 
conserved tyrosine residue. Instead, it utilises a stable manganese (IV)/Iron (III) 
cofactor for radical initiation [122].  
Chlamydiae have been shown to draw on host pools of ribonucleoside triphosphates 
(NTPs) by transporting NTPs, but not dNTPs, directly from the host cell [123]. 
Studies proposed that Chlamydia synthesise their DNA precursors directly from host 
supplied ribonucleotides, suggesting that the enzyme ribonucleotide reductase has an 
essential role in its replication [124]. Therefore, it is not surprising that NrdB is 
highly conserved across different species of Chlamydia, with our predicted 
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promiscuous T-cell epitope also highly conserved, making this an attractive vaccine 
target. This is in contrast to MOMP, which varies across strains and species, and has 
antigenically defined variable domains [66]. Recombinant ribonucleotide reductase 
subunit B (NrdB) was found to be immunogenic in humans naturally infected with 
C.trachomatis [125]. Recombinant NrdB was used to prime CD4+ T cells that were 
found to confer a degree of protection similar to that seen with CD4+ T cells primed 
with MOMP or a live challenge. 
2.4.7 Hsp70 (DnaK) 
Schmiel et al. [126] screened a genomic library for recombinant E.coli clones that 
adhered to eukaryotic cells in culture. One adherent clone has been extensively 
characterised and shown to contain several open reading frames (ORFs) including 
one encoding the chlamydial homolog of the stress protein Hsp70, also known as 
DnaK [127]. A portion of Hsp70, a cytoplasmic chaperone protein in most bacteria, 
was found by Raulston et al. [128] to be located in the outer membrane fraction in 
recombinant E.coli and in outer membrane complexes of chlamydial EBs. In a 
follow-up study, Raulston et al. [129] found that the C-terminal end of Hsp70 
becomes accessible to a monoclonal antibody only after brief exposure to 
dithiothreitol. These authors have proposed the following two step process for 
attachment or entry of C. trachomatis: (a) interaction of EBs with host cells by an 
unknown mechanism which triggers the reduction of the disulfide bond cross-linked 
outer membrane complex in EBs and exposes Hsp70 and (b) adherence of Hsp70, or 
a ligand presented by Hsp70, to a host cell receptor, a process that is dependent on 
ATPase activity associated with Hsp70. The possibility that Hsp70 might be surface 
exposed under some conditions is supported by the observation of Danilition et al. 
[130] that antibodies raised against Hsp70 react with C. trachomatis D (a trachoma 
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biovar) EBs by micro immunofluorescence and neutralise infectivity for cells in 
culture. 
2.4.8 Type III Secretion Apparatus 
Proteins can be secreted from bacteria by (a). Sec-dependent (Type II and IV) and 
(b). Sec-independent (Type I and III) which has no leader sequence. Type three 
secretion system (T3SS/TTSS) is a protein structure, found in several gram negative 
bacteria used to secrete proteins that help the bacteria infect multicellular, eukaryotic 
organisms. The proteins are secreted directly from the bacterial cell into the cells of 
the organism to be infected (host) using a needle-like structure which is the hallmark 
of the T3SS. The first clues that Chlamydia spp. express a T3S system were evident 
by Matsumoto [131] long before T3S was described in other pathogens.  
Genome sequences has now extended this initial observation to reveal that the 
genomes of C. trachomatis [54], C. muridarum [83], C. pneumoniae [83] and C. 
caviae [89] contain a set of genes capable of encoding a complex T3S system. 
Consistent with the report by Ru-ching et al. [132], the G+C content of the predicted 
T3S genes evident in Chlamydial spp. does not differ significantly from that of the 
overall genome and, although loosely arranged in four loci, chlamydial T3S genes 
are similarly dispersed throughout respective genomes.  
Complete T3S systems contain (a) accessory proteins represented by a set of 
cytoplasmic, T3S specific chaperones, (b) a set of membrane-associated gene 
products that act collectively to form a multipartite core secretory apparatus, and (c) 
a set of mobile “translocator” proteins, which assemble upon T3S activation and 
mediate translocation of effectors across a eukaryotic membrane [133]. 
Chaperones: T3S associated chaperones are a diverse group of proteins, which exert 
a variety of activities within the bacterial cytoplasm. Throughout characterised type 
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III systems, these proteins share limited amino acid sequence similarity, yet are 
typically small, have an acidic pI, and contain a predicted C-terminally localised 
amphipathic alpha helix. T3S chaperones are specific, associating with one or 
sometimes two secretion substrates. Hence, each secreted effector tends to have a 
dedicated chaperone, which is typically encoded by an adjacent gene.  
Chlamydial genomes contain at least seven predicted T3S-associated chaperones, all 
of which contain predicted amphipathic alpha helices in the annotated C. trachomatis 
serovar D and C. pneumoniae genomes. Three of these, Scc1 (CT088), Scc2 (CT576) 
and Scc3 (CT862), are encoded adjacent to genes of secreted proteins [134]. 
The Basal Apparatus: The core T3S apparatus strongly resembles a gram negative 
flagellar basal body in both protein content and structure. Secretion pores are 
anchored in both the inner and outer membrane and span the periplasm such that 
substrates pass from the bacterial cytoplasm to the extracellular environment in one 
step. In general, secretion pores in characterised T3S systems are composed of ca. 
15-20 membrane associated proteins. These core components are well conserved 
among type III systems, and chlamydial proteins may be compared to and their roles 
deduced from corresponding Yersinia components since the Ysc apparatus is by far 
the most thoroughly characterised. Outer membrane localised components of the 
secretin family of proteins oligomerise to form an outer membrane pore at the distal 
portion of the apparatus. This role is predicted to be filled by the YscC homolog 
CdsC of Chlamydia [135]. 
The extended apparatus: Chlamydiae are intimately associated with host cell 
membranes from the point of invasion until RBs differentiate back to EBs. Electron 
micrographs of necessary structures protruding through inclusion membranes at 
zones of contact with RBs reinforce the notion that chlamydial T3S may, indeed, also 
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be contact induced and polarised. If membrane contact activates chlamydial T3S, 
then dissociation from the inclusion membrane would result in loss of activity since 
it is unlikely that metabolically inert EBs continue to secrete. Similarly, association 
and dissociation from host membranes is thought to be key in the progression of the 
chlamydial developmental cycle.  
Once secreted beyond both bacterial membranes, effectors must still traverse the 
intervening space between the bacterium and the host cytosol and then cross a host 
membrane. This process is termed translocation and mediated by so-called 
translocator components of the type III apparatus. These proteins are themselves 
secreted and assemble external to the bacterium to form an extended conduit for the 
transfer of effector proteins directly into the host cytosol. In Yersinia spp., the 
translocator protein YopB, probably in association with YopD and YopK, 
intercalates into the eukaryotic membrane forming an effector-permissive pore while 
YscF and accessory proteins, such as LcrV and YscP assemble to form the conduit 
bridging the bacterium to the host membrane-localised pore [133]. YopB and YopD 
in Yersinia have homologues in C. pneumoniae and C. trachomatis termed 
Chlamydia outer proteins CopB and CopD [136]. This assertion is not based upon 
sequence similarity but rather similar size and hydrophobicity profiles. 
T3SS proteins of C. pneumoniae such as CopN have been evaluated as a vaccine 
candidate against C. pneumoniae infection in a mouse model [137]. In this study, the 
authors have demonstrated vaccine induced stimulation of cell mediated and 
antibody mediated immune responses to the C. pneumoniae challenge. 
2.4.9 Vaccine Development – History To Future 
Both human and animal chlamydial infections can be treated effectively with 
antibiotics [138]. However, once infection and pathology are established, treatment is 
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less effective. Many infections in humans are asymptomatic and treating only the 
individuals with clinical symptoms is not the ideal way to control the spread of 
infection [139]. Other way of identifying asymptomatic individuals would be to 
adopt a national screening programme, but, it is too costly and not practicable in 
developing countries. A vaccine would be much cheaper and have a greater impact 
on the prevalence of infections. Ideally, a combination of screening and vaccination 
is needed to control these infections. 
2.4.10 Whole Organism/ First generation vaccines 
Early animal and human vaccine studies in the 1950s and 1960s were primarily 
based on the use of inactivated or live whole chlamydial particles [140]. 
Interestingly, to date, the greatest success has been in developing whole organism 
killed or live attenuated vaccines against the animal pathogens C. abortus and C. 
felis. These commercially available vaccines in the market include highly effective 
live attenuated (chemically induced temperature sensitive mutant strain) and 
inactivated whole organism vaccines against ovine enzootic abortion (OEA), and 
inactivated vaccines against feline chlamydial infections [141-143]. Although, these 
veterinary vaccines have been evaluated for protection and safety in their target host 
species, but little is known about the immunological responses they elicit. However, 
similar approaches have proved unsuccessful in combating human chlamydial 
infections. In humans, although partial protection against ocular infection has been 
achieved with whole-organism vaccines, re-infection exacerbated disease in some 
individuals, correlating the pathological damage caused during chronic infections to 
the host responses [144]. The regulatory requirements for veterinary vaccines are less 
stringent than those in humans, where the proof of concept vaccines that can elicit 
appropriate correlates of protection is playing an increasing role in vaccine testing 
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and regulatory approval [145]. Hence, the follow up of these studies led to the 
termination of the use of whole organism vaccines. However, the bottom-line of 
these results signifies the importance of developing a stable genetic system for 
transformation of Chlamydiae to identify the causes of immunopathological damage.  
2.4.11 Subunit/Second generation vaccines 
In the early 1990s, attention has turned towards developing subunit vaccines in order 
to avoid the adverse effects of the vaccine formulations containing whole organisms. 
Subunit vaccines have the advantage of being safer and able to screen out the 
undesirable antigens responsible for immunopathology. Subunit vaccines include 
either the purified antigens from the microorganism or recombinant or synthetic 
proteins. MOMP was among the antigens used in early vaccine studies and has seen 
continuous use throughout the years in various animal models such as mouse model, 
pigs, guinea pigs and primates (Table 3) [58,146]. It was either used as part of 
extracted outer membrane complex, as purified native or recombinant protein, in the 
form of peptide, as plasmid, and as DNA. Caldwell et al. [32] for the first time 
identified the MOMPand characterised it as the structurally and immunologically 
dominant protein in the outer membrane. Chlamydial outer membrane complex 
(COMC) of C. muridarum was shown to induce protection against a genital 
challenge in mice [73]. The same research group in 2001 immunised mice with a 
purified, refolded preparation of C. muridarum MOMP in combination with Freund’s 
adjuvant and found significant protection against genital challenge [147]. Native C. 
muridarum MOMP in combination with nontoxic subunit B of cholera toxin (CTB-
CpG) elicited a vaccine induced antibody and cell mediated immune response along 
with significant protection against pulmonary challenge with C. muridarum [148].  
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Table 3. List of MOMP based vaccines. Various formulations of MOMP-based vaccines tested in different animal models (mouse, pigs and NHPs). 
 
Year MOMP formulation 
Route of 
vaccination 
Route of challenge Adjuvant Animal Model Reference 
1990 Outer membrane preparation s.c. Vagina Uninfected host cells Sheep Tan et al. 1990 [71] 
1993 OGP-MOMP preparations s.c. Vagina Freund's adjuvant Guinea Pigs Batteiger et al., 1993 [72] 
1994 MOMP, Hsp60 s.c. Vagina IFA BALB/cByJ Blander and Amortegui, 1994 [146] 
1997 nMOMP, COMC s.c. Ovarian Bursa CFA, IFA BALB/c Pal et al. 1997 [73] 
1999 pMOMP i.m. Ovarian Bursa, Vagina None 
BALB/c, C3H/HeN, 
C57BL/6 Pal et al. 1999 [149] 
2001 nMOMP s.c., i.m. Ovarian Bursa IFA, CFA BALB/c Pal et al. 2001 [147]  
2002 rMOMP i.v. Vagina Dendritic cell pulsed ex vivo C57BL/10 Shaw et al. 2002 [150] 
2003 rMOMP i.m. Vagina VCG BALB/c Eko et al. 2003 [151] 
2003 nMOMP s.c., i.m. Ovarian Bursa OspA C3H/HeN, BALB/c Pal et al. 2003 [152] 
2004 rMOMP t.c. Vagina CpG-1826, CT BALB/c Berry et al. 2004 [153] 
2005 nMOMP s.c., i.m. Ovarian Bursa CpG-1826, Montanide ISA 720 BALB/c Pal et al. 2005 [154] 
2006 nMOMP s.c., i.m., i.n. Ovarian Bursa LT-R72, MF59, LT-K63 C3H/HeN, BALB/c Pal et al. 2006 [155] 
2006 rMOMP i.n., i.v. Vagina CTB BALB/c Singh et al. 2006 [156] 
2007 rCPAF, rMOMP, rIncA i.n. Vagina IL-12 BALB/c Li et al. 2007 [157] 
2008 rMOMP s.c. Vagina CAF01 BALB/c, C57BL/6 Agger et al. 2008 [15 8] 
2008 rMOMP s.c. Vagina CAF01 C57BL/6 Hansen et al. 2008 [159] 
2009 rMOMP i.n. Vagina CTA1-DD BALB/c Cunningham et al. 2009 [160] 
2009 rMOMP i.n. Vagina Vault Nanoparticles C57BL/6 Champion et al. 2009 [161] 
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Year MOMP formulation 
Route of 
vaccination 
Route of challenge Adjuvant Animal Model Reference 
2009 rMOMP t.c. Vagina CT, CpG-1826, Lipid C BALB/c Hickey et al. 2009 [162] 
2009 rMOMP 
i.m., i.v., 
t.c. 
Vagina CTA2B, VCG C57BL/6 Ekong et al. 2009 [163] 
2009 nMOMP s.c., i.m. Ocular 
CpG ODN-2395, Montanide ISA 
720 
Cynomolgus 
monkeys 
Kari et al. 2009 [164] 
2009 
rMOMP, PmpG1, RplF, 
PmpE/F2 
s.c. Vagina DDA/TBD, AbISCO, CpG-1826 C57BL/6, BALB/c Yu et al. 2009 [165] 
2010 rMOMP Oral Vagina Lipid C, CpG-1826, CT BALB/c Hickey et al. 2010 [166] 
2010 nMOMP s.c., i.m. Vagina CpG-1826, Montanide ISA 720 C57BL/6 Farris et al. 2010 [167] 
2011 pMOMP i.v. Vagina GM-CSF, LTA, LTB, CpG Pigs Schautteet et al. 2011 [168] 
2011 nMOMP i.m., s.c. None 
CpG-2395, Montanide ISA 720 
VG 
Rhesus macaques Cheng et al. 2011 [169] 
2011 rMOMP i.n. Vagina CpG-10109, CT Guinea Pigs Andrew et al. 2011 [170] 
2012 pMOMP i.v., i.n., i.d. Vagina GM-CSF, LTA, LTB Pigs Schautteet et al. 2012 [171] 
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From the above mentioned studies, it is clear that some preparations can induce better 
protection than others due to the difference in extraction method which influences the 
conformational MOMP epitopes, necessary for protection.  
The next leap in chlamydial vaccine development was the production of large amounts of 
bacterial proteins by recombinant DNA technology. However, expression of rMOMP in E. 
coli is generally toxic, and does not represent the native MOMP with conformationally 
relevant epitopes. Many groups have used recombinant MOMP for their vaccine studies. 
Berry et al. [153] showed that transcutaneous immunisation of MOMP along with cholera 
toxin and CpG had enhanced IFN-γ secreting T cells, IgG and IgA antibody response in 
vaginal and cervical lavage fluid along with strong clearance of C. muridarum following 
intravaginal challenge. Protection against genital challenge in mice was demonstrated using 
Borrelia burgdorferi Outer surface protein (Osp) A along with MOMP [152]. Different 
vaccine formulations against intranasal challenge based on recombinant MOMP (rMOMP) 
and native MOMP (nMOMP) have also been trialled with recombinant C. muridarum 
MOMP able to elicit a protective immune response in mice, but the degree of protection 
obtained with nMOMP preparation was more robust than with rMOMP preparation [172]. 
The route of administration is one of the major factors contributing to the efficacy of a 
recombinant vaccine. Enhancement of the protective immune response was demonstrated by 
combining systemic and mucosal routes for vaccination than either systemic or mucosal 
immunisation alone [173]. 
Apart from mouse model, pathogen free pigs have also been used as an animal model to 
study the female genital tract infections caused by C. trachomatis (Table 3) [174]. 
Intravaginal vaccination with pWRG7079::MOMP has shown to induce protection against 
experimental genital C. trachomatis serovar E infection in pigs [168]. Schautteet et al. [171] 
have further evaluated a combined aerosol-vaginal delivery of a MOMP-based Chlamydia 
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trachomatis (serovar E) DNA vaccine in a pig genital challenge model. Following 
vaccination, significant protection was induced through mucosal route of vaccination and 
correlated with efficient T cell priming and significantly higher serum IgA titers (Table 3).  
Along with MOMP, several other proteins has also been recognised as potential vaccine 
candidates. A novel vaccine formulation using Chlamydia Protease like Activity Factor 
(CPAF) was shown to elicit robust resolution against genital C. muridarum infection as well 
as protection against oviduct pathology which was highly dependent upon production of 
endogenous gamma interferon [175]. Protective immune response against C. muridarum lung 
and genital tract infections was also reported using a novel epitope PmpG303-311 of PmpG1 
[165,176]. Li Z et al. [177] showed that when chlamydial glycogen phosphorylase was 
delivered intramuscularly it had significant protective immunity against C. muridarum 
intravaginal infection. The putative type III secretion effector protein Tarp elicits a C. 
muridarum specific immune response and offers some protection against pathology, but has 
little impact on the course of infection [178]. 
2.4.12 Protective Immunity 
Evaluation of protective immune responses is a critical component of vaccine development. 
Adoptive transfer studies with Chlamydia-specific T- cell clones and gene-knockout (MHC 
Class II, T-cell receptor αβ and IFN-γ) have demonstrated that an MHC class II-restricted, 
CD4+ Th1 response, mediated by IFN-γ and TNF-α is essential for resolving primary 
infection [140,179,180]. Dendritic cells, when pulsed with a chlamydial antigen (ex vivo), 
was reported to elicit increasing IL-12 levels, which further stimulated IFN-γ production 
[181]. Specifically, IFN-γ and IL-12 were reported to be essential for protection [182-184], 
while the Th2 cytokine IL-10 has been associated with a pathological response [185]. 
In contrast to the cellular immune responses, the importance of the humoral immune response 
to resolving infection is still a matter of debate. In the guinea pig model, Rank and Batteiger 
 Chapter 2: Literature Review 33 
[186], demonstrated the role of antibody in limiting primary infection. The predominant role 
of antibodies was identified against re-infection by enhanced antibody dependant cellular 
cytotoxicity (ADCC) in Fc receptor-knockout mice [187]. 
Taken together, natural immunity to C. muridarum genital infection in mice is mediated by 
CD4+ T cells, Th1-type cytokines, and antibodies. The effectiveness of a vaccine will 
therefore depend on its ability to induce such responses. 
Another major challenge in the field of Chlamydia vaccine research is the lack of 
standardisation in the procedures used to test various vaccines, which leads to difficulty in 
correlating the efficacy of vaccines relative to each other. Several important factors that 
impact the vaccine studies include mouse strain, route of infectious challenge, dose of 
infectious challenge, adjuvant, and the predictors (antigen) used to evaluate the cellular and 
humoral immune response to vaccination. Mouse strain used for infection was shown to 
impact the outcome of the infection in terms of infection titer, duration of infection, degree of 
upper genital tract infection, severity of the infection-induced pathology, and immune 
responses generated [188,189]. Carey et al. [190] demonstrated that infectious dose impacts 
on the course of infection and ascension of bacteria to the upper genital tract. Vaccines 
targeting the genital tract utilise either vagina or ovarian bursa as their routes of infection. 
Vaginal challenge, the natural route of chlamydial infection, allows us to study the ability of 
a vaccine to prevent infection and the resulting pathology. However, not every mouse 
challenged through the vagina develops pathology and thus the upper genital tract model, 
although not a natural one, is still useful in this regard. Both infection models have their 
advantages, but since most of the studies use only one model, it is difficult to evaluate and 
compare the efficacies of vaccines. Another major difference can be found in evaluating the 
humoral immune responses. Several groups use the vaccine antigen in ELISA, while few use 
the whole EBs [148]. Using whole EBs evaluates whether the antibody elicited by the 
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vaccine will recognise the actual agent of infection. However, vaccines utilising secreted 
proteins would not produce antibody that recognise whole EBs, thereby necessitating the use 
of the vaccine antigen in ELISAs. 
2.4.13 Live attenuated vaccines 
Given that most of the successful vaccines in the public health industry are live attenuated 
vaccines, it would be more appropriate to invest in developing a live attenuated Chlamydia 
vaccine [191]. Earlier efforts made through this line have failed due to lack of gene transfer 
system, cell free growth conditions, understanding basic metabolic capabilities and the 
difficulty in propagating clonal lineages of Chlamydia. However, advancement following the 
completion of the first Chlamydia genome project [54] in development of plaque cloning 
techniques [192] helped in screening live attenuated strains. O’Connell and Nicks [193], 
developed a plasmid cured C. muridarum strain which had reduced infectivity in vitro. 
Furthermore, frameshift mutations were induced in CT135 gene which altered the in vivo 
pathogenicity of C. trachomatis genital tract infection [194]. Live attenuated vaccines have 
many advantages such as processing and presentation of antigens similar to that of natural 
infection, expresses most of its important target immunogens while replicating, exposes both 
reticulate and elementary body specific antigens to the host’s immune system. However, a 
major potential drawback comes from the antigens that could give rise to aggravated 
immunopathologic responses. Understanding the antigen-specific basis for immunopathology 
and deleting them from the genome remains an important research priority. 
2.4.14 Non Human Primate (NHP) Models 
Theoretically, humans are the ideal model for human disease; however ethical and practical 
concerns prohibit many studies. The evolutionary closeness of NHPs with Homo sapiens 
establishes the biologically similar models with both predictive and selective abilities 
unavailable in other animal models [195]. Although the research done in rodents and other 
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small animal models has several advantages like low cost, ease of handling, and able to create 
gene knockouts, the results are always not translatable to human disease. 
Apart from being able to successfully fulfil Koch’s postulates to prove that Chlamydia causes 
Pelvic Inflammatory Disease (PID) and monitor the detailed progression of disease in vivo, 
the unique advantage of NHPs is their relatively long life span and similar menstrual cycle 
time periods to humans. Table 4 describes various NHP models used so far in studying PID. 
Though NHPs have numerous advantages they still have limitations such as not being cost 
effective, requires adequate facilities, veterinarian staff support and technical staff to care for 
the animals. 
The immunogenicity and vaccine efficacy of C. trachomatis nMOMP was investigated in 
Cynomolgus monkeys [164]. The results showed that systemically administered nMOMP is 
highly immunogenic and partially protective against ocular chlamydial challenge. Kari et al. 
[196] in an interesting study showed that Cynomolgus monkeys, when immunised with live 
attenuated (plasmid cured) strain of C. trachomatis, resolved the infection spontaneously 
without any pathology after ocular challenge. They even further correlated the differences 
between the partially and solidly protected animals based to MHC class II alleles. 
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Table 4. Historical NHP PID models and the pathological features found with each trial (adapted from Bell et al. [216]) 
 
Researcher Animal Chlamydial inoculum Site of inoculation Pathologic features 
Thygeson and Mengert, [197] Baboon Material from infant with inclusion blennorrhea cervix Cervicitis, purulent cervical discharge 
Alexander et al. [198] Taiwan monkey TRIC cervix Mild erythema of the lower genital tract 
Ripa et al. [199] Grivet Ct, 2×105 IFU/mL fallopian tube 
Histological changes in the upper genital tract, 
swollen reddened tubes, abundant lymphocytes in 
the tubal epithelium, clusters of desquamated 
cells, adhesions between mucosal folds 
Johnson et al. [200] Marmoset Ct, 5×105IFU/mL vagina 
Acute inflammatory reaction of the lower genital 
tract, PMNs, intracytoplasmic chlamydial 
inclusions 
Moller et al. [201] Grivet Ct, 2×105 IFU/mL cervix 
Reddened and swollen tubes, exudate from ostia, 
histological changes in the upper genital tract, 
lumen of tube diminished and tubal epithelium 
atrophic and flattened, demonstrated vertical 
spread of organism 
Johnson et al. [202] Marmoset Ct, 4.2–8.8×105 IFU/mL vagina 
Demonstrated that reinfection with either 
homologous or heterologous strain could result in 
infection however the shorter duration between 
inoculations resulted in marked immunity and 
decreased duration of infection 
Johnson et al. [203] Marmoset Ct, 5×105IFU/mL vagina 
Cervical erythema with occasional edema, 
cloudy, or purulent mucus, PMNs identified, 
endometritis, and salpingitis 
Patton et al. [204,205] Pigtailed macaque Ct, 6× 10
6 IFU/mL fallopian tube 
Acute salpingitis with marked edema and 
swelling, flocculent exudate, PMNs, isolation of 
Ct from cervix and tubes 
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Patton et al. [206] Cynomolgus rhesus Ct, 7× 10
6 IFU/mL Subcutaneous pocket model with fallopian tube implants 
Marked erythema, edema, and swelling, 
widespread inflammation with lymphocytic cells 
and PMNs, and plasma cells had infiltrated the 
stroma, infection duration shorter than that seen 
in intact model with direct tubal inoculation 
Patton et al. [207] Pigtailed macaque Ct, 2–4× 10
8 IFU/mL fallopian tube 
Chronic salpingitis with extensive tubal scarring, 
distal tubal obstruction, and peritubal adhesions 
Patton et al. [208] 
Pigtailed 
macaque Ct, 1× 10
6 IFU/mL cervix Acute and chronic salpingitis, peritubal adhesions 
Wolner-Hanssen et al. [209] Pigtailed 
macaque 
Ct, 1× 106 IFU/mL cervix 
Demonstrated that repeated cervical inoculation 
resulted protective immunity though there was no 
relationship between the antibody titer and 
reinfection 
Patton et al. [210] Pigtailed 
macaque 
Ct, 5× 103 IFU/mL Subcutaneous pocket model 
with fallopian tube implants 
Demonstrated a delayed hypersensitivity in 
response to inoculation with Ct in both previously 
infected pockets and noninfected pockets 
Van Voorhis et al. [211] Pigtailed macaque Ct, 1× 10
5 IFU/mL 
Subcutaneous pocket model 
with fallopian tube 
implants, cervix and 
fallopian tubes 
Suggests that a Th1-like cytokine response is 
seen with repeated infection with Ct 
Patton et al. [212] Pigtailed macaque Ct, 1× 10
5 IFU/mL cervix 
Demonstrated the azithromycin treatment in Ct 
infection ameliorated the immune response to Ct 
infection 
Patton et al. [213,214] Pigtailed macaque Ct, 5× 10
5 IFU/mL 
vaginal fornix, rectum 
Demonstrated the ability of NHP PID model for 
evaluating the safety and efficacy of topical 
microbicides 
Bell et al. [215] Olive baboon Ct, 1× 107 IFU/mL cervix Acute and chronic salpingitis, peritubal adhesions 
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2.5 CHLAMYDIAL INFECTIONS IN KOALAS 
Koalas (Phascolarctos cinereus) are the last existing members of the family 
Phascolarctidae, and serve as icons of Australia’s unique biodiversity. Despite the 
esteem that is held for this wildlife species, evidence continues to mount that in 
various regions of Australia, particularly in Queensland and New South Wales, wild 
koala population numbers have experienced serious declines over the last 30 years, 
with one recent study indicating that koala numbers in once previously secure koala 
populations in South-East Queensland have experienced an 80% decline since the 
mid 1990’s [217]. Anecdotal evidence presented at enquiries into the status of the 
koala have described similar declines over the same period, leading to localised 
extinctions of koala populations along the entire eastern seaboard of Australia 
(Senate Environment and Communications References Committee, 2012). In 
response to this accumulation of evidence of wild koala declines [217], the 
conservation status of the koala in these two Australian states was reviewed and 
changed with koalas now being classified as a “threatened” species. 
While there are several serious threats to the continued survival of the koala 
including, habitat loss, climate change, road accidents and dog attacks [218-221], 
disease has been reported as being not only a major threat, but one of the few threats 
that can potentially be addressed [222].  
Chlamydial infections in the koala continue to be the most common infectious 
disease affecting its survival, particularly when combined with habitat destruction. A 
significant percentage (32-40%) of the koalas coming annually to koala care centres 
or hospitals in NSW and Queensland have serious chlamydial disease, which often 
cannot be cured. Chlamydial infections in koalas lead to four major disease 
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syndromes: keratoconjunctivitis, respiratory tract disease and genital tract disease 
resulting in infertility and urinary tract infections resulting in incontinence [31]. 
Infection of the mucosal surfaces of the eye results in inflammation, characterised by 
serous discharge, blepharospasm and hyperaemia of the conjunctiva and sclera, 
progressing to purulent discharge, conjunctival hyperplasia and fibrosis. In some 
severe and chronic cases, the cornea is affected by opacity caused by oedema and 
pannus with or without pigmentation, and severe end-stage cases may have rupture 
and collapse of the globe. Clinical presentations are highly variable in severity and 
chronicity between koalas, and lesions may be active, with copious exudate, or 
inactive, with no exudate and mature scarring. Extensive and advanced fibrosis of the 
conjunctiva leads to reduction in the size of the palpebral fissure and sometimes 
entropion, and scarring of the cornea may lead to severe impairment of sight, or 
blindness [31].   
Urinary tract infections caused by chlamydial infections often manifests a brown 
urine staining and wetness of the fur of the rump and tail. This occurs as a result of 
cystitis leading to incontinence and loss of bladder function; hence, the colloquial 
terms ‘‘wet-bottom’’ and ‘‘dirty-tail’’. Koalas with severe cystitis show evidence of 
discomfort on urination, which is sometimes sufficiently painful to cause 
vocalisation or crying, and there may be gross haematuria [223]. In severe, chronic 
cases there may be alopecia, urine scalding and erythema, skin erosions and 
ulceration, secondary bacterial and yeast dermatitis of the skin around the common 
opening, and oedema and protrusion of the mucosa of the common vestibule. 
Sonographic changes in affected koalas include mild to marked thickening and 
irregularity of the bladder wall, reduction in lumen diameter, presence of urinary 
casts and flocculence of the luminal echo. Scarring of the bladder wall may be 
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evident as increased echogenicity. In a proportion of chronic, severe cases, there is 
marked dilatation of the ureter and renal pelvis (hydroureter and hydronephrosis) as a 
consequence of outflow obstruction, presumably caused by fibrosis around the 
intramural ureter as it passes through the bladder wall. Urethritis, prostatitis, 
ureteritis and nephritis are also reported in association with chlamydial infection 
[224,225]. Severe, chronic cystitis cases are often associated with extensive loss of 
bladder mucosa, marked loss of functional capacity and chronic haematuria. 
Reproductive tract disease associated with chlamydial infection is common in both 
male and female koalas. Reproductive disease is rarely apparent overtly, unless 
associated with concurrent urinary tract infection or general debility, and, in many 
female koalas, failure to produce joeys may be the only indication of reproductive 
tract disease. Female reproductive tract disease commonly results in gross 
pathological changes that are easily detected by sonography and/or caudal abdominal 
palpation. Such changes include unilateral or, more commonly, bilateral cystic 
dilatation of the ovarian bursae, oviducts and uteri, pyometron, metritis, vaginitis and 
urogenital sinusitis [223]. Acute reproductive tract disease in females may be 
associated with muco-purulent exudate from the common opening, but frequently 
there is no external evidence of infection. More chronic disease is indicated by cystic 
changes in the oviducts and ovarian bursae and sometimes thickening of the uterine 
walls, however, these changes may not always be present in cases of chronic 
reproductive tract disease. In contrast, male reproductive tract disease is infrequently 
diagnosed clinically because sonographic changes are uncommon [226]. Prostatic 
abscesses and other sonographic lesions have been reported in koalas, but generally 
definitive diagnosis of reproductive disease in male koalas relies upon histological 
examination of tissues collected during necropsy examination [226]. Recent studies 
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on disease prevalence in some South East Queensland (SEQ) wild koala populations 
showed reproductive disease prevalence in sexually mature female koalas of between 
31% and 57% across three populations. In each population, fecundity rates were 
consistently somewhat less than the proportion of female koalas without detectable 
reproductive tract disease, suggesting that a proportion of these koalas had 
reproductive disease that was not detected sonographically [226]. 
2.5.1  Taxonomy of koala Chlamydiae 
Initially in the mid-1970s, the chlamydial species in koalas was classified as C. 
psittaci based on cell culture observations. However, with advances in fundamental 
molecular biology techniques, it was revealed that there were indeed two distinct 
types of C. psittaci (type I and type II) in the koala [227]. These types were 
subsequently reclassified to C. pneumoniae and C. pecorum respectively, based on 
the nucleotide sequence analysis of ompA, the gene encoding the chlamydial MOMP 
[228-230]. In 1999, a taxonomic revision was proposed that saw the two species 
infecting koalas, C. pneumoniae and C. pecorum, moved into a new genus, 
Chlamydophila, alongside seven other species [5]. This amendment of the genus 
Chlamydia, however, was not widely accepted and was re-established by merging all 
nine species in the family Chlamydiaceae back into a single genus, Chlamydia [231]. 
In this thesis, the two main chlamydial pathogens of the koala will be referred to as 
Chlamydia pecorum and Chlamydia pneumoniae, according to the revised 
nomenclature. In 2003, Devereaux et al. [232] revealed molecular evidence to 
suggest that novel Chlamydia-like bacteria also existed in koala, however these 
bacteria remain uncultured and have not been formally classified.  
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2.5.2 Epidemiology 
Various studies have previously described the clinical diseases of koalas and often 
suggested that koalas are more prone to diseases than other marsupials [225,233-
237]. Even though a variety of approaches have been used to detect and analyse 
chlamydial infections in koalas over the last 15 or more years, they all indicate that 
these organisms are common majority of Australia’s wild koala populations. While 
early studies used serological approaches, these were unreliable. It is the molecular 
methods involving PCR that have provided accurate data on the prevalence of 
chlamydial infections in wild koalas [31].  
To understand the epidemiology of koala chlamydial infections, a molecular 
epidemiology study was conducted in wild koala populations which revealed a high 
prevalence of Chlamydia in males and females at both ocular and urogenital sites 
[238]. Jackson et al. [239] used MOMP genotyping to demonstrate significant 
diversity in C. pecorum strains infecting koalas. Northern NSW and SE Queensland 
contain a significant proportion of Australia’s koala population whilst also having 
highest levels of chlamydial infection and disease. Jackson et al. [240] used 
molecular methods to study the epizootiology in two wild populations of koalas, 33 
koalas on the Mutdapilly site (55kms west of  Brisbane) and 20 koalas on the 
Coombabah site (60 km south of Brisbane). In the Mutdapilly population, 73% of the 
animals were infected with C. pecorum while 21% were infected with C. 
pneumoniae. Infections were present at similar levels in both genders and at ocular 
and urogenital sites. This makes C. pecorum the most important focus for vaccine 
development and antibiotics. Moreover, infections caused by the koala biovar of C. 
pneumoniae were usually of lower intensity in comparison with C. pecorum 
infections within the same population. This study also revealed the transmission of 
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disease is mostly due to a combination of sexual contact and vertical transmission. 
Another unpublished source of information is from animals that come into koala 
hospitals and wildlife care centres. Friends of the Koala Care Centre in Lismore 
which has one of the largest populations of koalas (approx. 10,000) in NSW receives 
550 koalas annually of which 40% show clinical signs of chlamydial disease. The 
Australian Wildlife Hospital is another significant centre for sick and injured koalas. 
They have received 2168 koalas since the hospital opened in 2004 and of these, 32% 
(684) were admitted primarily due to overt signs of chlamydiosis. This data 
demonstrates how widespread and significant chlamydial infections are in the 
Northern NSW and SE Queensland areas of the koalas range. 
The increasing use of species-specific PCR and sequencing approaches has revealed 
the presence of additional chlamydial infections in the koala. Devereaux et al. [232] 
demonstrated the presence of novel chlamydial infections in koalas. They found that 
Unknown Koala Chlamydia (UKC) sequences cluster separately from other 
Chlamydia species and assigned them to “Chlamydia like bacteria”. Three different 
clusters of UKC were detected having nine novel koala Chlamydiales genotypes. 
These novel Chlamydiales are found predominantly as co-infections with C. pecorum 
and C. pneumoniae. Female koalas had the highest UKC rates at urogenital site 
whereas their male counterparts had highest UKC rate at ocular site. 
It still remains unknown as to the origins of the chlamydial strains infecting koalas. 
Studies have indicated that several genotypes of C. pecorum isolated from koalas are 
not host restricted, and were found to be identical to those found in sheep/cattle from 
Australia and some of which are also present in Europe [239]. This led to the 
hypothesis that some strains of koala Chlamydia today came via infections in sheep 
and cattle of Australia, brought by European settlers [241].  
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Fundamental to management of the disease in koalas is an understanding the 
diversity of C. pecorum infections in wild populations. Previous studies have 
reported the diversity of ompA genotypes of C. pecorum isolated from wild koalas, 
primarily based on partial sequences of MOMP identified just one ompA VD1-3 
genotype in a semi-urban koala population [242] or five ompA VD3-4 genotypes 
identified among 15 isolates of koala C. pecorum across Australia [239]. Given that 
diversity exists across the entire ompA gene, it is mis-leading to only evaluate part of 
this gene for typing studies and particularly for vaccine development. On the other 
hand, tarP and ORF663 genes were also identified as useful neutral and contingency 
markers to represent the intra-species genetic diversity of koala C. pecorum [243]. 
2.5.3 Diagnosis of chlamydial infections in koalas 
Chlamydial infections when apparent are detected using veterinary techniques. 
Current veterinary diagnosis of chlamydial diagnosis are provided by Whittington 
[244], and Blanshard [223]. However, there are significant group of animals in the 
wild which are positive for infection/organism but have no clinical symptoms. 
For laboratory diagnosis of chlamydial infections in the koala, swab sampling of 
mucosal sites such as conjunctiva and lower genital and urinary tract sites have 
proven to be reliable. 
A tissue culture protocol has been designed for the isolation of C. psittaci 2 (before 
re-speciation) from koalas by Grice and brown [245]. Based on inclusion 
morphology and cycloheximide sensitivity, the clinical isolates were identified as C. 
psittaci serotype 2. While cell culture methods were initially used to diagnose and 
describe the chlamydial pathogens of koalas [246], it is a laborious and time taking 
process.  
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Some of the techniques like slide EIA technique and Immuno dot blot have also been 
used for detecting chlamydial infections in koalas and have shown mixed results 
[27,247]. Both cell culture and antibody detection tests have several disadvantages 
such as (i) requirement of viable cells and transport problems in case of cell culture, 
and (ii) the slow response of koala to antigens which can take up to three months for 
producing anti-chlamydial antibodies [248].  
Wood and Timms [249] studied the sensitivity, specificity and usefulness of three 
DFA (direct fluorescent antibody) kits and six ELISA kits in koalas and revealed that 
direct fluorescent-antibody kits were least sensitive than ELISA kits. However 
among six ELISA kits, Clearview kit was the most sensitive (91%), followed by 
IEDIA (88%) and Surecell kit (73%). Clearview test was proven to be a simple, rapid 
and sensitive test for detecting chlamydial infections in koalas and still in use by 
field workers [250]. 
PCR has revolutionised the diagnosis and description of Chlamydia in humans, 
koalas and other animals [251]. Various studies have been conducted for detecting, 
genotyping and prevalence of chlamydial infections in koalas using PCR. The first 
study was used to investigate the epizootiology of chlamydial infections in two 
geographically distinct populations [240]. This study has used a Chlamydia genus-
specific PCR targeting the ompB gene and DNA hybridisation using C. pecorum or 
C. pneumoniae species specific DNA for speciation of positive samples. Order, 
genus and species-specific conventional or nested PCR assays, targeting the 16S 
rRNA gene and ompA gene, have been employed to screen swab, blood and semen 
samples collected from infected koalas for the presence of C. pecorum or C. 
pneumoniae DNA [20,232,252]. More recently, quantitative genus or species-
specific PCR assays targeting the 16S rRNA gene have been developed and utilised 
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for detection, speciation, measure the shedding over time, as well as to correlate the 
chlamydial infectious load with clinical disease presentation [253,254].  
While PCR-based methods have proven to be the most sensitive and reliable method 
for screening chlamydial infections in the koala, these methods are not suitable for 
point-of-care field testing of captured koalas or where molecular testing might not be 
available. In koalas, a series of Chlamydia-genus specific ELISA and direct 
fluorescent antibody kits were earlier trialled for detection of chlamydial infections 
in koala with mixed results [249]. Field analysis revealed that one qualitative antigen 
detection kit, the Clearview Chlamydia test, was sensitive and specific for 
chlamydial species infecting the koala. However, these tests performed poorly for 
both sensitivity and specificity. More recently, Hanger et al. showed that Clearview 
assay, while not as sensitive as qPCR-based methods, is potentially a suitable 
diagnostic tool for the rapid diagnosis of active chlamydial infections by field 
workers [250] 
2.5.4 A need for a koala vaccine 
Current systemic antimicrobial drugs used for chlamydial infections at the major 
koala treatment facilities include enrofloxacin and chloramphenicol [223]. Although 
systemic antimicrobial drugs are used for treating chlamydial infections, several 
studies [255,256] have shown that the current treatment regimes are not efficient in 
controlling the spread of infections in wild koalas. Moreover, the usage of these 
antibiotics have been shown to affect the microflora of the koala gastrointestinal tract 
and apparent limitations on the complete clearance of chlamydial infections of the 
lower genital tract [257]. 
A Chlamydia vaccine is the most realistic approach to the rapidly spreading disease 
in koalas. Early trails of a human trachoma vaccine, using whole killed Chlamydia, 
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resulted in enhanced disease in recipients [258]. Evidence in both humans and 
animals [259] has shown that crude whole chlamydial antigens result in severe 
disease pathology when administered to animals that have already had a previous 
chlamydial infection. Since then vaccine research has been focused on antigens 
eliciting protective immunity without exacerbating inflammatory response.  
The MOMP of Chlamydia is the best studied antigen to date and has been shown to 
elicit significant protection against infection. The major problem with MOMP based 
vaccines is the sequence based diversity in surface exposed variable domains of 
different serovars giving protection against homologous serovars rather than serovars 
showing variability in MOMP sequence. 
As a first step towards developing a vaccine for koalas Carey et al. [260] has 
immunised groups of healthy female koalas with a combination of three chlamydial 
antigens (MOMP, NrdB, and CT0512) mixed with three different adjuvants 
(Immuno stimulating complex [ISC], Alhydrogel and TitreMax Gold), previously 
used in veterinary vaccines. High levels of antigen specific peripheral blood 
leukocytes proliferation were observed in animals immunised with ISC and plasma 
antibody was present against all three antigens in all animals in the ISC and 
Alhydrogel groups. This preliminary data showed that a multi-subunit vaccine 
approach could provide protection against chlamydial infection in the koala. These 
antigens were not derived from koala Chlamydia species, however, and further 
studies into the efficacy of a C. pecorum recombinant protein based vaccine for 
koalas is warranted. 
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3.2 ABSTRACT 
The long term survival of the koala (Phascolarctos cinereus) is at risk due to a range 
of threatening processes. A major contributing factor is disease caused by infection 
with Chlamydia pecorum, which has been detected in most mainland koala 
populations and is associated with ocular and genital tract infections. A critical 
aspect for the development of vaccines against koala chlamydial infections is a 
thorough understanding of the prevalence and strain diversity of C. pecorum 
infections across wild populations. In this study, we describe the largest survey (403 
koalas from eight wild populations and three wildlife hospitals) examining the 
diversity of C. pecorum infections. 181 of the 403 koalas tested (45%) positive for C. 
pecorum by species-specific quantitative PCR with infection rates ranging from 20 to 
61% in the eight wild populations sampled. The ompA gene, which encodes the 
chlamydial major outer membrane protein (MOMP), has been the major target of 
several chlamydial vaccines. Based on our analysis of the diversity of MOMP amino 
types in the infected koalas, we conclude that, (a) there exists significant diversity of 
C. pecorum strains in koalas, with 10 distinct, full length C. pecorum MOMP amino 
types identified in the 11 koala locations sampled, (b) despite this diversity, there are 
predicted T and B cell epitopes in both conserved as well as variable domains of 
MOMP which suggest cross-amino type immune responses, and (c) a recombinant 
MOMP-based vaccine consisting of MOMP “F” could potentially induce heterotypic 
protection against a range of C. pecorum strains. 
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3.3 INTRODUCTION 
The koala (Phascolarctos cinereus) is an arboreal, folivorous marsupial native 
to Australia, and the only living representative of the family Phascolarctidae. 
Recently, the Australian Federal Government (April 2012) listed koala populations in 
Queensland, New South Wales and the Australian Capital Territory as “vulnerable”. 
The decline across various populations in Australia, particularly in previously 
densely populated areas, has been attributed to several factors, including, habitat loss 
due to land clearing (Melzer et al., 2000), chlamydial disease (Jackson et al., 1999), 
motor vehicle trauma (Dique et al., 2003) and dog attacks (Lunney et al., 2007). 
Chlamydial infections are a major cause of disease in koalas (Polkinghorne et al., 
2013). Two species, C. pecorum and C. pneumoniae, have been isolated from many 
koala populations, with C. pecorum being the most widespread and pathogenic of the 
two species (Jackson et al., 1999). The clinical manifestations of C. pecorum include 
keratoconjunctivitis (ocular disease) leading to blindness, as well as urinary and 
genital tract disease, resulting in inflammation and fibrosis of the bladder and the 
upper female genital tract (Blanshard and Bodley, 2008). The impact of these 
infections is further highlighted by a recent study which found that older koalas with 
clinical signs of chlamydiosis made up the most frequent admission group to a koala 
rehabilitation facility over 30 years (Griffith et al., 2013). 
The gross and histological similarity between chlamydial lesions in koalas and those 
induced by C. trachomatis in humans (Hemsley and Canfield, 1997) is suggestive of 
similar disease pathologies. In humans, the diversity of the major outer membrane 
protein (MOMP), which is encoded by the ompA gene (Kaltenboeck et al., 1993), is 
an important factor in pathogenesis via immune evasion and subsequent infection by 
multiple MOMP serovars. MOMP has been considered a potential vaccine candidate 
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for C. trachomatis in primate models (Kari et al., 2009) as well as C. pecorum in 
koalas (Kollipara et al., 2012; Kollipara et al., 2013a). The strains of C. trachomatis 
have been divided into 15 serovars based on variations in the MOMP. This sequence 
variation is mainly limited to the four surface-exposed variable domains which are 
interspersed between five conserved domains. Originally, serovars were 
distinguished based on their recognition by patient sera (Wang et al., 1985), however 
the ompA sequences for each serovar have now been well characterised. Organisms 
assigned to a serovar group on the basis of their translated ompA sequences are 
referred to here as amino types/aminovars. 
Outer membrane protein A (ompA) genotyping targeting variable domains 3 and 4 
has been used previously to investigate C. pecorum infections in wild koala 
populations (Jackson et al., 1997), usually with the goal of better understanding C. 
pecorum transmission. However, the analysis of ompA sequence variation is also 
relevant to the utility of MOMP as a target for an effective C. pecorum vaccine. For 
such vaccine development, which will use full length MOMP protein, it is 
appropriate to sequence and analyse full length ompA from a range of C. pecorum 
isolates across the koala’s natural habitat range. As such, the primary objectives of 
this study were to, (a) investigate the polyphyletic nature of full length ompA 
sequences in several C. pecorum wild koala populations and (b) examine the 
implications of MOMP diversity for developing an efficient C. pecorum vaccine for 
koalas. 
3.4 MATERIALS AND METHODS 
Koala samples 
Two types of samples were collected from across the entire range of wild koalas. The 
first involved the sampling of wild koalas presenting for veterinary treatment because 
 Chapter 3: Genetic diversity of Chlamydia pecorum strains in wild koala locations across Australia and the 
implications for a recombinant C. pecorum major outer membrane protein based vaccine. 78 
of injury or illness (termed wildlife hospital koalas) at (a) Tanilba Bay Veterinary 
Hospital, Port Stephens, New South Wales (NSW), (b) Port Macquarie Koala 
Hospital, Port Macquarie, NSW and (c) Adelaide Hills Animal Hospital, Stirling, 
South Australia (Figure 1). At these facilities, swabs were collected as a part of 
routine testing for the care of diseased animals and their use in this study was 
approved by the Queensland University of Technology (QUT) Animal Ethics 
Committee and approved under Tissue Use Notification # 1100000718.  
The second source of samples came from independent field sampling and 
investigations into the health of wild koala populations in Queensland (termed 
natural/wild koala populations). These locations included St Bees Island, North 
Stradbroke Island, Elanora, Narangba, Brendale, East Coomera and Lower 
Beechmont in Queensland and Byron Bay, NSW (Figure 1). A standardised 
veterinary assessment of koalas was conducted on captured koalas and swab samples 
were taken from the conjunctiva, nasal cavity and urogenital sinus/cloaca (females), 
or from the urethra (males) and stored for later PCR screening.   
Detection of C. pecorum infection using a specific PCR assay 
All swab samples from koalas sampled as a part of independent field studies or 
collected as a part of routine veterinary treatment were screened for the presence of 
C. pecorum by a species-specific quantitative PCR (qPCR) targeting the 16S rRNA 
gene, as described in Marsh et al. (2011). 
C. pecorum ompA sequencing  
To evaluate the level of genetic diversity in the MOMP-encoding ompA gene from 
koala C. pecorum strains, C. pecorum positive DNA samples detected by our qPCR 
screening of koala swab samples was used a template for conventional PCR 
amplification of the near full length ompA gene (1140 bp) for each sample. Primers 
 Chapter 3: Genetic diversity of Chlamydia pecorum strains in wild koala locations across Australia and the 
implications for a recombinant C. pecorum major outer membrane protein based vaccine. 79 
used in this reaction were ompAfor (5’ – ATGAAAAAACTCTTAAAATCGG – 3’) 
and ompArev (5’ – TTAGAATCTGCATTGAGCAG - 3’). PCR conditions were a 
single cycle of initial denaturation at 95°C for 5 minutes, 40 cycles of denaturation at 
95°C for 30 sec, primer annealing at 54°C for 40 sec, primer extension at 72°C for 90 
sec, followed by a final extension at 72°C for 7 minutes. ompA sequences were 
determined by direct sequencing of the PCR product using ompAfor/ompArev 
following the use of a BigDyeTerminator 3.1 Sequencing kit (Life Technologies, 
Victoria, Australia) and subsequent purification according to the manufacturer’s 
instructions. Dideoxy sequencing was performed at the QUT DNA sequencing 
facilities, using an Applied Biosystems ABI3500 Gene analyser.  
Prediction of B and T cell epitopes 
Major B cell epitopes across 10 koala and five livestock C. pecorum isolate MOMP 
sequences [E58 (Cattle), iB1 (Sheep), iB3 (Sheep), iB5 (Sheep), iC4 (Goat) 
(Mohamad et al., 2008)] were predicted by use of the Immune Epitope Database 
using Bepipred Linear Epitope prediction tool 
(http://www.cbs.dtu.dk/services/BepiPred/). T cell epitopes were predicted based on 
the strongest affinity of the MOMP peptides to bind to MHC class II molecules of 
human (DPA/DPB/DQA/DQB/DP/DQ/DR) and mouse (H2-IAb/IAd/IEd) 
(http://tools.immuneepitope.org/main/html/tcell_tools.html), respectively.  
C. pecorum ompA sequence analysis 
For the purpose of this study, the definition of a new ompA genotype was based on 
an ompA sequence with > 1% nucleotide differences across the 1170 bp sequence 
when compared to previously described genotypes, commencing with ompA 
genotype designations (A – E) that were previously described using only VD3-VD4 
sequences of several koala C. pecorum strains (Jackson et al., 1997). When an ompA 
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sequence was found to be different to previously detected ompA sequences but the 
number of nucleotide changes was < 1%, then the new sequence was designated as 
X’ (eg. ompA genotype E’ is >99% identical to genotype E). Each of these ompA 
genotypes were translated into MOMP amino acid sequences and were designated an 
amino type based on the criteria followed for an ompA genotype designation. Full 
length representative ompA genotype and translated MOMP amino type  sequences 
detected in this study (A, B, E’, F-K) were uploaded to Genbank with the following 
accession numbers: A – KF150132, B – KF150133, E’ – KF150134, F – KF150135, 
F’ – KF150136, G- KF150137, H – KF150138, I – KF150139, J – KF150140, K – 
KF150141.  
To further understand the phylogenetic position of the koala C. pecorum strains 
detected in this study, a mid-rooted phylogenetic tree was constructed using an 
alignment of the MOMP sequences from C. pecorum strains of koala as well as 
livestock with an out group of a C. psittaci strain [Cattle - BE53 (EU684923)/ E58 
(EU837071)/ SBE (EU684916); Sheep – 824 (EU684922)/ AB10 (EU684917)/ AKT 
(EU684918)/ iB1 (EU684924)/ iB2 (EU684925)/ iB3 (EU684926)/ iB4 (EU684927)/ 
iB5 (EU684928)/ LW679 (EU684921)/ VB2 (EU684919)/ W73 (EU684929)/ R69 
(EU684930); Goat - iC2 (EU684931)/ iC3 (EU684932)/ iC4 (EU684933)/ M14 
(EU684920); Swine -  L71 (GQ228185)/ 1710S (GQ228167) (Mohamad et al., 2008) 
and C. psittaci 6BC (Parakeet; CP002549) (Voigt et al., 2011)]. The Neighbour 
Joining method (Saitou and Nei, 1987) and the Jukes-Cantor genetic distance model 
with 1000 Bootstrap repetitions were used in generating the phylogenetic trees. 
Evolutionary analysis of ompA coding sequences 
Maximum Likelihood analysis of MEGA 5.2.1 was used to estimate the degree of 
selection for each codon by calculating the number of synonymous (s) and non-
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synonymous (n) substitutions across the coding regions of ten full-length C. pecorum 
ompA sequences. These estimates are conducted on HyPhy software package using 
the joint Maximum Likelihood reconstructions of ancestral states under a Muse-Gaut 
model of codon substitution (Muse and Gaut, 1994) and Felsenstein model of 
nucleotide substitution (Felsenstein, 1981). Specific evaluation of the selective 
pressure [neutral (dN/dS = 1), purifying (dN/dS < 1), or positive (dN/dS > 1) 
selection] acting on the ompA genotypes was calculated using the formulae: 
 
 
 
 
A chi-square test with one degree of freedom was performed to establish whether or 
not the frequency distribution of positively selected coding sites differ from other 
coding sites across the 10 full length MOMP amino type sequences. 
3.5 RESULTS 
Detection of C. pecorum in wild koalas 
All koala swab samples were screened for C. pecorum DNA using a species-specific 
16S rRNA qPCR. Of the 403 koalas screened, 181 koalas (45%) were positive for C. 
pecorum. Within the eight sampled wild populations, infection levels ranged from 20 
– 61% (Figure 1). Among the six wild koala populations tested in South East 
Queensland (244 koalas), C. pecorum infections were present in 96 koalas (39%). In 
the Central Queensland population, 10 of 36 (28%) wild koalas from St. Bees Island 
tested positive for C. pecorum while only one of the five wild koalas sampled in the 
Byron Bay population in NSW was PCR positive for C. pecorum (20%). Among the 
No. synonymous substitutions (s) 
No. non-synonymous substitutions (n) 
No non-synonymous sites (N) 
dN/dS 
No. synonymous sites (S) 
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admissions to the three veterinary hospitals, 74 of the 118 koalas (63%) were 
positive for C. pecorum. 
Typing and C. pecorum amino type diversity 
All the samples that were positive for C. pecorum infection by the qPCR assay were 
typed based on the full length sequence of the ompA gene (1120 bp). Figure 1 shows 
the C. pecorum MOMP amino types identified in the koalas included in this study. 
As shown in Figure 1, the most prevalent C. pecorum MOMP amino type F was 
detected in the majority of locations studied (9/11), except the South Australian 
koalas. The next most prevalent amino type was “G” which was found in four 
geographically well separated populations in Queensland, NSW and South Australia. 
Amino type A, previously described over 15 years ago in koalas from populations in 
Queensland and NSW (Jackson et al., 1997) was detected at one location in NSW 
(Tanilba bay) and South-East Queensland (Lower Beechmont), respectively. Amino 
type B, previously detected in Raymond Island, Victoria (Jackson et al., 1997) was 
detected in South Australian koalas only (Adelaide Hills). Amino types E’ and H 
were detected only in the South East Queensland koala populations (Narangba, 
Lower Beechmont and East Coomera). Amino type F’ was found only in one NSW 
location (Port Macquarie). Amino types I, J and K were present only in the NSW 
koala locations (Port Macquarie and Tanilba Bay). Koalas at Tanilba bay hospital (A, 
F, G, I, J and K) was the only location to be infected with six different amino types. 
There was no significant association between the infecting MOMP amino type and 
anatomical infection site or gender (data not shown). 
Phylogenetic analysis of MOMP amino types 
Figure 2A shows a mid-point rooted, neighbour-joining phylogenetic tree of the 10 
C. pecorum MOMP amino types identified in this study. Because of their biological 
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relevance, only the translated sequences of full length ompA peptide sequences were 
aligned. The amino acid dissimilarities between these 10 MOMP amino types 
detected in koala C. pecorum samples ranged from <1% to 15%. Most of the amino 
acid polymorphisms are clustered within the variable domains of MOMP (Figure 3). 
The tree separates into two main clades from the base. Amino types E’, F and F’ 
cluster to form a small clade with only 1-3 amino acid differences between them and 
the rest (A, B, G, H, I, J and K) cluster into a larger clade with 4 – 37 amino acid 
differences between them. The highest number of amino acid polymorphisms (55 
amino acids) was found between amino types A and F.  
When MOMP sequences isolated from various C. pecorum strains of livestock 
animals were compared to the koala isolates (Figure 2B), we found that koala C. 
pecorum isolates were phylogenetically grouped together with few similarities to 
strains isolated from sheep (iB3, iB4) and goat (M14) in Europe. However, C. 
pecorum B strain reported in this study as well as our previous study (Jackson et al. 
1997) has been found to be closely related to the other livestock isolates. 
Estimation of selection across coding sequences of C. pecorum amino types 
A total of 363 coding sites were present across all the 10 full-length koala C. 
pecorum ompA genotypes (positions containing gaps have been eliminated) 
(Supplementary information). After analysing each of the 363 coding regions, 170 
coding sites (47%) were found to have mutations across all ompA genotypes. Of the 
170 codons, we identified 106 codons (29%) with synonymous (s) substitutions and 
23 codons (6%) with non-synonymous (n) substitutions. Both substitutions (s and n) 
were present at 41 codons (11%). Within the variable domains (VDs), 9 of the 106 
(8.5%) codons had synonymous substitutions, 14 of the 23 (61%) codons had non-
synonymous substitutions and 26 of the 41 (63%) codons had both synonymous and 
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non-synonymous substitutions. At the conserved domains (CDs), we found 97 
codons with synonymous substitutions, 9 codons with non-synonymous substitutions 
and 15 codons with both synonymous and non-synonymous substitutions. 
Interestingly, 140 (38.5%) of the 363 coding sites across all ompA genotypes have 
undergone purifying selection (dN/dS < 1) (labelled red in supplementary table) and 
6 (1.6%) have undergone positive selection (dN/dS > 1), respectively (labelled green 
in supplementary table). All the six codons under positive selection pressure are 
present at the variable domains. Based on chi-squared test analysis, we reject the null 
hypothesis that positively selected coding sites present in the variable domains are 
distributed at random. Table 1 shows the substitutions present at various in silico B 
and T cell epitopes. Neither synonymous nor non-synonymous substitutions were 
found at B cell epitope 1 as well as T cell epitopes 6 and 7. Among all the epitopes, 
B cell epitope 3 was having the most number of coding sites with non-synonymous 
substitutions. 
Prediction of B and T cell epitopes across several MOMP amino types 
Figure 3 shows the major B and T cell epitope in silico predictions across the MOMP 
sequences representing 10 koala and five livestock C. pecorum MOMP amino types. 
Of the six major predicted B cell epitopes, four were present in the variable regions 
(78’-110’; 164’ – 177’; 244’ – 261’; 322’ – 336’) specific to each MOMP amino type 
and the other two (24’ – 34’; 41’ – 54’) were conserved across the 10 koala C. 
pecorum MOMPs. Within the predicted B cell epitopes located in the variable 
domains, 20 amino acid residue changes (62%) were observed at B cell epitope three, 
7 amino acid residue changes (54%) exist at B cell epitope four, 9 amino acid residue 
changes (53%) occur at B cell epitope five, and 10 amino acid residue changes (71%) 
were present at B cell epitope six (Figure 3). Interestingly, all 10 major predicted T 
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cell epitopes were present in the conserved regions of the MOMPs. With the 
exception of T cell epitopes 4, 5, 9 and 10, where 2 – 6 amino acid residue changes 
have been observed, the remaining six predicted T cell epitopes were 100% 
conserved across koala and sheep C. pecorum MOMP sequences.   
3.6 DISCUSSION 
Using a range of techniques, several previous studies have examined chlamydial 
infections in koalas, and have consistently reported infections to be common in both 
free-ranging wild and hospitalised koalas across Australia (Carrick et al., 1996; 
Jackson et al., 1997; Griffith et al., 2013). Although early studies used serological 
tests (Ueno et al., 1991; Girjes et al., 1993), culturing (Grice and Brown, 1985) and 
antigen detection kits (Wood and Timms, 1992), it is the molecular methods 
involving PCR that have provided the greatest insights into the epidemiology and 
diversity of various C. pecorum infections in koalas (Hanger et al., 2013; Wan et al., 
2011; Ellis et al., 1993).  
The chlamydial MOMP is an approximately 40 kDa highly disulphide cross-linked 
surface exposed protein that comprises around 60% of the outer membrane of 
member species of the Chlamydiaceae (Caldwell and Judd, 1982). It functions as a 
redox-gated porin molecule and contributes to the structural rigidity of the 
chlamydial EB through its intra- and inter-molecular disulphide bonds. Despite these 
important functions, studies have previously demonstrated a significant level of 
amino acid sequence variation at the four surface exposed variable domains (VDs) of 
MOMP and this parallels the diversity of MOMP reported for the human pathogen, 
C. trachomatis (Lister et al., 2004; Stevens et al., 2010). In koalas, previous studies 
have reported the diversity of ompA genotypes of C. pecorum isolated from wild 
koalas, primarily based on partial sequences of MOMP such as VD1-3 (Higgins et 
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al., 2012) or VD3-4 (Jackson et al., 1999; Marsh et al., 2011). Given that diversity 
exists across the entire ompA gene, it is mis-leading to only evaluate part of this gene 
for typing studies and particularly for vaccine development. The current study 
therefore is the first to examine the diversity of full length koala C. pecorum MOMP 
sequences from a larger cohort of koalas, allowing us to more fully understand the 
diversity of this important chlamydial protein in C. pecorum strains infecting 
Australian koalas.    
In our study, we found 10 new full length C. pecorum MOMP amino types from 11 
koala locations across Australia (based on eight wild koala populations and 
admissions to three wildlife hospitals) (Fig. 1). Of the 10 amino types reported in our 
study, five amino types (A, E’, F, G and H) were present in the South East 
Queensland koala populations and eight amino types (A, B, F, F’, G, I, J and K) were 
present in the NSW and South Australian locations. Interestingly, two out of three 
sampled locations in NSW were infected with multiple (three to six) amino types. 
Furthermore, MOMP amino types B, F’, I, J and K were found only in koalas 
admitted to southern wildlife hospitals which may suggest the geographical 
restriction of some C. pecorum strains. Two major clades have emerged for the 10 
MOMP types (Figure 2). The smaller, basal/ancestral clade consists of three amino 
types (E’, F, and F’) which are widespread across the majority of the sampled 
locations, except the South Australian koalas (perhaps because only four animals 
were sampled at this location). The more recently diverged amino types (A, B, G, H, 
I, J and K) cluster to form a larger clade with several sub-branches and are 
apparently restricted to a smaller number of geographical locations. Five populations 
were infected with just a single MOMP type, and of these, C. pecorum amino type F 
was found in four populations (80%).  
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C. trachomatis in humans have been so far classified into 18 serovariants (A, B, Ba, 
C, D, Da, E, F, G, H, I, Ia, J, Ja, K, L1, L2 and L3) based on the immunoreactivity of 
the MOMP or ompA gene polymorphism (Nunes et al., 2009; Fields and Barnes, 
1992). The prevalence and substantial genetic diversity of multiple C. pecorum 
MOMP amino types found in koalas is reminiscent of the MOMP diversity observed 
with human serovars of C. trachomatis. Recently, the largest molecular 
epidemiological study reported on human C. trachomatis infections (2534 patients) 
typed variable domain 2 of the ompA gene and identified eight VD2 ompA genotypes 
(Zhang et al., 2012). In contrast, using the same typing scheme (VD2) in the current 
study, we found six C. pecorum VD2 ompA genotypes after screening just 403 
koalas. Interestingly, similar to C. trachomatis genotypes (Nunes et al., 2009), 
mutations were found at both the VDs and CDs of the C. pecorum ompA coding 
sites, indicating a general mutational trend through-out the entire gene 
(Supplementary table). However, 80% (97 of 121) of the mutated codons in the CDs 
were silent (synonymous) and just 18% (9 of 49) of the mutated codons in the VDs 
were silent. In contrast, at variable domains, 82% (40 of 49) of all mutated codons 
resulted in amino-acid substitutions. Considering that MOMP is the major 
chlamydial membrane component and unambiguously a dominant antigen, these 
findings point towards an evolutionary selection used by C. pecorum to deal with the 
environment and the host immune pressures. 
In support of a chlamydial evasion strategy, many mutations occurred within the in 
silico defined B and T cell epitopes across all C. pecorum genotypes (Table 1). 
Furthermore, 40 (69%) of 90 codons in B cell epitope regions and only 17 (12%) of 
the 139 codons at T cell epitope regions resulted in amino acid replacements. 
Although four of the predicted high affinity T cell epitopes are highly conserved 
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across all 10 MOMP amino types, six epitopes are located in the variable domain 
four with 1 – 6 amino acid changes between them. High levels of diversity ranging 
from 53% - 71% exist among four B cell epitopes located in the variable domains 
(Figure 3). Our previous findings have shown that wild koalas, when naturally 
infected with a particular C. pecorum ompA amino type, produced highly specific 
immune responses to their respective infecting strain with limited cross reactivity to 
other strains (Kollipara et al., 2012). The highly specific epitopes recognised by the 
plasma antibodies of the naturally infected koalas were present at the variable 
domains (Kollipara et al., 2013b). Despite these observations, and the significant 
MOMP sequence diversity within its variable domains, this protein has been 
extensively used in several vaccine studies in both mouse, guinea pig and nonhuman 
primate models (reviewed in Farris and Morrison, 2011). However, one of the major 
limitations of using MOMP-based chlamydial vaccines which use MOMP in native 
conformation is that the immune responses are limited to the homologous serovars 
(Taylor, 2008; Kari et al., 2009). Kari et al. (2009) demonstrated that primates, when 
immunised with native MOMP, produced serum neutralising antibodies that showed 
precise strain specificity, even though the heterologous strains differed by only four 
amino acids. These findings suggest that the conserved epitopes are poorly presented 
to the immune system in the natural infection but can potentially be used as targets 
for MOMP-based vaccines.  
Recent studies by our group and others, however, have reported that recombinant 
MOMP-based vaccines can induce protection against highly diverse amino 
types/serovars (Kollipara et al., 2012; Kollipara et al., 2013; Tifrea et al., 2013). 
Kollipara et al. (2012) demonstrated that when wild koalas naturally infected with C. 
pecorum amino type G were immunised with the homologous recombinant MOMP 
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G protein, the animals developed antibody responses not only to the homologous 
(MOMP G) but also to the heterologous MOMPs (MOMP A, MOMP F and MOMP 
H). Even though 52 amino acid differences (14%) occur between MOMP G and 
MOMP F, 35 amino acid differences occur between MOMP G and MOMP A (9%), 
and 26 amino acid differences (7%) occur between MOMP G and MOMP H, the 
vaccinated animals produced strong antibody responses to all three amino types. 
Kollipara et al. (2013) further showed that animals immunised with individual 
MOMPs (either MOMP A/ MOMP F/ MOMP G) produced strong antibody and 
lymphocyte proliferation responses to both homologous as well as heterologous 
MOMPs. The vaccine enhanced antibody responses effectively neutralised 
heterologous strains of koala C. pecorum. Most interestingly, they did not find any 
significant differences in vaccine enhanced immune responses between monovalent 
or polyvalent MOMP vaccine groups. Several C. pecorum prevalence studies in 
koalas have reported increasing levels of ompA genetic diversity at the four variable 
domains. However, the experimental findings thus far indicate that irrespective of 
amino acid replacements between the various MOMPs, it is feasible to develop a 
vaccine with just single recombinant MOMP (Kollipara et al., 2012; Kollipara et al., 
2013). In spite of surrogate parameters used to evaluate the efficacy of a vaccine in 
koalas in previous studies, there was no difference in immune responses elicited 
either by monovalent or polyvalent MOMP-based vaccine. An important finding 
observed in our current study as seen in Figure 1, demonstrates that C. pecorum 
MOMP amino type F is highly widespread and belongs to the ancestral clade of the 
phylogenetic tree (Figure 2). This suggests that a monovalent MOMP-based vaccine 
formulated with recombinant MOMP “F” protein would be able to induce immune 
responses against several amino types circulating across various populations. 
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Furthermore, to increase the range of protection against the potentially larger 
diversity of C. pecorum infections in wild koala populations, an ideal MOMP-based 
vaccine should consist of a MOMP antigen which represents the most widespread 
amino type across several koala populations and belongs to the ancestral clade of the 
MOMP phylogenetic tree. 
In addition to the koalas, C. pecorum has also been associated with a variety of 
clinical disease manifestations in sheep, including arthritis, conjunctivitis and enteric 
infections (Kaltenboeck et al., 1993; Philips and Clarkson, 1998). Interestingly, when 
we included some MOMP sequences from livestock isolates and compared them to 
our koala C. pecorum isolates, we found that all the predicted B and T cell epitopes 
identified in the 10 koala C. pecorum MOMP amino type sequences were also 
present (and common) across the five sheep C. pecorum MOMP sequences analysed 
(Figure 3). This finding suggests the feasibility of developing an effective MOMP-
based C. pecorum vaccine that could protect against a range of host C. pecorum 
isolates.  
The findings of this current study, alongside the findings of previous studies by our 
group and others ((Kollipara et al., 2012; Kollipara et al., 2013; Tifrea et al., 2013), 
have a number of major implications for the development of an effective MOMP-
based C. pecorum vaccine in koalas  as well as other animal hosts, In summary, these 
findings include: (a) the presence of several in silico, immunodominant B and T cell 
epitopes in conserved as well as variable domains of MOMP, (b) evidence that the 
MOMP “F” protein is the most widespread and basal amino type and likely to be 
most appropriate MOMP antigen to induce heterotypic protection against a range of 
isolates. While the evaluation of a recombinant MOMP protein-based C. pecorum 
vaccine is ongoing (Kollipara et al., 2012; Kollipara et al., 2013), we expect that 
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careful consideration of these factors will eventually lead to the design of an 
effective vaccine and much needed tool to control C. pecorum infections in both wild 
and domesticated animals.  
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3.9 TABLES 
Table 1. List of all in silico defined B and T cell epitopes with their respective codon positions across 
the full length ompA, number of codons at each epitope and the number of substitutions [either 
synonymous (s) or non-synonymous (n) or both (s + n)] 
 
Codon position No. of codons Epitope Codon with Substitutions 
24-33 10 B cell epitope 1 No substitutions 
41-53 13 B cell epitope 2 1 (n) 
78-111 29 B cell epitope 3 6 (s) + 6 (n) + 13 (s+n)  
165-179 13 B cell epitope 4 3 (s) + 1 (n) + 6 (s+n) 
246-265 13 B cell epitope 5 5 (s) + 2 (n) + 3 (s+n) 
326-342 12 B cell epitope 6 4 (s) + 5 (n) + 3 (s+n) 
178-193 15 T cell epitope 1 5 (s)  
180-195 15 T cell epitope 2 5 (s) + 1 (n)   
273-288 15 T cell epitope 3 5 (s) 
341-356 15 T cell epitope 4 2 (s) + 1 (n) + 2 (s+n) 
342-357 15 T cell epitope 5 2 (s) +  2 (s+n) 
 2-17 15 T cell epitope 6 No substitutions 
  3-18 15 T cell epitope 7 No substitutions 
 4-19 15 T cell epitope 8 1 (n) 
310-325 15 T cell epitope 9 6 (s) + 1 (n) + 5 (s+n) 
304-318 14 T cell epitope 10 6 (s) + 1 (n) + 3 (s+n) 
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3.10 FIGURES 
 
 
Figure 1. A map of the eastern half of Australia illustrating the geographical location 
of the koala locations along with their C. pecorum prevalence as well as various 
MOMP amino types present in them. 
 
 
 
 
 
 
 
 
 Chapter 3: Genetic diversity of Chlamydia pecorum strains in wild koala locations across Australia and the 
implications for a recombinant C. pecorum major outer membrane protein based vaccine. 97 
 
Figure 2. A mid-point rooted phylogenetic tree based on 10 full length MOMP 
sequences. Inferred by the neighbour-joining methods with bootstrapping support 
(1000 replicates) [A]; Phylogenetic tree of 32 full length MOMP sequences from C. 
pecorum isolates of koala (black), cattle (brown), sheep (green), goat (pink) and pig 
(blue) with an out-group of C. psittaci 6BC strain (red) [B]. 
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Figure 3. Alignment of highly diverse full length 10 koala and 5 livestock C. 
pecorum MOMP amino type sequences with predicted B and T cell epitopes. The 
predicted MOMP Variable domains can be found at residues 80 – 180 (VD1), 166 – 
176 (VD2), 235 – 264 (VD3) and 329 – 344 (VD4).  
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3.11  SUPPLEMENTARY TABLE 
Supplementary Table: Spreadsheet of coding sites across 10 full length ompA genotypes. Each 
codon is accompanied by the number of synonymous substitutions (s), number of non-synonymous 
substitutions (n) and dN/dS ratio. In silico defined B and T cell epitopes are labelled along the 
respective coding regions. NOTE: If dN/dS = 1 implies neutral selection, dN/dS < 1 implies purifying 
selection (red colored) and dN/dS > 1 implies positive selection (green colored). 
 
Codon 
number 
Codon 
Start Triplet Syn (s) Nonsyn (n) dN/dS  
B cell 
epitope T cell epitope 
1 1 ATG 0 0 Undefined     
2 4 AAA 0 0 Undefined   
T cell epitopes 6, 
7 and 8 
(overlapping) 
3 7 AAA 0 0 Undefined   
4 10 CTC 0 0 Undefined   
5 13 TTA 0 0 Undefined   
6 16 AAA 0 0 Undefined   
7 19 TCG 0 0 Undefined   
8 22 GCG 0 0 Undefined   
9 25 TTT 0 0 Undefined   
10 28 TTA 0 0 Undefined   
11 31 TCC 0 0 Undefined   
12 34 GCC 0 0 Undefined   
13 37 GCA 0 0 Undefined   
14 40 TTT 0 0 Undefined   
15 43 TTT 0 0 Undefined   
16 46 GCT 0 0 Undefined   
17 49 GGT 0 0 Undefined   
18 52 AAC 0 2 Undefined   
19 55 GCC 0 0 Undefined     
20 58 TCC 0 0 Undefined     
21 61 TTA 0 0 Undefined     
22 64 CAC 0 0 Undefined     
23 67 GCT 0 0 Undefined     
24 70 TTG 0 0 Undefined 
B cell 
epitope 1 
  
25 73 CCT 0 0 Undefined   
26 76 GTA 0 0 Undefined   
27 79 GGG 0 0 Undefined   
28 82 AAC 0 0 Undefined   
29 85 CCA 0 0 Undefined   
30 88 GCA 0 0 Undefined   
31 91 GAG 0 0 Undefined   
32 94 CCA 0 0 Undefined   
33 97 AGT 0 0 Undefined   
34 100 TTA 0 0 Undefined     
35 103 TTA 0 0 Undefined     
36 106 ATT 0 0 Undefined     
37 109 GAT 0 0 Undefined     
38 112 GGG 0 0 Undefined     
39 115 ACG 0 0 Undefined     
40 118 GTA 0 1 Undefined     
41 121 TGG 0 0 Undefined 
B cell 
epitope 2 
  
42 124 GAA 0 0 Undefined   
43 127 GGT 0 0 Undefined   
44 130 ATG 0 1 Undefined   
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Codon 
number 
Codon 
Start Triplet Syn (s) Nonsyn (n) dN/dS  
B cell 
epitope T cell epitope 
45 133 TCA 0 0 Undefined   
46 136 GGA 0 0 Undefined   
47 139 GAT 0 0 Undefined   
48 142 CCA 0 0 Undefined   
49 145 TGT 0 0 Undefined   
50 148 GAT 0 0 Undefined   
51 151 CCT 0 0 Undefined   
52 154 TGC 0 0 Undefined   
53 157 GCT 0 0 Undefined   
54 160 ACT 0 0 Undefined     
55 163 TGG 0 0 Undefined     
56 166 TGC 0 1 Undefined     
57 169 GAC 0 0 Undefined     
58 172 GCG 0 0 Undefined     
59 175 ATT 0 0 Undefined     
60 178 AGC 0 0 Undefined     
61 181 TTA 0 0 Undefined     
62 184 CGC 0 0 Undefined     
63 187 GTA 0 0 Undefined     
64 190 GGA 0 0 Undefined     
65 193 TTT 0 0 Undefined     
66 196 TAC 0 0 Undefined     
67 199 GGA 0 0 Undefined     
68 202 GAT 0 0 Undefined     
69 205 TAT 0 0 Undefined     
70 208 GTT 0 0 Undefined     
71 211 TTC 0 0 Undefined     
72 214 GAC 0 0 Undefined     
73 217 AGA 0 0 Undefined     
74 220 GTC 0 0 Undefined     
75 223 CTT 1 0 0     
76 226 AAA 1 0 0     
77 229 ACA 0 0 Undefined     
78 232 GAT 0 0 Undefined 
B cell 
epitope 3 
  
79 235 GTG 1 0 0   
80 238 CCA 1 1 0.51   
81 241 AAA 2 1 0.07   
82 244 CAG 0 4 Undefined   
83 247 TTT 0 0 Undefined   
84 250 ACA 0 3 Undefined   
85 253 ATG 0 0 Undefined   
86 256 GGG 2 0 0   
87 259 CCT 2 3 0.67   
88 262 ATA 2 3 0.71   
89 265 CCT 0 0 Undefined   
90 271 TCA 1 0 0   
91 274 AGT 0 4 Undefined   
92 277 ACT 0.8333 3.1667 1.23   
93 280 TCT 1 3 0.96   
94 283 GCT 1 1 0.50   
95 286 GCA 1 1 0.49   
96 289 GAC 1.5 2.5 0.39   
97 292 TCA 0 0 Undefined   
98 295 GCT 0 5 Undefined   
99 298 ACA 1 1 0.52   
100 301 CCA 0 5 Undefined   
101 304 ACA 1 5 2.11   
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Codon 
number 
Codon 
Start Triplet Syn (s) Nonsyn (n) dN/dS  
B cell 
epitope T cell epitope 
102 307 GAG 1 2 0.28   
103 310 AGA 1 0 0   
104 313 AAT 0.5 5.5 1.71   
105 316 AAC 1 0 0   
106 319 GCA 0 1 Undefined   
107 322 GCG 1 0 0   
108 325 TAT 0 0 Undefined   
109 328 GGG 3 0 0     
110 331 AAA 2 0 0     
111 334 CAT 1 0 0     
112 337 ATG 0 0 Undefined     
113 340 CAT 1 0 0     
114 343 GAT 0 0 Undefined     
115 346 GCG 0 0 Undefined     
116 349 GAG 1 0 0     
117 352 TGG 0 0 Undefined     
118 355 TTC 0 0 Undefined     
119 358 ACA 0 0 Undefined     
120 361 AAT 1 0 0     
121 364 GCA 0 0 Undefined     
122 367 GGT 1 0 0     
123 370 TAC 0 0 Undefined     
124 373 ATT 0 0 Undefined     
125 376 GCG 1 0 0     
126 379 CTA 1 0 0     
127 382 AAT 0 0 Undefined     
128 385 ATT 1 0 0     
129 388 TGG 0 0 Undefined     
130 391 GAC 1 0 0     
131 394 CGT 1 0 0     
132 397 TTC 1 0 0     
133 400 GAC 2 0 0     
134 403 ATC 1 1 0.34     
135 406 TTT 0 0 Undefined     
136 409 TGT 1 0 0     
137 412 ACC 1 0 0     
138 415 TTA 0 0 Undefined     
139 418 GGA 0 0 Undefined     
140 421 GCC 2 0 0     
141 424 ACT 0 0 Undefined     
142 427 AGC 0 0 Undefined     
143 430 GGG 0 0 Undefined     
144 433 TAT 1 0 0     
145 436 TTT 0 0 Undefined     
146 439 AAA 0 0 Undefined     
147 442 GGA 0 0 Undefined     
148 445 AAT 0 0 Undefined     
149 448 TCT 0 0 Undefined     
150 451 TCA 0 0 Undefined     
151 454 TCT 0 0 Undefined     
152 457 TTC 0 0 Undefined     
153 460 AAC 1 0 0     
154 463 CTT 1 1 0.45     
155 466 ATT 0 0 Undefined     
156 469 GGT 1 0 0     
157 472 TTA 1 0 0     
158 475 ATT 0 0 Undefined     
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Codon 
number 
Codon 
Start Triplet Syn (s) Nonsyn (n) dN/dS  
B cell 
epitope T cell epitope 
159 478 GGG 1 0 0     
160 481 ATC 1 1 0.37     
161 484 TCT 1 0 0     
162 487 GGA 0 0 Undefined     
163 490 TCC 1 0 0.70 
B cell 
epitope 4 
  
164 493 TCT 1 3 1.32   
165 496 CTT 1 0 0   
166 499 GAA 1 4 0.61   
167 502 GGC 1.5 5.5 1.33   
168 505 AAA 0.5 1.5 0.27   
169 508 TAT 0 2 Undefined   
170 511 CCA 0 0 Undefined   
171 514 AAC 1 0 0   
172 517 GCA 1 1 0.50   
173 520 AAT 1 2 0.27   
174 523 ATT 0 0 Undefined   
175 526 TCT 0 0 Undefined 
T cell epitopes 1 
and 2 
(overlapping) 
continued.. 
176 529 AAC 0 0 Undefined   
177 532 GGC 1 0 0   
178 535 GTA 0 0 Undefined   
179 538 GTA 2 0 0   
180 541 GAG 0 0 Undefined   
181 544 CTC 2 0 0   
182 547 TAT 0 0 Undefined   
183 550 ACA 0 0 Undefined   
T cell epitopes 1 
and 2 
(overlapping) 
184 553 GAT 2 0 0   
185 556 ACA 0 0 Undefined   
186 559 ACC 2 0 0   
187 562 TTC 0 0 Undefined   
188 565 TCT 0 0 Undefined   
189 568 TGG 0 0 Undefined   
190 571 AGT 0 0 Undefined   
191 574 GTT 0 1 Undefined   
192 577 GGA 0 0 Undefined     
193 580 GCT 0 0 Undefined     
194 583 CGT 3 0 0     
195 586 GGA 0 0 Undefined     
196 589 GCT 1 0 0     
197 592 TTA 2 0 0     
198 595 TGG 0 0 Undefined     
199 598 GAA 1 0 0     
200 601 TGT 0 0 Undefined     
201 604 GGA 2 0 0     
202 607 TGT 2 0 0     
203 610 GCA 2 0 0     
204 613 ACT 0 0 Undefined     
205 616 TTA 1 0 0     
206 619 GGA 0 0 Undefined     
207 622 GCA 1 0 0     
208 625 GAG 2 0 0     
209 628 TTC 0 0 Undefined     
210 631 CAA 0 0 Undefined     
211 634 TAC 0 0 Undefined     
212 637 GCA 0 0 Undefined     
213 640 CAA 1 0 0     
214 646 AAA 0 0 Undefined     
215 649 CCT 0 0 Undefined     
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Codon 
number 
Codon 
Start Triplet Syn (s) Nonsyn (n) dN/dS  
B cell 
epitope T cell epitope 
216 652 CGC 0 0 Undefined     
217 655 GTT 0 0 Undefined     
218 658 CAA 1 0 0     
219 661 GAA 0 0 Undefined     
220 667 AAC 2 0 0     
221 670 GTT 2 0 0     
222 673 CTT 5 0 0     
223 676 TCT 1 0 0     
224 679 AAC 0 0 Undefined     
225 682 GTA 0 0 Undefined     
226 685 GCA 1 0 0     
227 688 CAA 1 0 0     
228 691 TTT 1 0 0     
229 694 ACC 2 0 0     
230 697 GTA 0 1 Undefined     
231 700 CAC 1 0 0     
232 703 AAA 1 1 0.2     
233 706 CCT 0 0 Undefined     
234 709 CAA 0 1 Undefined     
235 712 GGA 1 0 0     
236 715 TAC 1 0 0     
237 718 ATA 0 1 Undefined     
238 724 AAA 1 1 0.1     
239 727 TCT 1 2 0.9     
240 730 TTG 2 0 0 
B cell 
epitope 5 
  
241 733 CCT 0 0 Undefined   
242 736 CTT 0 0 Undefined   
243 739 CCA 1 0 0   
244 745 AAT 0 2 Undefined   
245 748 GCA 1 0 0   
246 751 GGA 0 0 Undefined   
247 754 ACG 1 0 0   
248 757 AGC 1.6667 6.3333 0.8   
249 760 AAT 0 3 Undefined   
250 763 GCT 1 1 0.4   
251 775 GAC 2 3 0.4   
252 781 AAA 1 0 0   
253 784 AAT 0 0 Undefined     
254 787 GCT 2 0 0     
255 790 ACG 1 0 0     
256 793 ATC 0 0 Undefined     
257 796 AAC 1 0 0     
258 799 TAT 2 0 0     
259 802 CAT 1 0 0     
260 805 GAG 1 0 0   
T cell epitope 3 
261 808 TGG 0 0 Undefined   
262 811 CAA 0 0 Undefined   
263 814 GTT 0 0 Undefined   
264 817 GGT 0 0 Undefined   
265 820 GCA 0 0 Undefined   
266 823 GCT 2 0 0   
267 826 TTG 0 0 Undefined   
268 829 TCT 0 0 Undefined   
269 832 TAT 2 0 0   
270 835 AGG 0 0 Undefined   
271 838 CTC 0 0 Undefined   
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Codon 
number 
Codon 
Start Triplet Syn (s) Nonsyn (n) dN/dS  
B cell 
epitope T cell epitope 
272 841 AAT 1 0 0   
273 844 ATG 0 0 Undefined   
274 847 CTT 2 0 0   
275 850 GTT 1 2 0.9     
276 853 CCG 2 0 0     
277 856 TAC 2 0 0     
278 859 ATC 2 0 0     
279 862 GGC 2 0 0     
280 865 ATT 1.5 2.5 0.6     
281 868 CAG 1 0 0     
282 871 TGG 0 0 Undefined     
283 874 TCT 2 0 0     
284 877 AGA 0 0 Undefined     
285 880 GCT 0 0 Undefined     
286 883 ACC 2 1 0.3     
287 886 TTC 2 0 0     
288 889 GAT 0 0 Undefined     
289 892 GCA 1 0 0     
290 895 GAT 1 0 0     
291 898 ACT 1 0 0   
T cell epitopes 9 
and 10 
(overlapping) 
292 901 ATC 1 0 0   
293 904 CAA 0 0 Undefined   
294 907 ATT 0 0 Undefined   
295 910 GCG 2 0 0   
296 913 CAG 1 0 0   
297 916 CCA 0 0 Undefined   
298 919 AGA 0 1 Undefined   
299 922 TTA 5 0 0   
300 925 GCT 1 0 0   
301 928 TCG 0 0 Undefined   
302 931 ACT 1 1 0.5   
303 934 ATC 2 1 0.2   
304 937 TTC 2 1 0.1   
305 940 TAT 1 1 0.2   
306 943 CTA 3 1 0.2   
307 946 ACT 1 0 0   
308 949 ACG 2 0 0   
309 952 TGG 0 0 Undefined   
310 955 AAT 3 0 0   
311 958 CCT 3 0 0   
312 961 ACA 2 0 0     
313 964 TTA 2 0 0 
B cell 
epitope 6 
  
314 967 TTG 5 0 0   
315 970 GGA 2 0 0   
316 973 GAA 0 2 Undefined   
317 976 AGA 2 4 1.0   
318 979 ACA 1 0 0   
319 982 TCA 0 5 Undefined   
320 985 GGA 0 3 Undefined   
321 988 ACA 1.3333 7.6667 1.0   
322 997 GAC 0 3 Undefined   
323 1000 CAA 2 1 0.1   
324 1003 TAT 0 2 Undefined 
T cell epitopes 4 
and 5 
(overlapping) 
325 1006 GCT 0 0 Undefined   
326 1009 GAC 1 1 0.1   
327 1012 TCC 1.8333 3.1667 0.8   
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Codon 
number 
Codon 
Start Triplet Syn (s) Nonsyn (n) dN/dS  
B cell 
epitope T cell epitope 
328 1015 CTA 1 0 0   
329 1018 CAA 0 0 Undefined   
330 1021 ATT 1 0 0   
331 1024 GTT 0 0 Undefined   
332 1027 TCT 0 0 Undefined   
333 1030 CTT 0 0 Undefined   
334 1033 CAA 0 0 Undefined   
335 1036 ATT 0 0 Undefined   
336 1039 AAC 0 0 Undefined   
337 1042 AAA 0 0 Undefined   
338 1045 TTG 0 0 Undefined   
339 1048 AAG 0 0 Undefined   
340 1051 TCT 1 0 0     
341 1054 AGA 0 0 Undefined     
342 1057 AAA 0 0 Undefined     
343 1060 GCT 0 0 Undefined     
344 1063 TGT 0 0 Undefined     
345 1066 GGT 0 0 Undefined     
346 1069 GTT 0 0 Undefined     
347 1072 TCC 0 0 Undefined     
348 1075 ATG 0 0 Undefined     
349 1078 GGA 0 0 Undefined     
350 1081 GCA 0 0 Undefined     
351 1084 ACT 0 0 Undefined     
352 1087 TTA 0 0 Undefined     
353 1090 CTT 0 0 Undefined     
354 1093 GAT 0 0 Undefined     
355 1096 GCC 1 0 0     
356 1099 GAT 0 0 Undefined     
357 1102 AAA 0 0 Undefined     
358 1105 TGG 0 0 Undefined     
359 1108 GCA 0 0 Undefined     
360 1111 ATC 0 0 Undefined     
361 1114 AAT 0 0 Undefined     
362 1117 GGA 0 0 Undefined     
363 1120 GAG 0 0 Undefined     
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4.2 INTRODUCTION 
The koala (Phascolarctos cinereus) is a native Australian arboreal marsupial and the 
only surviving member of the family, Phascolarctidae. Despite its position as an 
icon of the unique biodiversity in this country, wild koala populations in 
geographically dispersed regions throughout Australia continue to experience serious 
declines in numbers, leading to localised extinctions. The rapidity of this decline can 
be attributed to anthropogenic influences [1] such as (i) land clearing and loss of 
habitat, resulting in the fragmentation of koala colonies [2]; (ii) motor vehicle trauma 
[3]; and (iii) dog attacks [1]. Disease is also a major cause of mortality in the koala. 
Indeed, a recent modelling study showed that targeting disease, among the many 
variables adversely affecting koala survival would have the greatest potential impact 
on stabilising population decline [4].   
The main aetiological agents of disease in the koala belong to the family 
Chlamydiaceae, obligate intracellular bacteria and pathogens of both humans and 
animals. The Chlamydiae have been the subject of some taxonomic confusion over 
the past 10 years. In 1999 [5], proposed a new chlamydial taxonomy based on two 
genera, Chlamydia and Chlamydophila, and nine species. Whilst this new taxonomy 
was used by some Chlamydiologists, it was not widely accepted or adopted [6]. This 
taxonomic confusion was finally resolved in 2011 with the publication of Volume 4 
of the 2nd Edition of Bergey’s Manual of Systematic Bacteriology which describes 
one species, Chlamydia and nine species. In this report we will therefore use the 
single genus Chlamydia, to refer to Chlamydia pecorum and Chlamydia pneumoniae, 
rather than the Chlamydophila taxonomy. C. pneumoniae is a cause of atypical 
pneumonia in humans [7] and is associated with disease in a range of animal host 
species including the koala [8]. C. pecorum is primarily an animal pathogen and a 
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cause of disease in cattle, sheep, pigs and wildlife, such as the koala [9]. C. 
pneumoniae and C. pecorum have been detected in most wild koala populations 
screened with C. pecorum found to be significantly more widespread and the more 
pathogenic of the two species [10,11]. In the koala host, chlamydial infections have 
been associated with a spectrum of diseases ranging from ocular disease leading to 
blindness, rhinitis and pneumonia, as well as urinary and genital tract disease, 
resulting from inflammation and fibrosis of the bladder and the upper female genital 
tract [12]. Whilst human chlamydial infections can be treated with antibiotics, this is 
not a preferred option available for eliminating disease in wild koala populations 
[13,14]. An effective vaccine to prevent the adverse consequences of chlamydial 
infections in koalas would provide an important management tool to stop the 
population decline in this species.  
MOMP encoded by the ompA gene and conserved across the members of the 
Chlamydiaceae, is a highly immunogenic protein and the leading vaccine antigen 
candidate for both human and animal chlamydial vaccines [15]. Despite this, 
vaccination with MOMP does have its challenges; primary amongst these is that the 
surface-exposed variable domains of human C. trachomatis MOMP are genetically 
diverse, as a consequence of immune selection. As such, in human C. trachomatis 
vaccination models, immunization with MOMP from one serovar will only elicit 
protection against the same and closely related serovars [16]. A possible solution to 
this problem would be to include other antigens that are conserved across 
serovars/genotypes of C. trachomatis (or C. pecorum), together with MOMP, in a 
multi-subunit vaccine. This approach has been shown, in a number of studies using 
the mouse model, to provide enhanced protection against infection with C. 
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muridarum or C. trachomatis, and in some studies this approach even provided 
protection against heterologous serovars [17-19].  
In a first step to evaluate the feasibility of a chlamydial vaccine in the koala, our 
group recently evaluated the immunological response of healthy koalas to a multi-
subunit chlamydial vaccine, derived from non-koala chlamydial species [20]. In 
contrast to earlier reports suggesting that the koala was ‘immunologically lazy’ [21], 
we observed high levels of antigen-specific peripheral blood mononuclear cell 
(PBMC) proliferation (lasting >1 year) and sustained plasma antibody levels against 
three antigens, including MOMP, in immunized animals. Importantly, koala IgG 
antibodies were able to inhibit in vitro infection of McCoy cells with C. muridarum 
(80-90% inhibition at a 1:10 dilution), the strain from which MOMP was derived 
and, also partially neutralized in vitro infectivity of a koala strain of C. pneumoniae 
(30-40%), suggesting some cross-reactivity with the C. pneumoniae species.  
Whilst these results are very encouraging, the study was performed in healthy, 
Chlamydia-free koalas and utilized chlamydial antigens from chlamydial species that 
do not infect koalas. Therefore, questions remain about (1) the safety and 
immunological response to vaccination in animals with evidence of a previous or 
ongoing chlamydial infection and (2) the choice of the vaccine antigens themselves. 
In regards to the latter question, the main antigen used in our previous trial was 
MOMP. Molecular analyses of koala C. pecorum MOMP-encoding ompA gene 
sequences from geographically distinct wild koala populations has revealed extensive 
sequence diversity (10 – 30%) amongst the surface-exposed variable domains of this 
protein [11,22,23], similar to that seen for C. trachomatis serovars [24]. Because of 
this diversity it is unlikely that a vaccine based on a single C. pecorum MOMP 
would provide protection across the genetically diverse and distinct C. pecorum 
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strains detected in wild koalas. A possible solution to this problem is the addition of 
MOMP from other C. pecorum strains or other antigens that are conserved across 
multiple koala isolates. 
In the present study, to address these important questions, we immunized healthy 
koalas as well as koalas with clinically significant ocular or urogenital tract disease 
with a multi-subunit vaccine containing a single koala C. pecorum MOMP genotype 
together with NrdB, an antigen highly conserved across all chlamydial species. By 
closely monitoring the (i) clinical health of the animals, (ii) the antibody-based 
immunological response of vaccinated animals, (iii) the cross-reactivity of koala 
antibodies to different MOMP genotypes, and (iv) lymphocyte proliferation against 
vaccine candidates, we show that koala vaccination is safe and induces an immune 
response that may provide ongoing protection from natural C. pecorum infections in 
the future.  
4.3 MATERIALS AND METHODS 
Koala C. pecorum strains used in the study 
Four strains of koala C. pecorum were used in this study. All strains came from wild 
koala populations in South East Queensland, Australia, that were sampled as part of 
other studies [23]. Swab samples were collected from either the urogenital tract or 
conjunctiva of koalas showing clinical signs of chlamydial disease, and were tested 
by a C. pecorum-specific PCR assay [25]. Genomic DNA extracted from positive C. 
pecorum swab samples was amplified by a PCR that targets the full-length ompA 
gene. The products were sequenced and then assigned an ompA genotype. For this 
purpose, ompA genotypes originally designated in [22], were used as the starting 
point. For newly detected C. pecorum strains, an ompA sequence that had more than 
1% base pair differences to previously designated genotypes was assigned a new 
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genotype. The four strains that were selected for this study represent different ompA 
genotypes: genotype A (Ipswich/Tabi/LE; geographical location/koala name/left 
eye), genotype F (Nar/DeeDee/UGT), genotype G (Mt.Cotton/MarsBar/UGT), 
genotype H (Coomera/Ned/UGT). 
Production of recombinant MOMP and NrdB proteins for vaccination 
E. coli strains JM109 and BL21 (DE3) pLysS competent cells were used for 
molecular cloning and protein expression and purification, respectively. E. coli 
strains transformed with the respective expression constructs were grown in Luria-
Bertani broth (LB; 10 g tryptone, 5 g yeast extract, 10 g NaCl per L), containing 75 
ug/ml ampicillin, at 37°C with constant shaking. E. coli cell growth in liquid media 
was assessed by measuring OD600. Koala C. pecorum NrdB and four genetically 
distinct koala C. pecorum MOMPs (A, F, G and H) were PCR-amplified, cloned, 
expressed and purified for use in the vaccine trial. The full-length nrdB gene was 
PCR amplified using primers NrdBXhoI (5’–
TTTTCTCGAGAAAGCAGATATTCTCAGTGG-3’) and NrdBKpnI (5’– 
TTTTGGTACCTTACCAACTCAAACTTGCCG – 3’) and Vent DNA polymerase 
(New England Bioscience) from C. pecorum genotype G (Mars Bar isolate) DNA 
template. Truncated ompA genes for each C. pecorum MOMP genotyped strain, 
excluding the N-terminal signal peptide sequence, were similarly amplified using 
primers OmpAXhoI (5’–AAAAACTCGAGTTGCCTGTAGGGAACCC–3’) and 
OmpAKpnIn (5’ – AAAAAGGTACCTTAGAATCTGCATTGAGCAG – 3’). Each 
PCR product was amplified to generate PCR products with 5’ – XhoI and 3’ – KpnI 
restriction sites and were ligated into a N-terminal polyhistidine (His) pRSET-A 
expression vector (Invitrogen), following XhoI/KpnI double digestion, which was 
similarly digested. His-tag expression constructs were transformed into BL21 (DE3) 
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pLysS competent E. coli cells and grown in LB media with 100 ug/mL ampicillin at 
37°C. At an OD600 of 0.4 – 0.6, His-tagged protein expression was induced by the 
addition of 1 mM IPTG for 4 h. Cells expressing recombinant C. pecorum MOMP 
were harvested by centrifugation and resuspended in lysis buffer I (50 mM phosphate 
buffer pH 7.0, 8M urea, 2 mM PMSF, 50 uL Protease Inhibitor Cocktail (Sigma) and 
1 mg/mL lysozyme). Lysed cells were incubated with TALON metal affinity resin 
(Clontech) at 4 °C for 1 h with gentle mixing. Resin was then repeatedly washed 
with wash buffer I (50 mM phosphate buffer pH 7.0, 300 mM NaCl, and 8M urea) 
and protein was eluted with elution buffer I (50 mM phosphate buffer pH 7.0, 300 
mM NaCl, 150 mM imidazole and 8M urea) by centrifugation. 
Cells expressing recombinant C. pecorum NrdB were harvested by centrifugation 
and resuspended in lysis buffer II (50 mM phosphate buffer pH 7.0, 2 mM PMSF, 50 
uL Protease Inhibitor Cocktail (Sigma) and 1 mg/mL lysozyme) and lysed by 
repeated freeze/thawing. Lysed cells were incubated with TALON resin at 4 °C 
overnight with gentle mixing. Resin was repeatedly washed by gravity-flow with 
wash buffer II (50 mM phosphate buffer pH 7.0, 500 mM NaCl, 5 mM imidazole and 
0.1 % Triton X-100) before being eluted with elution buffer II (50 mM phosphate 
buffer pH 7.0, 500 mM NaCl, 150 mM imidazole).  
Purified protein samples were dialysed into PBS and recombinant protein yield 
determined by the Bicinchoninic Acid (Thermo Fisher Scientific, Australia) method 
using an ovalbumin standard curve as a control. Purified protein samples were 
resolved on 12 % SDS-PAGE gels and detected following Coomassie blue staining 
and Western blotting (after transfer to nitrocellulose) with a monoclonal anti-His 
antibody (Sigma-Aldrich, Castle Hill, Australia). Purified recombinant C. pecorum 
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proteins were used for (a) koala immunizations, (b) ELISA assays, (c) Western blot 
assays and lymphocyte proliferation assays. 
Experimental groups of koalas and immunization schedule 
22 wild koalas admitted to the Australia Zoo Wildlife Hospital (Beerwah, 
Queensland) for treatment of a variety of afflictions, were used for this study. The 
koalas were assigned into two groups. Group A (A1, A2 and A3) were free of 
clinically detectable chlamydial disease and negative to C. pecorum - specific 16S 
rRNA quantitative PCR (qPCR) and serological assays. Group B animals (B1 and 
B2) showed clinical evidence of classic chlamydial disease and positive results to our 
C. pecorum-specific 16S rRNA qPCR and serological tests. For the purposes of this 
study, the classic chlamydial disease signs were kerato-conjunctivitis and/or 
cytological or sonographic evidence of urogenital tract disease (prostatitis [males] 
and metritis/ovarian bursitis [females] and/or cystitis [both sexes]).  After admission 
to the wildlife hospital, each koala received a thorough veterinary health assessment 
and was treated for their respective conditions. Koalas were only recruited into the 
vaccine trial on completion of treatment. Koalas with chlamydiosis were treated with 
parenteral chloramphenicol and adjunctive therapies as prescribed by the consulting 
veterinarian. At the time of recruitment into the trial, the koalas were deemed, by the 
respective consulting veterinarians, to have completed their treatment and be suitable 
for release.  
The 18 koalas recruited for the main trial (given three doses of either vaccine or 
placebo) were divided into 4 groups (Table 1): (A1) No detectable clinical signs of 
chlamydial disease on admission to hospital and receiving the vaccine (4 koalas); 
(A2) No clinical disease on admission but receiving the placebo (2 koalas); (B1) 
Showing signs of clinical disease on admission and receiving the vaccine (8 koalas); 
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(B2) Showing signs of clinical disease on admission but receiving the placebo (4 
koalas). 
Table 1. List of all koalas in the vaccine trial. Group A includes healthy, qPCR and serologically 
negative animals, further divided into A1 (three shot vaccine), A2 (placebo) and A3 (two shot 
vaccine). Group B includes diseased, qPCR and serologically positive animals, further divided into B1 
(vaccine) and B2 (placebo). 
 
Group Immunization 
Number 
of 
animals 
Clinical signs 
of disease at 
start of trial 
Koala Identifiers 
A1 Vaccine (3 Shot) 4 No Whistler/Cedar/Lilly/Alfreda 
A2 Placebo (3 Shot) 2 No AriBruce/Captain 
A3 Vaccine (2 Shot) 4 No Sam/Satchmo/Ben/Mia 
B1 Vaccine (3 Shot) 8 Yes 
Romeo/Maggie/Nixon/FelixPitt/Mitchy/P
opeye/Wylie/Meryl 
B2 Placebo (3 Shot) 4 Yes Katey/Juliette/Kathy/Thompson 
In a parallel sub-study we compared immunization of healthy animals with three 
doses (above animals, group A1) to immunization with two doses of vaccine. These 
additional four koalas were assigned to group A3 and had no clinical disease on 
admission. 
Animals receiving three subcutaneous immunizations were vaccinated on days 0, 28 
and 56. The two-dose group received subcutaneous immunizations on days 0 and 56.  
Each dose of vaccine consisted of 50 µg of recombinant genotype G MOMP protein, 
50 µg of recombinant G NrdB protein mixed with 50 µg Immuno Stimulating 
Complex (ISC, Pfizer Animal Health) in 0.5 mL PBS. Animals in placebo groups 
received ISC alone.   
Sample collection 
Each of the koalas was anaesthetised for veterinary assessment and samples collected 
on day zero, and then at monthly intervals five additional times.  A 10 ml sample of 
 Chapter 4: Vaccination of healthy and diseased koalas (Phascolarctos cinereus) with a Chlamydia pecorum multi-
subunit vaccine: evaluation of immunity and pathology. 119 
blood was collected into a blood tube containing the anticoagulant lithium heparin. 
The blood samples were stored at 4 °C until further processing occurred later in the 
day.  Swabs were collected from each of the following sites using aluminium-shafted 
cotton-tipped swabs (Copan; Interpath Services, Melbourne): left conjunctiva, right 
conjunctiva and urogenital sinus (females) or urethra (males). All the swabs were 
stored at -80 °C in 0.5 ml PBS and 1mM Phenylmethanesulphonyl fluoride (PMSF) 
cocktail. 
Scoring of clinical disease 
During general anaesthesia at each sampling event, each koala was also subjected to 
a thorough veterinary health assessment, which included sonographic examination of 
the urinary and reproductive tracts, close examination of the eyes, and urinalysis, 
including microscopic examination of urine sediment. Clinical assessment included 
measurement of packed cell volume (PCV) and total plasma protein (TPP) and 
microscopic examination of a Diff Quick stained blood smear.  
Chlamydial disease signs present at ocular and urogenital tract sites were scored for 
each koala using specific criteria. Scoring for ocular and urogenital tract was done on 
a 0 – 3 scale. At the ocular site, koalas with no detectable disease were assigned as 0; 
1 - animals with acute/sub-acute kerato-conjunctivitis; 2 – koalas with chronic 
kerato-conjunctivitis without evidence of disease; 3 – koalas with chronic, active 
kerato-conjunctivitis, characterised by active disease. At the urogenital tract, animals 
with no detectable disease were assigned 0; 1 – koalas with acute or sub-acute 
cystitis; 2 – chronic, inactive cystitis and; 3 – koalas with chronic, active cystitis. To 
ensure consistency, all clinical assessments were carried out by the same experienced 
veterinary staff.  At the time of clinical assessments, veterinary staff was kept blind 
regarding the groupings of the animals into vaccine or placebo groups.  
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Prior to recovery from anaesthesia, vaccinations or placebos were administered by 
subcutaneous injection over the right thorax caudal to the right elbow. Following 
vaccination, koalas were monitored closely by hospital staff for signs of swelling at 
vaccination sites or systemic reactions to vaccination for 48 hours post vaccination. 
Determination of C. pecorum infection status in vaccine trial animals 
Apart from the scoring system mentioned above, we assessed the disease status with 
C. pecorum 16S rRNA gene specific qPCR [25] on pre-immunization swabs and 
MOMP immune blots using pre-immunisation sera from all the animals in the trial. 
Measurement of anti-MOMP and anti-NrdB antibody responses 
Enzyme-linked immunosorbent assay (ELISA) 
ELISA’s were performed as per Carey et al. [20] except for using host specific C. 
pecorum MOMP G and NrdB as antigens. 
Western blot 
Western blots were performed with recombinant C. pecorum His-tagged MOMP A, 
F, G and H as antigens. 5 µg aliquots of each of the antigens were loaded onto 0.75 
mm wide 12 % SDS-PAGE gels (110 V for 1 hr). Following transfer onto 
nitrocellulose membranes (Pall Corporation, Australia) at 90 V for 1 hr, membranes 
were blocked for non-specific binding in blocking buffer (5 % Skim milk in 1xTBS) 
overnight at 4 ˚C or for 2 hrs at room temperature. Post blocking, plasma samples 
were added on to the membrane at 1:1000 dilutions in blocking buffer and incubated 
overnight at 4 ˚C or 2 hrs at room temperature. Membranes were then washed 4x 
with 1xTBS-T for 5 min each. Secondary antibody (anti-koala IgG raised in sheep) 
was added at 1:1000 dilution in blocking buffer and incubated for 1 hr at room 
temperature. Membranes were again washed 4x with TBS-T for 5 min each. Finally, 
tertiary antibody (anti sheep IgG-HRP raised in rabbit; Southern Biotech/ Invitro 
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Technologies, Cleveland, Australia) was added onto the membranes at 1:1000 in 
blocking buffer for 1 hr at room temperature. Membranes were then washed 5x with 
TBS-T for 5 min each. Blots were visualised for bands by adding Enzymatic 
Chemiluminescence substrate (Thermo Fisher Scientific, Australia).    
In vitro neutralization assay  
HEp-2 cells were seeded in 48 well plates (Greiner bio one; Interpath, West 
Heidelberg, Australia) and grown overnight until 70-80 % confluent. C. pecorum 
genotype G purified EBs (50,000 IFU) were added to the plasma samples (diluted 
1:10 in cell culture medium) and incubated for 1 hr at 37 ˚C under 5% CO2. Medium 
was removed from the HEp-2 monolayers and replaced with plasma samples and 
incubated for 4 hrs. Post incubation, samples were replaced with fresh media 
containing 1 µg/ml cycloheximide (Sigma-Aldrich, Castle Hill, Australia). Cells 
were further incubated for 48 hrs and then fixed with 100 % methanol. Monolayers 
were initially stained with anti-chlamydial EB raised in rabbit for 1 hr followed by 
washing and then incubated with goat anti-rabbit IgG BIOT (Southern Biotech/ 
Invitro Technologies, Cleveland, Australia). Wells were washed with 4x TBS-T and 
then stained with Strepatavidin-HRP (Southern Biotech/ Invitro Technologies, 
Cleveland, Australia). Finally, the monolayers were stained with 3, 3’-
Diaminobenzidine (DAB; Thermo Fisher Scientific, Australia), prepared in stable 
peroxide substrate buffer (Thermo Fisher Scientific, Australia). Both cells and 
inclusions were counted under the microscope and a mean of 10 fields of view for 
each well were counted and the neutralization percentage determined compared to 
media only controls.  
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Measurement of anti-MOMP and anti-NrdB lymphocyte proliferation response 
Blood samples were centrifuged at 233xg (Beckman Coulter Allegra X-15R) for 5 
min. Plasma was frozen for further studies at -80 ˚C. 10 ml of 1x PBS was used to 
dilute and resuspend the blood cells, which were mixed thoroughly. The cell 
suspension was then carefully layered onto a 10 ml Ficoll-PaqueTM PREMIUM (GE 
Healthcare, Rydalmere, Sydney) and centrifuged at 650xg for 25 min with the brake 
off. PBMC’s were isolated from the buffy coat interface and suspended in a fresh 
tube containing 20 ml 1x PBS. Cells were further washed two times with 1x PBS at 
400×g for 10 min and counted. Cells were suspended at 2x106 cells/ml in PBS 
containing 5 % fetal calf serum. Carboxyfluorescein succinimidyl ester (CFSE; 
Sigma-Aldrich, Castle Hill, Australia) was used at 5 µM to label the cells, which 
were incubated for 5 min in the dark. Cells were then washed two times with cold 1x 
PBS containing 5 % fetal calf serum (Southern Biotech/ Invitro Technologies, 
Cleveland, Australia) to quench the excess dye. Finally, the cell pellet was suspended 
in culture medium (RPMI 1640 containing 5 % fetal calf serum, 2 mM L-glutamine, 
10 mg/ml streptomycin sulphate, 2 μg /ml gentamycin and 50 μM 2-β-
mercaptoethanol). A 1:1 mixture of cells (2x105) and antigens (8 μg of C. pecorum 
recombinant MOMP and recombinant NrdB) were added into 96 well flat bottom 
plates (In Vitro Technologies, Noble Park North, Australia). Concanavalin A (Sigma-
Aldrich, Castle Hill, Australia) at a concentration of 2.5 µg/ml was used as a positive 
control and culture media with labelled cells were used as negative controls. Plates 
were then incubated for 5 days at 37 ˚C in 5% CO2.  After 5 days, cells were washed 
in 1x PBS and then fixed in 4 % paraformaldehyde and stored in the dark at 4 ˚C 
until analysis. Estimation of PBMC’s proliferation was performed using a Beckman 
Coulter flow cytometer (FC500, Gladesville, NSW) and analysed using FlowJo 
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software (Tree Star Inc., Oregon). Proliferation was expressed as the % of PBMC 
that had undergone two or more cell divisions.  
Statistics 
All statistical analyses were performed using Graph-Pad Prism version 5 (Graph Pad 
Software, LaJolla, CA, USA). Group A1, A3 and B1 data presented are the mean of 
4, 4 and 8 koalas, respectively (± SE of the mean). Two-way ANOVA with 
Bonferroni’s Post test with the P value set at < 0.05 was used to analyse the antibody 
titers in plasma and conjunctival swab samples. In vitro neutralization and PBMC 
proliferation studies were analysed using unpaired t-tests with the P value set at < 
0.05. 
4.4 RESULTS 
 
Evaluation of vaccine safety in healthy and diseased koalas 
None of the koalas showed any adverse signs immediately after immunization or 
when observed for the following 48 h. Furthermore, no koalas showed evidence of 
swelling or abscess formation at the vaccination site at subsequent monthly 
veterinary examinations up to 140 days (20 weeks) when the study was terminated.  
Evaluation of clinical disease in vaccinated, diseased and healthy koalas 
Table 2 shows the clinical disease score for each vaccinated animal (vaccine versus 
placebo groups) following vaccination. Nine of the 12 Group B animals did not show 
any worsening of their clinical disease score when observed for up to 140 days 
following vaccination. Three koalas, all of which had cystitis, demonstrated 
progressive worsening of sonographic findings, specifically, increasing bladder wall 
thickening and persistent haematuria on at least one evaluation. Two of these 
received the placebo (three dose regime) while one received the vaccine.  
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Table 2. Clinical disease score for all the group B (diseased) animals up to 20 weeks. (* Worsening of lesions during the trial) 
Animal 
Identifier 
Complication/Site of 
Infection Day 0 Day 28 Day 56 Day 84 Day 112 Day 140 
Change in 
disease 
score at the 
end of the 
trial  
(20 weeks 
(+/-)) 
Average 
change 
Group B1(Vaccine) 
  
Romeo Conjunctivitis/Right Eye 3 3 2 2 2 2 -1   
Nixon Conjunctivitis/Left Eye 2 2 2 0 0 0 -2   
Popeye Conjunctivitis/Left Eye 3 3 3 3 3 2 -1   
Felix Pitt Conjunctivitis/Both Eyes 2 2 2 2 2 2 0 -0.74 
Maggie Cystitis/Urogenital tract 2 2 2 0 0 0 -2   
Wylie Cystitis/Urogenital tract 3 3 3 3 3 3 0   
Meryl Cystitis/ Urogenital tract 2 2 2 2 2 2 0   
Mitchy* Cystitis/ Urogenital tract 2 2 3 2 2 2 0   
Group B2 (Placebo) 
  
Katey* Cystitis/ Urogenital tract 3 3 2 2 3 3 0   
Kathy* Cystitis/ Urogenital tract 2 3 3 3 3 3 1   
Juliette Cystitis/ Urogenital tract 2 2 2 2 2 2 0 0.25 
Thompson Conjunctivitis/Left Eye 2 2 2 2 2 2 0   
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Vaccination elicits MOMP-specific IgG in healthy animals and boosts pre-
existing immunity in diseased animals 
Figure 1 demonstrates the enhancement of MOMP G IgG titers in healthy and 
diseased animals, following vaccination. Groups A1 (healthy animals, vaccine x3) 
and B1 (disease positive, vaccine x3) had developed strong plasma MOMP G IgG 
antibodies (Fig. 1A and B). Group B1 animals had clinical signs of chlamydial 
disease on entry into the trial and not surprisingly therefore had pre-existing low anti-
Chlamydia antibody levels on day 0 at both systemic and mucosal sites. In plasma, 
similar kinetics were observed in both the groups against MOMP G i.e. both the 
groups reached an end point titre (EPT) of 1 x 105 by day 84, which started to plateau 
beyond 20 weeks. At the ocular site (Fig. 1C and D), group A1 animals had minimal 
antibodies on day 0 and reached an EPT of 3 x 102 by day 140. However, B1 animals 
started with 1.6 x 102 EPT and reached a peak of 5 x 102 EPT by day 140. In both 
groups, vaccination induced a significant increase in MOMP IgG in plasma and 
secretions that was sustained out to day 140. 
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Fig. 1. MOMP G antibody titres (IgG) in plasma and ocular swabs following 
vaccination in groups A1 (healthy animals) (A and C) and B1 (diseased animals) (B 
and D). n = 4 animals in group A1 and 8 animals in group B1 at each time point. 
Two-way ANOVA was performed with Bonferroni's post tests. Error bars represent 
SE. *P, 0.01–0.05; **P, 0.001–0.01; ***P < 0.001. 
Figure 2 shows the enhancement of NrdB IgG titers in healthy and diseased animals. 
Although both the vaccine groups showed strong enhancement of NrdB antibodies in 
plasma from day 0, interestingly group A1 animals only reached an EPT of 3 x 104, 
whereas B1 animals reached its peak of 8 x 104 EPT by day 112 and dropped down 
later (Fig. 2A and B). At ocular sites, group A1 reached its peak of 3 x 102 EPT by 
day 112, whereas group B1 animals showed significant titers only from day 84 and 
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reached a similar EPT to that in A1 animals by day 140 (Fig. 2C and D). Both 
MOMP G and NrdB antibodies for the two groups at both sites were statistically 
significantly higher by the end of the trial (20 weeks) with a P value set at 0.05.  
 
Fig. 2. NrdB antibody titres (IgG) in plasma and ocular swabs following vaccination 
in groups A1 (healthy animals) (A and C) and B1 (diseased animals) (B and 
D). n = 4 animals in group A1 and 8 animals in group B1 at each time point. Two-
way ANOVA was performed with Bonferroni's post tests. Error bars represent SE. 
*P, 0.01–0.05; **P, 0.001–0.01; ***P < 0.001. 
Specificity of the antibody response following vaccination 
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Figure 3 shows immunoblot analysis of the immune-reactivity of plasma from 
vaccinated animals (all vaccinated using genotype G MOMP protein) against 
recombinant MOMP proteins of C. pecorum genotypes A, F, G and H. Animals 
given the placebo (groups A2 and B2) did not develop any new antibody response 
that was not present on day 0 of the trial, as expected. Group A1 animals (disease-
free, vaccinated with genotype G MOMP) had developed antibodies by day 140 that 
recognised all four MOMP types. Group B1 animals (disease-positive) were all 
infected with genotype F C. pecorum, (data not shown) except one animal, which 
had a genotype G infection, prior to the start of the trial. Following immunization, 
these animals also developed antibodies that recognised all four MOMPs (A, F, G 
and H). Given that the recombinant MOMP G used for vaccination was a His-tagged 
protein and the genotype A, F and H MOMPs used in the Western blot were also 
His-tagged proteins, a potential explanation for these results could be that the 
immunized animals produced a strong antibody response against the His tag common 
to all MOMPs and that the immunoassay is detecting reactivity against this tag rather 
than the MOMP itself. To rule out this possibility, we blotted day 140 plasma from 
animals in Group B1 against a Legionella TSP His-tagged protein (provided by 
Ms.Amba Lawrence/Dr.Willa Huston). As can be seen in Figure 3, plasma from 
MOMP G-immunized koalas had no reactivity against this non-chlamydial his-
tagged protein. 
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Fig. 3. Immunoblot analysis of the specificity of post immunized plasma to various 
rec MOMP genotypes from animals belonging to various groups A1 + A3, A2, B1 
and B2 (representative blots shown); and false positive check with an anti-his blot 
against non chlamydial his-tagged protein. 
 
Development of plasma neutralizing antibodies following vaccination 
The percentage of in vitro neutralizing antibodies against C. pecorum genotype G 
was determined in the plasma samples (1/10 dilution) collected at day 0 and day 140. 
Plasma collected from each individual animal on day 0 of the vaccine trial was used 
as controls. All samples on days 0 and 140 were normalised to no plasma (infection 
only) controls. As shown in Figure 4, plasma from groups B1, A1 and A3, all 
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immunized with MOMP G plus NrdB, had a significantly enhanced percentage of in 
vitro neutralizing antibodies compared to the relevant placebo control plasma 
(groups A2 and B2). Neutralizing activity against the immunising genotype G was 
significantly higher in animals that were disease free (A1) compared to animals that 
had a previous C. pecorum infection (B1, p<0.05).  
 
Fig. 4. Percentage of vaccine induced in vitro neutralization against C. 
pecorum genotype G infection in the plasma at 20 weeks post first immunization. 
Plasma on day 0 was used as a pre-immunized control. (A) Healthy animal's vaccine 
groups (A1) vs. Placebo group (A2). (B) Diseased animal's vaccine group 
(B1) vs. Placebo group (B2). Unpaired t-tests were performed to determine the 
significance of differences between the groups at 20 weeks post vaccination. Error 
bars represent SD. *P, 0.01–0.05; **P, 0.001–0.01; ***P < 0.001. 
 Chapter 4: Vaccination of healthy and diseased koalas (Phascolarctos cinereus) with a Chlamydia pecorum multi-
subunit vaccine: evaluation of immunity and pathology. 131 
 
 
Development of lymphocyte proliferation responses following vaccination 
To assess the cell-mediated immune response following immunization, PBMC were 
collected on day 140 and labelled with CFSE. Proliferation was determined by dye-
dilution assay following in vitro stimulation with MOMP G and NrdB as shown in 
Figure 5. Around 20 % of PBMC’s in immunized healthy (Group A1) and 15 % in 
immunized diseased (Group B1) underwent two or more rounds of division 
following in vitro antigen stimulation. Cell proliferation (3 %) was also evident in 
the placebo control groups (A2 and B2). The results for both vaccine groups were 
statistically significant (p < 0.05) compared to their respective placebo groups. 
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Fig. 5. CFSE labelled lymphocyte proliferation assay (CLPA) using PBMC 
stimulated with respective antigens (8 μg/well) in all the animals, expressed as 
percentage of proliferating cells. (A) Healthy animal's vaccine groups 
(A1) vs. Placebo group (A2). (B) Diseased animal's vaccine group (B1) vs. Placebo 
group (B2). Unpaired t-tests were performed to determine the significance of 
differences between the groups at 20 weeks post vaccination. Error bars represent 
SD. *P, 0.01–0.05; **P, 0.001–0.01; ***P < 0.001. 
 
Comparison of two versus three immunizations for the development of anti-
Chlamydia immune responses      
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Because immunization of wild koalas will likely involve capture and release, which 
are both costly and traumatic for the animals, we compared immune responses in 
animals immunized three times on days 0, 28 and 56 with animals immunized twice 
on days 0 and 56. As can be seen in Figure 6, MOMP-specific antibody in plasma 
was higher in animals immunized three times at day 84 compared to those 
immunized twice (Fig. 6A), however, similar EPTs were seen in both groups at day 
140 when the experiment was terminated. NrdB-specific antibody EPTs in plasma 
were significantly lower than MOMP-specific EPTs, however, at day 140 there was 
no difference in the EPT between animals immunized two and three times (Fig. 6B). 
Similar EPTs against both antigens were also seen in ocular swab secretions in 
animals immunized two and three times (Fig. 6C and D). Importantly, when plasma 
from both groups of animals were assayed for in vitro neutralizing activity against 
genotype G C. pecorum, there was no significant difference in activity between 
animals immunized with the different schedules (Fig. 6E). The percent of PBMCs 
induced to proliferate following in vitro stimulation with MOMP plus NrdB was also 
equivalent in animals immunized either two or three times (Fig. 6F).  
 Chapter 4: Vaccination of healthy and diseased koalas (Phascolarctos cinereus) with a Chlamydia pecorum multi-
subunit vaccine: evaluation of immunity and pathology. 134 
 
Fig. 6. Antibody titres (IgG) in plasma and ocular swabs following vaccination in 
groups A1 vs. A3 against recombinant MOMP G (A and C) and recombinant NrdB 
(B and D); in vitro neutralization percentages against C. pecorum G infection and % 
of proliferating cells to vaccine in groups A1 vs. A3. n = 4 animals in each group at 
each time point (E and F). Two-way ANOVA was performed with Bonferroni's post 
tests on combined data at day 0 and day 140. Unpaired t-tests were performed to 
determine the significance of differences between the groups at 20 weeks post 
vaccination. Error bars represent SD. *P, 0.01–0.05; **P, 0.001–0.01; ***P < 0.001. 
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4.5 DISCUSSION 
 
Chlamydia continues to be a major threat to the long-term survival of the koala. 
Recent studies suggest that addressing the issue of chlamydial disease may have a 
significant benefit in populations that are already in decline [26-32]. Antibiotics 
administered by oral and subcutaneous routes have proven not entirely effective for 
the clearance of chronic chlamydial infections [33]. Furthermore, antibiotic treatment 
can adversely affect the unique microbial flora essential for digestion of eucalyptus 
leaves [13,14]. Therefore, developing a vaccine appears to be the best approach for 
controlling C. pecorum infections in koalas. 
Our previous vaccine study [20] was designed to test here adjuvants for safety and 
demonstrate both humoral and cell mediated immune responses against C. 
muridarum MOMP, CT512 and C. trachomatis serovar D NrdB antigens in healthy 
koalas. Although this work demonstrated strong humoral and cell mediated immune 
responses, it did not demonstrate (i) humoral immune responses to host specific C. 
pecorum antigens, (ii) neutralizing antibodies to host specific C. pecorum infections, 
or (iii) immune responses in wild koalas previously infected with Chlamydia. The 
current study was designed to evaluate the ability of a vaccine formulated with the 
koala C. pecorum genotype G MOMP, NrdB and the adjuvant ISC, to induce 
significant systemic and mucosal immune responses in wild koalas. Importantly, the 
study assessed the vaccine not only in healthy koalas but also in koalas that were 
already infected with C. pecorum. To our knowledge, this is the first report to assess 
a Chlamydia subunit vaccine in an animal species adversely affected by naturally 
occurring ocular and genital tract chlamydial infections.  
Previous vaccine trials in mouse or guinea pig models have showed worsening of 
clinical signs due to cross reacting antigens such as Hsp60, resulting in 
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immunopathogenic consequences at ocular or female genital tract sites [34-36]. 
However, studies in mice and guinea pigs, using MOMP, have been shown to elicit 
partial protection [37-39]. In the current study, three koalas that had originally been 
treated for cystitis demonstrated a slight worsening of clinical signs (increased 
bladder thickness and haematuria) during the trial period. Of these, one koala had 
received the course of vaccination, and two had received the placebo course. 
Although we cannot rule out a causal association between administration of vaccine 
or placebo and the worsening of clinical signs in these koalas, worsening of clinical 
signs is a common sequel to treatment in some koalas, particularly those with 
chronic, severe cystitis (Gillet, A. pers. Comm.). Whilst these few animals showed 
minor worsening of clinical signs during the trial (but returned to normal levels by 
the 140 day period) the majority of animals did not show any worsening of pathology 
at all. Four animals in group B1 actually demonstrated improvement in lesions 
(decrease in disease score) over the study’s time course, whereas no worsening (no 
change in disease scores) of the lesions was observed for the remaining animals in 
the group. 
In this study, we were able to demonstrate that koalas already showing clinical signs 
of chlamydiosis had low level, pre-existing immune responses to C. pecorum MOMP 
and NrdB. This pre-existing response, however, did not prevent the development of 
strong vaccine-induced responses against heterologous MOMP from other C. 
pecorum genotypes nor the highly conserved antigen NrdB. Animals in groups B1 
and B2 started with background IgG titers against both MOMP (Fig. 1) and NrdB 
(Fig. 2) in both plasma and ocular secretions, due to their previous infections. Pre-
existing IgG levels against MOMP were higher than IgG anti-NrdB levels. Following 
subcutaneous immunization, both healthy and diseased koalas developed equally 
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high levels of plasma anti-MOMP IgG antibodies (Fig. 1A and 1B) during the 140-
day trial. However, MOMP-specific IgG titres in ocular swabs were higher in 
diseased animals than the healthy group at day 140 when the trial was terminated 
(Fig. 1C versus figure 1D) although this was not statistically significant. Following 
subcutaneous immunization, NrdB-specific IgG levels in plasma from diseased 
animals were significantly higher than in healthy animals (Fig. 2A versus 2B) 
whereas IgG anti-NrdB titres in ocular swabs were similar in both groups (Fig. 2C 
versus 2D). The vaccine-induced responses in both groups against MOMP were 
higher than that against NrdB, consistent with the highly immunogenic nature of 
MOMP. Importantly, the subcutaneous immunization route used was able to elicit 
both systemic (plasma) and mucosal (ocular) IgG responses. This data confirms the 
ability of naturally infected and diseased animals to mount specific immune 
responses following immunization with our C. pecorum-specific vaccine candidate 
antigens. Importantly, it also shows that our recombinant vaccine antigens can 
stimulate the immune response of naturally infected animals, confirming that the 
presentation of our antigens is adequate for stimulation of responses relevant to 
whole C. pecorum.  
In addition to demonstrating the strong production of plasma IgG following 
immunization, importantly, we  have shown that these antibodies are functional by 
demonstrating that they are able to inhibit chlamydial infection in vitro. To rule out 
any effect of pre-existing immunity due to natural infection (group B animals) or any 
effect of innate immune mediators, any neutralizing activity in pre-immune day 0 
plasma was subtracted from the neutralizing activity of day 140 plasma. Plasma from 
immunized healthy animals resulted in 40% neutralization of C. pecorum G 
infectivity in vitro (Fig. 4A) whilst day 140 plasma from immunized, diseased 
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animals was able to inhibit infection by 20% (Fig. 4B, p<0.05). This may be 
attributed to the disease status of the animals (i.e. the pre-immunization plasma from 
all the diseased animals already had low levels of neutralizing antibodies when 
compared to healthy animals). This is the first time a multi-subunit vaccine has been 
shown to elicit an antibody response sufficient to neutralize koala C. pecorum 
infections in vitro. 
A major and perhaps promising aspect of our results was the observation of cross-
reactivity of MOMP antibody responses from vaccinated healthy and diseased koala 
cohorts to different MOMP proteins (Fig. 3). Although there are major differences 
(up to 50 amino acid differences) between major C. pecorum amino types, current 
data suggests that immunization with MOMP genotype G can produce cross-reacting 
antibodies against several of the common genotypes affecting koalas. These findings 
are consistent with studies in non-human primate models immunized with C. 
trachomatis nMOMP [40,41]. B cell epitopes predicted using Bepipred 1.0 server 
[42] in the MOMP from the four genotypes of C. pecorum identified two major 
epitopes (more than 10 amino acids each) in the conserved regions of these MOMPs, 
which we predict may be responsible for producing cross-reacting antibodies (data 
not shown). The observation of cross-reactivity induced by immunization with a 
single MOMP protein will be important in our planning for vaccination of koala 
populations, infected with multiple genotypes of C. pecorum [22,23].   
Protection against chlamydial infection in other animal models has been shown to be 
dependent on the induction of cell-mediated immunity, particularly interferon 
gamma-secreting CD4 T cells. In both groups of immunized koalas we were able to 
show, using the CFSE dye dilution assay that between 10 and 20% of cells within a 
lymphocyte gate underwent two or more rounds of cell division following in vitro 
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stimulation with MOMP and NrdB (Fig. 5). Similar to the neutralization data (Fig. 
4), the levels of lymphocyte proliferation were slightly lower in immunized, diseased 
animals, although this difference was not significant. This is likely due to all but one 
of these animals having been infected with genotype F whereas genotype G MOMP 
was used in the vaccine. We were unable to determine the cytokine profile of 
proliferating cells, nor their phenotype (CD4 or CD8) due to a lack of reagents 
available for the koala.  
Use of an injectable vaccine in wild koala populations would require the capture and 
restraint of animals, which is both traumatic for the animals, expensive, and requires 
skilled animal handlers. For this reason, if fewer booster immunizations can be used 
to elicit protection this would represent a major advantage in a wildlife setting. 
Comparison of our data from koalas receiving either three or two immunizations 
shows that at the end of the 140 day trial, similar levels of IgG against both MOMP 
and NrdB were seen in plasma and ocular swabs using both regimes (Fig. 6), 
although, as expected, titers increased more rapidly in the three vaccination group. 
Importantly, levels of plasma neutralizing antibody activity and lymphocyte 
proliferation were also equivalent in the two and three-shot vaccine groups, 
suggesting that a single booster immunization was able to elicit similar immune 
responses as two booster shots. Our current vaccine formulation uses the adjuvant, 
ISC. In a previous trial [20] this adjuvant was shown to be superior to the other two 
adjuvants trialled and it continues to produce a strong antibody and cell mediated 
immune response in these koalas.  
Whilst these results are very promising for vaccinating koalas under controlled 
(captive) situations, there remain some challenges to utilizing the vaccine more 
extensively in wild populations. We see these challenges being addressed in a 
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stepwise fashion. The next stage will be to vaccinate wild koalas (females initially), 
to attach radio collars to these vaccinated animals, and then release them back into 
their native habitat where they will interact with, and potentially become infected 
following sexual contact with Chlamydia positive male koalas. The vaccinated 
animals can subsequently be captured and sampled to assess the effectiveness of the 
vaccine. We are close to initiating such a field study. Another group of koalas that 
could benefit from vaccination are those animals that are rescued and presented to 
wildlife hospitals because of injuries due to car accidents or severe disease. Whilst 
the exact numbers are unknown, it is thought that as many as 5000 koalas per year 
are in this category. These animals could be vaccinated (whilst still in care and 
monitored for a short period) before being released back into the wild. Whilst it will 
be challenging to vaccinate all the wild koalas, it should be possible to deliver an 
effective chlamydial vaccine to a significant number of at-risk animals in the near 
future.  
In summary, we have shown that a multi-subunit chlamydial vaccine can be safely 
administered to both healthy koalas as well as koalas that have a previous or current 
chlamydial infection. Importantly, vaccination did not worsen pre-existing lesions 
and similar levels of systemic (plasma) and mucosal (ocular) antibodies and 
lymphocyte proliferation were achieved in both healthy and diseased koalas 
following vaccination. Neutralizing antibody in the plasma of healthy animals was 
significantly higher than that in immunized/diseased animals. Importantly, plasma 
from both groups was able to react against MOMP from genotypes other than the 
immunizing genotype suggesting that induction of immunity against multiple 
genotypes may be possible. Whilst there are obvious logistical problems associated 
with vaccination of wild koalas that need to be overcome, our results provide strong 
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evidence that development of a chlamydial vaccine to protect this iconic marsupial is 
feasible.  
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5.2 INTRODUCTION 
Many koala populations throughout Australia are under threat of collapse with 
serious declines leading to localised extinction. The nature of these declines can be 
attributed to confounding anthropogenic pressures such as land clearing and habitat 
fragmentation [1], motor vehicle trauma [2], dog attacks and disease. A reduction in 
mortalities due to disease is predicted to provide the greatest potential impact on 
stabilising these declining koala populations [3].  Chlamydia is an obligate 
intracellular bacteria and the main cause of disease in the koala [4-6]. The most 
widespread and pathogenic chlamydial species infecting the koala is Chlamydia 
pecorum. Ocular infections cause keratoconjunctivitis leading to blindness [7,8]. 
Rhinitis and pneumonia are associated with respiratory infections and urinary tract 
infections cause cystitis and continual urine soiling or ‘wet bottom’ [5]. Infections of 
the genital tract can cause severe inflammation and fibrosis resulting in cystitis and 
infertility [4]. Many koalas, conversely, are asymptomatically infected [9]. While 
antibiotics present a treatment option for chlamydial infections, they can also 
adversely affect the intestinal microflora and health of the animals [10]. Thus, an 
effective vaccine to prevent the adverse consequences of chlamydial infections in 
koalas is important for the management of declining koala populations. 
The feasibility of a chlamydial vaccine for the koala was previously evaluated by 
assessing the immunological response of healthy koalas to a multi-subunit 
chlamydial vaccine derived from non-koala specific chlamydial species [11]. High 
levels of antigen-specific peripheral blood mononuclear cell (PBMC) proliferation (> 
1 year) and sustained plasma antibody levels in immunized animals were observed. 
More recently, healthy koalas and koalas with overt ocular or urogenital tract disease 
were immunized with a multi-subunit vaccine derived from koala C. pecorum [12]. 
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This study showed that koala vaccination is safe and induces an immune response 
that may provide ongoing protection from natural C. pecorum infections. The major 
antigenic components of both this trial [12] and the earlier study [11], were 
recombinant chlamydial outer membrane protein (MOMP), encoded by the ompA 
gene. MOMP is a major target of the immune response, eliciting significant 
protection against infection in small-animal models [13, 14]. A major problem of 
MOMP-based vaccines comes from the sequence diversity present in its surface-
exposed variable domains. In human genital Chlamydia trachomatis infections, 
MOMP immunization from one serovar will only elicit protection against the same 
or closely related serovars [15]. Sequence analyses of the surface-exposed variable 
domains encoded by C. pecorum MOMP-encoding ompA from geographically 
distinct wild koala populations have revealed significant diversity (10-30%) 
[16,17,18]. While these results appear promising, more work needs to be done to 
elucidate the specificity of any cross-reactivity and whether immunization with 
single recombinant C. pecorum MOMP or multiple MOMP proteins will impact on 
this outcome. 
In the current study, we investigated these questions by vaccinating captive female 
koalas with different combinations of C. pecorum MOMP to evaluate the efficacy of 
single versus polyvalent vaccines to protect against the wide diversity of C. pecorum 
strains circulating in wild koala populations. Our results show that multi-component 
MOMP vaccines are effective in producing strong, heterologous cell mediated 
(measured by lymphocyte proliferation) and humoral (systemic and mucosal 
antibodies) immune responses in koalas. 
5.3 MATERIALS AND METHODS 
Koala C. pecorum strains used in this study 
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Marsh et al., 2011 [18] used VD3/4 region of the ompA gene and designated 9 koala 
C. pecorum genotypes in koalas from across their range. For our current vaccine 
trial, we selected three genotypes (A, F and G) based on two facts (a) these 
genotypes represent the diversity of the nine characterized genotypes, and (b) all 
these genotypes have been detected in South East Queensland wild populations and 
we plan to do a field trial in this area in the future. Three unique strains of koala C. 
pecorum A, F and G, were isolated from the eyes or urogenital sites of individual 
free-range koalas sampled during screening of wild koala populations in Queensland 
[12,18]. All isolates were propagated in cell culture and recombinant MOMPs from 
their ompA genes were produced for immunization studies. Purified EBs from the 
three strains were inactivated for use in lymphocyte proliferation assays. Inactivation 
of the EBs was carried by exposure to UV light from a G15T8 UV lamp (Philips, 
Holland) at a distance of 5 cm for 45 min at room temperature [19]. 
 
Experimental groups of koalas  
Twelve healthy female koalas, aged three to seven years, were used for this study 
and were housed at Lone Pine Koala Sanctuary, Fig Tree Pocket, Queensland. 
Wildlife species such as koalas are extremely precious to obtain and use them in 
vaccine trials. For this reason we did not include a placebo group in this particular 
trial, however, we have included a placebo group in our previous trial [12] and we 
did not observe any Chlamydia MOMP specific immune responses in healthy 
animals. The Lone Pine Koala Sanctuary is regularly monitored for Chlamydia status 
and no animals have had clinical signs of disease for at least 10 years. Prior to 
starting this trial, all trial animals were serologically screened by western blots and 
shown to be antibody negative, indicating no previous or current chlamydial 
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infections. The work was approved by the QUT Animal Ethics Committee (Approval 
# 0700000559). 
Immunization schedule 
Koalas recruited into this study were divided into four groups of three koalas per 
group, with group 1 receiving MOMP A; group 2 receiving MOMP F; group 3 
receiving MOMP G; and group 4 receiving MOMP A plus MOMP F. Although our 
previous study [13] has assessed the value of reducing the number of immunizations 
using MOMP and NrdB as immunogens, the current trial was primarily aimed at 
evaluating differences in immunogenicity or specificity of various MOMP 
vaccinations even after several boosters. Hence all the animals were immunized 
subcutaneously with vaccine on weeks 0, 4 and 8. Each dose of the vaccine consisted 
of 50 µg of recombinant MOMP mixed with 50 µg Immuno Stimulating Complex 
(ISC, Pfizer Animal Health) in 0.5 mL PBS. 
 
C. pecorum cell culture, Production of recombinant MOMP proteins for vaccination, 
Sample collection, Enzyme-linked immunosorbent assay (ELISA), In vitro 
neutralization assay, Measurement of lymphocyte proliferation response, Prediction 
of major B and T cell epitopes of MOMP and Statistical analysis are all provided as 
Supplementary Information. 
5.4 RESULTS  
Evaluation of vaccine safety 
None of the 12 koalas immunized in this study showed any adverse signs of swelling 
or abscess formation around the vaccination site either immediately after vaccination 
or at any time during the 44 weeks of the trial. In addition, no adverse changes in 
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body temperature, eating patterns or general demeanour were observed as a result of 
administering the vaccine. 
Characterisation of humoral immune response to all MOMPs tested 
Figure 1 demonstrates the production of IgG antibodies in plasma against each of the 
three MOMPs (A, F and G) following immunization. All 12 animals had negligible 
antibody levels to the MOMP antigens prior to immunization. The three groups that 
were immunized each with single MOMP types, A, F and G (groups 1, 2 and 3) 
respectively, developed antibodies that recognized not only the MOMP type used for 
immunization, but also cross reacted to all three MOMP types. In all the groups, the 
titers peaked around 10 weeks post- immunization and started to plateau, or 
decreased slightly by week 21. Interestingly, regardless of which MOMP was used as 
the immunising antigen, the lowest level of antibodies was seen against MOMP F, 
compared to the titers with the other two MOMPs. This effect was even observed in 
group 2 animals which were immunized with MOMP F. Although the titres were 
different between the various groups, the kinetics of the responses was generally 
similar. 
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Fig. 1. Antibody titers (IgG) against four MOMPs in plasma following immunization 
in groups 1 (MOMP “A” immunized), 2 (MOMP “F” immunized), 3 (MOMP “G” 
immunized) and 4 (MOMP “A” plus “F” immunized) [A, B, C and D]. n = 3 
animals in each group at each time point. Differences in antibody titers at 21 weeks 
against three MOMPs in each group were compared using Kruskal-Wallis One way 
ANOVA (non parametric test). None of them were statistically significant. Arrows 
indicate the vaccination time points. Error bars represent SD. 
Figure 2 demonstrates the production of MOMP IgG antibodies at ocular and 
urogenital sites. Similar to the plasma responses, the individual and dual MOMP 
groups developed antibodies against all three antigens at both ocular and urogenital 
sites. All the animals started with negligible antibodies prior to vaccination and 
reached a peak of 2-5 x 101 EPT and 5-10 x 101 EPT by 21 weeks post 
immunization, at ocular and urogenital sites, respectively. Interestingly, there was no 
significant difference in the titers produced against different MOMPs at ocular versus 
urogenital sites.  
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Fig. 2. Antibody titers (IgG) against four MOMPs in groups 1 (MOMP “A” 
immunized), 2 (MOMP “F” immunized), 3 (MOMP “G” immunized) and 4 (MOMP 
“A” and “F” immunized) at ocular [A, B, C and D] and urogenital sites [E, F, G and 
H]. n = 3 animals in each groups at each time point. Differences in antibody titers at 
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21 weeks against three MOMPs in each group were compared using Kruskal-Wallis 
One way ANOVA (non parametric test). None of them were statistically significant. 
Arrows indicate the vaccination time points. Error bars represent SD. 
Vaccine induced production and specificity of plasma neutralising antibodies 
The development of in vitro neutralizing antibodies following immunization (Figure 
3) is expressed as the fold change of C. pecorum A, F and G infections between 
plasma collected pre-immunization compared to plasma collected from the animals 
21 weeks post- immunization. Pre-immunized plasma samples collected from each 
individual animal were used to establish the background level of infection in the cell 
culture assay. While there were some minor differences between the groups, the 
main observations were; (a) plasma from all immunized animals were able to 
neutralize infections at a dilution of 1:10 (neutralization levels ranging from 2.3 fold 
to 7.0 fold) and (b) the in vitro neutralization effect was seen across different C. 
pecorum genotypes. Interestingly, although animals in the groups 1, 2, and 3 were 
immunized with recombinant MOMP A, F and G respectively, post-vaccinated 
plasma samples were able to neutralize both homologous and heterologous C. 
pecorum infections. Moreover, comparing the neutralization effect between the 
individual (groups 1, 2 and 3) and combined (group 4) MOMP groups, there were, 
(a) similar levels of vaccine enhanced in vitro neutralization in the C. pecorum A 
infection between group 1 (MOMP A immunized) and group 4 (MOMP A and F 
immunized) and (b) only 3% more neutralization against C. pecorum F infection 
among group 2 koalas (MOMP “F” immunized) than the multiple MOMP group 
(group 4). Surprisingly, group 3 koalas, immunized with MOMP “G”, had the lowest 
(though not statistically significant) neutralization percentage (12.75% or 2.3 fold) 
against its homologous C. pecorum G infection, compared to the other heterologous 
groups.  
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Across all the four groups there was an average of 3.4 fold vaccine enhanced 
neutralization against C. pecorum A infection, 3.2 fold against C. pecorum F 
infection and 3.8 fold neutralization against C. pecorum G infection. 
Cell mediated immune responses following vaccination 
To evaluate the cell-mediated immune response, PBMCs were collected at weeks 10 
and 21 post-immunization and labelled with CFSE. Proliferation was analysed by 
dye-dilution assay following in vitro stimulation with recombinant MOMP proteins 
A, F and G (Fig. 4). We observed strong Chlamydia MOMP-specific, lymphocyte 
proliferation responses for all immunized groups. The overall strongest lymphocyte 
proliferation responses (15 – 30%) were observed in animals vaccinated with MOMP 
genotype G. As observed for the antibody responses, we observed both heterologous 
as well as homologous lymphocyte proliferation responses, with no significant trends 
in the levels of heterologous responses. Although groups 1, 2 and 3 were immunized 
with individual MOMPs A, F and G respectively, 5 – 30 % of the lymphocytes 
among all the groups underwent two or more rounds of division following multiple 
MOMP stimulation. There was no significant difference in the proliferative 
percentage of lymphocytes between individual and dual MOMP immunization 
groups. 
To further characterise the lymphocyte proliferation response of animals immunized 
with recombinant MOMP protein, we measured the animal’s proliferation response 
to whole UV inactivated EBs (Figure 5). Encouragingly, all groups responded by 
producing strong proliferation responses (2-8%) to the intact EBs, against both 
homologous and heterologous strains, with no significant difference between the 
individual and dual MOMP immunized groups.  
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Fig. 3. Fold change of C. pecorum genotype A, F and G infections [A, B and C] 
between pre and post immunized plasma samples in four groups 1 (MOMP “A” 
immunized), 2 (MOMP “F” immunized), 3 (MOMP “G” immunized) and 4 (MOMP 
“A” and “F” immunized). Mann-Whitney test (non parametric test) was performed 
on the infection percentages between pre-immunized and 21 weeks post immunized 
samples for each group against three C. pecorum infections. None of them were 
significant. Error bars represent SD.  
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Fig. 4. CFSE labelled lymphocyte proliferation assay (LPA) using PBMCs from 10 
and 21 weeks stimulated with respective MOMP antigens (8 µg/well) in groups 1, 2, 
3 and 4 [A, B, C and D] expressed as percentage of proliferating cells. Error bars 
represent SD. n = 3 animals per group. 
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Fig. 5. CFSE labelled lymphocyte proliferation assay (LPA) using PBMCs from 44 
weeks stimulated with C. pecorum A, F and G UV inactivated elementary bodies in 
groups 1, 2, 3 and 4 expressed as the percentage of proliferating cells. Error bars 
represent SD. n = 3 animals per group.  
 
Major B and T cell epitope predictions in the target MOMP proteins 
Figure 6 shows the major B and T cell epitope predictions in the MOMP protein in 
the three C. pecorum strains. Of the six major predicted B cell epitopes, four were in 
the variable regions (55’-85’; 141’ – 154’; 221’ – 237’; 298’ – 312’) specific to each 
MOMP amino type and the other two (1’ – 11’; 18’ – 30’) were conserved across the 
three MOMPs. Interestingly, all major predicted T cell epitopes using human and 
mouse MHC molecules as the comparison were present in the conserved regions of 
the MOMPs.
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Fig. 6. Alignment of three diverse whole C. pecorum MOMP amino acid sequences with predicted B and T cell epitopes. 
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5.5 DISCUSSION 
C. pecorum strains infecting koalas demonstrate significant antigenic diversity, 
posing challenges for the development of effective vaccines. An important 
consideration for the development of a MOMP-based anti-chlamydial vaccine 
therefore is the induction of cross strain/genotype/serovar protection, since multiple 
strains/genotypes/serovars cause genital and conjunctival infections in koalas.  
Previous studies on the development of a koala Chlamydia vaccine have shown the 
potential of healthy vaccinated koalas to induce humoral and cell mediated immune 
responses to chlamydial antigens [11] and the enhancement of immune responses in 
both healthy and naturally diseased animals upon vaccination with host specific C. 
pecorum MOMP G and NrdB antigens [12]. The current study evaluated several 
MOMP-based vaccines, formulated with C. pecorum genotypes MOMP A, MOMP F 
and MOMP G, to induce systemic and mucosal immune responses in healthy, 
Chlamydia-free koalas. This is the first report of a multi-MOMP vaccine in animals 
or humans, and importantly, it demonstrated that significant, heterologous immune 
responses can be generated using this approach. 
In this study, healthy, non-Chlamydia infected koalas had no pre-existing immune 
responses to any of the C. pecorum MOMPs A, F and G prior to vaccination. 
Following vaccination, the koalas in each of the three groups were immunized with 
just a single MOMP (MOMP A, F or G), they all developed a broad repertoire of 
plasma antibodies that could recognize homologous as well as heterologous MOMPs. 
Interestingly, plasma IgG antibodies to MOMP F had the lowest titer in both 
homologous (group 2) as well as heterologous groups (groups 1, 3 and 4). 
Furthermore, group 2 koalas (immunized with MOMP F) had the lowest plasma IgG 
responses to both homologous as well as heterologous MOMPs.  Importantly, 
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subcutaneous immunization was able to generate significant levels of IgG that cross-
reacted with all heterologous MOMP genotypes at both the ocular and urogenital 
sites. This data strongly suggests the presence and conservation of major B cell 
epitopes across all the MOMPs. As shown in Fig. 6 and from the alignment of the 
amino acid sequences from all 10 currently known koala C. pecorum MOMPs (data 
not shown), predicted B and T cell epitopes that appear critical in heterologous 
vaccine response are conserved, not just in the three strains analyzed in our current 
study, but across all 10 currently known koala C. pecorum ompA genotypes. 
In addition to the development of a broad repertoire of antibodies, importantly, these 
plasma antibodies are functional since we showed neutralisation of various C. 
pecorum in vitro infections. Even though animals in groups 1, 2 and 3 were 
immunized with only single recombinant C. pecorum MOMPs, they still effectively 
cross neutralized the heterologous infections. Interestingly, there was no significant 
difference between various individual (groups 1, 2 and 3) and combined (group 4) 
MOMP groups in cross neutralizing C. pecorum infections. One notable observation 
was that although group 2 koalas immunized with MOMP “F” had lower total 
antibody titers (2.5 X 104 EPT) compared to the other MOMPs, at 21 weeks post 
vaccination, they were still equally efficient in neutralizing homologous as well as 
heterologous C. pecorum infections (17.5%  or 3.7 fold). In comparison, Group 3 
animals immunized with MOMP “G” had higher average antibody titers of 4.7 X 104 
EPT at 21 weeks, but had a lower neutralizing percentage, although this was not 
significant statistically. However, among all the vaccinated koalas, group 1 animals 
(MOMP “A”) had both the highest average titers of 5.1 X 104 EPT and resulted in 
24% or 4.9 fold neutralization of the three C. pecorum strains. 
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Non-human primate studies with C. trachomatis have demonstrated that neutralizing 
antibodies produced as a result of immunization with native MOMP of either an 
ocular serovar [20] or genital serovar [21] were highly serovar-specific, even though 
there were only two amino acid differences between the serovars in their MOMP 
sequences. By comparison, in our current study, although MOMP sequence diversity 
of the three C. pecorum amino types ranged from 9.5 – 14.5% (35 – 54 amino acids), 
no diversity was observed between the first two in silico predicted B cell epitopes. 
Another interesting observation from our study relates to the conformation of the 
MOMP used for immunization. Several primate studies have used native MOMP, 
arguing that this better represents the conformation on EBs, and should result in the 
production of more effective antibodies. In our study, we were able to demonstrate 
the production of cross neutralizing antibodies after immunizing with a non-
conformational recombinant MOMP. 
The cellular immune response against chlamydial infections has been shown to be 
protective in various animal models [22, 23]. In our study, we were able to 
demonstrate lymphocyte proliferation from immunized animals following in vitro 
stimulation with three recombinant MOMPs. Even though the animals in the three 
groups were immunized with a single MOMP antigen, they were still able to 
proliferate following stimulation with heterologous MOMPs at 10 and 21 weeks, 
with no significant difference in responses between either the homologous and 
heterologous antigens or individual versus dual MOMP immunized groups. Most 
importantly, we also showed that 2.5-8.0% of the lymphocytes had the ability to 
proliferate against UV inactivated whole EBs of different amino types. When in 
silico T cell epitope searches of MOMP were performed (Fig. 6), the top 10 peptides 
with strong binding affinity to MHC class II molecules from human and mouse were 
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in the conserved regions of all MOMPs, as has been shown for human T cell 
responses to MOMP from different serovars of C. trachomatis [24]. This suggests 
that koala T lymphocytes also recognize highly conserved epitopes in the conserved 
region of MOMP.  
Whilst the results from our previous [12] and current vaccine trials are quite 
promising, several challenges still remain if we are to deliver the vaccine to wilder 
groups of koalas. The next key questions that need to be addressed are: (a) do male 
koalas respond in a similar way to our vaccine (b) can we develop a single dose, long 
acting (2-5 years) vaccine (c) does vaccination reduce the infectious load and future 
development of adverse pathology. 
In summary, both the humoral and cell mediated immune responses following 
vaccination demonstrate the ability of the koala to produce responses that cross react 
to various C. pecorum MOMPs as well as to whole EBs. Moreover, B and T cell 
predictions of various linear MOMPs indicate the presence of conserved epitopes 
which may be responsible for this cross reactivity. The findings in this study have 
demonstrated similar kinetics between individual and combined MOMP groups in (a) 
development of vaccine enhanced plasma antibodies (b) neutralization effect against 
various C. pecorum infections (c) lymphocyte proliferation against various MOMPs 
and whole EBs between the individual and the combined MOMP groups.  
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5.7 SUPPLEMENTARY INFORMATION  
C. pecorum cell culture 
Human epithelial (HEp-2) cell monolayers were maintained in Dulbecco’s Modified 
Eagle Medium (DMEM) supplemented with 5% fetal calf serum (FCS), 50 µg/µl 
gentamicin and 10 mg/L streptomycin. HEp-2 cells were seeded in T-25 flasks and 
left for 24 h until they were 80% confluent. Monolayers were then inoculated with C. 
pecorum A, F and G at a multiplicity of infection calculated to result in 40%, 90% 
and 90% of the host cells infected, respectively. Infected monolayers were 
centrifuged at 233xg for 10 min at 25oC. Three hours post-infection, the inoculum 
was replaced with fresh DMEM containing 1µg/ml cycloheximide.  C. pecorum A, F 
and G infections were further incubated for 72 h and 40 h, respectively. All the 
infected monolayers were washed with PBS and then incubated at 37oC for 
approximately 5 min with 2x trypsin (just enough to cover the monolayer). 
Trypsinized cells from the flasks were pooled into a 50 mL Falcon tube, topped up 
with DMEM media containing FCS and centrifuged at 500xg for 5 min. The pellet 
was resuspended in 5mL of PBS and probe sonicated (Microson XL2000; Newtown, 
Connecticut) on ice 4x 15 sec each with 15 sec time gaps in between. Host cell debris 
upon sonication was pelleted at 900xg for 5 min. The supernatant was carefully 
removed and subjected to another clarifying centrifugation at 900xg for 5 min to 
remove as much host cell debris as possible. The supernatant was then aliquoted into 
1.7mL microfuge tubes and centrifuged at 18000xg for 10 min at 4˚C. Finally, the 
pellet was resuspended in SPG and stored at -80˚C. These purified EBs from the 
three C. pecorum ompA genotypes were subsequently used for in vitro neutralization 
assays. 
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A batch of purified EBs was inactivated for use in lymphocyte proliferation assays. 
Inactivation of the EBs was carried out by exposure to UV light from a G15T8 UV 
lamp (Philips, Holland) at a distance of 5 cm for 45 min at room temperature [19].  
Production of recombinant MOMP proteins for vaccination 
E. coli strains JM109 and BL21 (DE3) pLysS competent cells were used for 
molecular cloning and protein expression and purification, respectively. E. coli 
strains transformed with the respective expression constructs were grown in Luria-
Bertani broth (LB; 10 g tryptone, 5 g yeast extract, 10 g NaCl per L), containing 75 
ug/mL ampicillin, at 37°C with constant shaking. E. coli cell growth in liquid media 
was assessed by measuring OD600. 
Koala C. pecorum MOMP variants (A, F and G) were PCR-amplified, cloned, 
expressed and purified for use in the vaccine trial. Truncated ompA genes for each C. 
pecorum MOMP genotyped strain, excluding the N-terminal signal peptide sequence, 
were amplified using primers OmpAXhoI (5’ – 
AAAAACTCGAGTTGCCTGTAGGGAACCC – 3’) and OmpAKpnI (5’ – 
AAAAAGGTACCTTAGAATCTGCATTGAGCAG – 3’). Each PCR product was 
amplified to generate PCR products with 5’ – XhoI and 3’ – KpnI restriction sites and 
were ligated into a N-terminal polyhistidine pRSET-A expression vector 
(Invitrogen), following XhoI/KpnI double digestion, which was similarly digested. 
His-tag expression constructs were transformed into BL21 (DE3) pLysS competent 
E.coli cells and grown in LB media with 100 ug/mL ampicillin at 37°C. At an OD600 
of 0.4 – 0.6, His-tagged protein expression was induced by the addition of 1 mM 
IPTG for 4 h. Cells expressing recombinant C. pecorum MOMP were harvested by 
centrifugation and resuspended in lysis buffer I (50 mM phosphate buffer pH 7.0, 8M 
urea, 2 mM PMSF, 50 µL Protease Inhibitor Cocktail (Sigma) and 1 mg/mL 
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lysozyme). Lysed cells were incubated with TALON metal affinity resin (Clontech) 
at 4°C for 1 h with gentle mixing. Resin was then repeatedly washed with wash 
buffer I (50 mM phosphate buffer pH 7.0, 300 mM NaCl, and 8M urea) and protein 
was eluted with elution buffer I (50 mM phosphate buffer pH 7.0, 300 mM NaCl, 
150 mM imidazole and 8M urea) by centrifugation. 
Purified protein samples were dialysed into PBS and recombinant protein yield 
determined by the Bicinchoninic Acid method using an ovalbumin standard curve as 
a control. Purified protein samples were resolved on 12% SDS-PAGE gels and 
detected following Coomassie blue staining and Western blotting (after transfer to 
nitrocellulose) with a monoclonal anti-histidine antibody (Sigma-Aldrich, Castle 
Hill, Australia). Purified recombinant C. pecorum proteins were used for (a) 
immunisations, (b) ELISA assays and lymphocyte proliferation assays. 
Sample collection 
Each of the koalas was regularly monitored by a veterinarian to ensure no adverse 
response to the immunizations. Samples for analysis of the immune response were 
collected four weeks prior, as well as six, 10, 21 and 44 weeks post vaccination. A 
four mL sample of venous blood was collected into EDTA, stored at 4˚C and 
processed within 24 h. Swabs were collected from eyes (left and right conjunctiva) 
and urogenital tract and were stored at – 80˚C in 0.5 mL PBS containing 1 mM 
PMSF.  
Enzyme-linked immunosorbent assay (ELISA)        
96 well ELISA plates (Greiner Bio One medium binding; Interpath, West 
Heidelberg, Australia) were coated either with recombinant C. pecorum MOMP A or 
MOMP F or MOMP G (2 µg/well) proteins, respectively in Borate-buffered saline 
(pH = 8.4) and incubated for 2 h at 37˚C. Post incubation, wells were washed 3x with 
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PBS-T and then blocked in 5% skim milk in PBS-T for 1 h at 37˚C. Plasma samples, 
serially diluted two fold in PBS-T on a separate plate, were added to the test wells 
(50 µL/well). All plasma samples were initially diluted to 1/100. All the mucosal 
secretions (urogenital tract and conjunctival sites) were initially diluted to 1/20. 
Plates were then washed 4x with PBS-T and then incubated with sheep anti- Koala 
IgG (50 µL/well) and incubated for further 1 h at 37˚C. Finally, after four washes, 
HRP-labelled rabbit anti-sheep IgG (1:1000 Southern Biotech/Invitro Technologies, 
Cleveland, Australia) was added (50 µL/well) to the wells and incubated for 1 h at 
37˚C. After five washes with PBS, 50 µL/well of TMB substrate (50 µL TMB in 5 
mL of PCB) was added and incubated for 5 min at room temperature. The HRP-
TMB reaction was stopped by adding 50 µL/well of 1 M H2SO4. The optical density 
was then read at 450 nm (Bio-Rad, North Ryde, Australia). End point titers of all the 
samples were statistically compared to the mean plus two times the standard 
deviation of the negative controls. 
In vitro neutralization assay 
HEp-2 cells were seeded in 48 well plates (Greiner bio one; Interpath, West 
Heidelberg, Australia) and grown overnight until 70-80% confluent. C. pecorum A, F 
and G purified EBs were added to the plasma samples (diluted 1:10 in cell culture 
medium) and incubated for 1 h at 37˚C under 5% CO2. Medium was removed from 
the HEp-2 monolayers and replaced with plasma samples and incubated for 4 h. Post 
incubation, samples were replaced with fresh media containing 1 µg/mL 
cycloheximide (Sigma-Aldrich, Castle Hill, Australia). Cells were further incubated 
for 48 h and then fixed with 100% methanol. Monolayers were initially stained with 
anti-chlamydial EB raised in rabbit for an hour followed by washing and then 
incubated with goat anti-rabbit IgG BIOT (Southern Biotech/ Invitro Technologies, 
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Cleveland, Australia). Wells were washed with 4xTBS-T and then stained with 
Streptavidin-HRP (Southern Biotech/ Invitro Technologies, Cleveland, Australia). 
Finally, the monolayers were stained with 3, 3’-Diaminobenzidine (DAB) (Thermo 
Fisher Scientific, Australia) prepared in peroxide substrate buffer. Both cells and 
inclusions were counted under the microscope and a mean of 10 fields of view for 
each well were counted and thus the neutralisation percentage determined compared 
to pre immunised controls. 
Measurement of lymphocyte proliferation response 
Blood samples were centrifuged at 233xg (Beckman Coulter AllegraX-15R) for 5 
min. Plasma was frozen for further studies at -80˚C. 10mL of 1x PBS was used to 
dilute and resuspend the blood cells, which were mixed thoroughly. The cell 
suspension was then carefully layered onto a 10 ml Ficoll-PaqueTM PREMIUM (GE 
Healthcare, Rydalmere, Sydney) and centrifuged at 650xg for 25 min with the brake 
off. PBMC’s were isolated from the buffy coat and suspended in a fresh tube 
containing 20 mL 1x PBS. Cells were further washed two times with 1x PBS at 
400xg for 10 min and counted. Cells were suspended at 2x106 cells/mL in PBS 
containing 5% fetal calf plasma. Carboxyfluorescein succinimidyl ester (CFSE; 
Sigma-Aldrich, Castle Hill, Australia) was used at 5 µM to label the cells, which 
were incubated for 5 min in the dark. Cells were then washed two times with cold 
1xPBS containing 5% fetal calf plasma Southern Biotech/ Invitro Technologies, 
Cleveland, Australia to quench the excess dye. Finally, the cell pellet was suspended 
in culture medium (RPMI 1640 containing 5% fetal calf plasma, 2 mM L-glutamine, 
10 mg/mL streptomycin sulphate, 2 μg /mL gentamycin and 50 μM 2-β-
mercaptoethanol). A 1:1 mixture of cells (2x105) collected at 10 and 21 weeks and 
antigens (8 μg of C. pecorum rec MOMP A, F and G) were added into 96 well flat 
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bottom plates (In Vitro Technologies, Noble Park North, Australia). In addition, 
PBMCs isolated at 44 weeks post-immunization were also analysed against whole 
UV inactivated EBs of C. pecorum strains A, F, and G. Concanavalin A (Sigma-
Aldrich, Castle Hill, Australia) at a concentration of 2.5 µg/mL was used as a 
positive control and culture media with labelled cells were used as negative controls. 
Plates were then incubated for 5 days at 37˚C in 5% CO2.  After 5 days, cells were 
washed in 1x PBS and then fixed in 4% paraformaldehyde and stored in the dark at 
4˚C until analysis. Estimation of PBMC’s proliferation was performed using a 
Beckman Coulter flow cytometer (FC500, Gladesville, NSW) and analysed using 
FlowJo software (Tree Star Inc., Oregon). Proliferation was expressed as the % of 
PBMC that had undergone more than one cell division.  
Prediction of major B and T cell epitopes of MOMP 
Major B and T cell epitopes across all three MOMP amino types were predicted by 
use of the Immune Epitope Database using Bepipred Linear Epitope prediction tool 
(http://www.cbs.dtu.dk/services/BepiPred/) and the strongest affinity to bind to MHC 
class II molecules of human (DP/DQ/DR) and mouse (H2-IAb/IAd/IEd) 
(http://tools.immuneepitope.org/main/html/tcell_tools.html), respectively. 
Statistical analysis   
Statistical analyses were performed using Graph-Pad Prism version 5 (Graph Pad 
Software, LaJolla, CA, USA). Data from each group was presented as the mean of 
three koalas, respectively (± SD of the mean). Kruskal-Wallis one way ANOVA 
along with Dunns post test was used to analyse the antibody titers and Man-Whitney 
test to analyse in vitro neutralisation data. 
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6.2 ABSTRACT 
Chlamydial infection in koalas is common across the east coast of Australia and 
causes significant morbidity, infertility and mortality. An effective vaccine to prevent 
the adverse consequences of chlamydial infections in koalas (particularly blindness 
and infertility in females) would provide an important management tool to prevent 
further population decline of this species. An important step towards developing a 
vaccine in koalas is to understand the host immune response to chlamydial infection. 
In this study, we used the Pepscan methodology to identify B cell epitopes across the 
Major Outer Membrane Protein (MOMP) of four C. pecorum strains/genotypes that 
are recognized, either following (a) natural live infection or (b) administration of a 
recombinant MOMP vaccine. Plasma antibodies from the koalas naturally infected 
with a C. pecorum G genotype strain recognised the epitopes located in the variable 
domain (VD) four of MOMP G and also VD4 of MOMP H. By comparison, plasma 
antibodies from an animal infected with a C. pecorum F genotype strain recognised 
epitopes in VD1, 2 and 4 of MOMP F, but not from other genotype MOMPs. When 
Chlamydia-free koalas were immunised with recombinant MOMP protein they 
produced antibodies not only against epitopes in the VDs but also in conserved 
domains of MOMP. Naturally infected koalas immunised with recombinant MOMP 
protein also produced antibodies against epitopes in the conserved domains. This 
work paves the way for further refinement of a MOMP-based Chlamydia vaccine 
that will offer wide cross-protection against the variety of chlamydial infections 
circulating in wild koala populations. 
6.3 INTRODUCTION 
The koala is the only surviving member of the family Phascolarctidae and is 
considered an icon of Australia’s unique biodiversity. Despite this esteem, wild koala 
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populations in geographically diverse regions throughout the country continue to 
decline. This decline has been attributed to several variables such as (a) habitat loss, 
resulting in fragmentation of koala colonies [1]; (b) disease [2]; (c) motor vehicle 
trauma [3]; and (d) dog attacks [4]. A recent study showed that addressing disease, 
amongst the many variables affecting koala survival would have the greatest 
potential impact on stabilising population decline [2]. Disease caused by infections 
of the obligate intracellular bacterial pathogen, Chlamydia pecorum, is a major threat 
to the ongoing survival of this species [5]. C. pecorum infections in koalas have been 
associated with a spectrum of diseases ranging from keratoconjunctivitis (ocular 
disease) leading to blindness, rhinitis and pneumonia, as well as urinary and genital 
tract disease, resulting in inflammation and fibrosis of the bladder and the upper 
female genital tract [6-10]. An effective vaccine to prevent the complications of 
chlamydial infections in koalas would provide a valuable management tool to stop 
the decline in wild populations by (a) reducing the infectious load in infected 
animals, and (b) preventing the further development of chlamydial pathology in 
healthy animals and development of pathology in already infected animals. 
An ideal chlamydial vaccine should be able to induce both cellular and humoral 
immune responses in the host [11]. The Major Outer Membrane Protein (MOMP), 
which constitutes 60% of the chlamydial outer membrane, has been the most widely 
used antigen either in its native or recombinant form in several vaccine studies [12-
15]. Initial efforts to develop a MOMP-based vaccine demonstrated a vaccine 
induced cell-mediated immune response lasting for more than a year as well as a 
humoral immune response (Chlamydia-neutralizing antibody) lasting > 35 weeks 
[16]. Following this study, our group further evaluated the safety and efficacy of a C. 
pecorum MOMP-based multi-subunit vaccine in diseased as well as healthy koalas 
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[17]. Strong antibody (including neutralizing antibodies) and lymphocyte 
proliferation responses were recorded in all vaccinated healthy and clinically 
diseased koalas. Vaccine induced antibodies specific for MOMP G, one of the 
thirteen known C. pecorum ompA genotypes (A-H; unpublished data) were observed 
not only in plasma but also in ocular secretions.  
In the most recent study, we evaluated the immunogenicity of a vaccine consisting of 
either monovalent or polyvalent MOMPs [18]. Animals immunized with individual 
MOMPs developed strong antibody and lymphocyte proliferation responses to both 
homologous as well as heterologous MOMP proteins. Importantly, we also showed 
that vaccine-induced antibodies effectively neutralized heterologous strains of koala 
C. pecorum in an in vitro assay. Finally, we also demonstrated that the immune 
responses in monovalent as well as polyvalent MOMP vaccine groups were able to 
recognize whole chlamydial elementary bodies, illustrating the feasibility of 
developing an effective MOMP-based C. pecorum vaccine that could protect against 
a range of strains. A promising aspect of our most recent trials [17, 18] was the 
cross-reactivity of MOMP antibody responses from vaccinated healthy and diseased 
koalas, giving hope for the generation of a MOMP-based vaccine that will offer wide 
cross-protection against the variety of genetically distinct C. pecorum strains 
circulating in wild koala populations. In the present study, we further investigated the 
MOMP B cell epitopes responsible for the cross reactivity of the vaccine induced 
plasma antibodies in our previous vaccine trials. We examined (a) the specific 
MOMP epitopes that were recognized by koalas naturally infected with C. pecorum, 
(b) epitopes recognized by healthy animals immunized with either MOMP A, 
MOMP F, MOMP G or MOMP A plus F, and (c) epitopes recognized by the 
diseased animals immunized with MOMP G. 
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6.4 MATERIALS AND METHODS 
Koalas used in this study 
Nine koalas were analysed as part of this study, consisting of (a) five wild animals 
with a current or recent C. pecorum infection and overt signs of disease at the time of 
sampling, and (b) four captive healthy animals, with no evidence of infection or 
disease (Table 1). Among the diseased animals, three koalas were tested and found to 
be infected with C. pecorum ompA genotype F and the remaining two koalas were 
tested and found to be infected with C. pecorum ompA genotype G, [17]. One koala 
(Popeye) in the C. pecorum G group and two koalas (Nixon/Felix Pitt) in the C. 
pecorum F group were subcutaneously immunized with a vaccine consisting of 
MOMP G and ISC (adjuvant), as previously described [17]. Kathy received the 
placebo (adjuvant only). Four healthy animals with no signs of infection or disease 
were immunized with individual MOMP types (A, F and G) or together (A and F), 
respectively [18].  
The sampling and analysis of samples from wild koalas received for treatment at 
Australian Zoo Wildlife Hospital was performed under permission of the Queensland 
State Government Department of Environment and Heritage Protection (Scientific 
Purposes Permit WISP 06056009). All animal work was approved by the 
Queensland University of Technology Animal Ethics Committee (Approval 
#0700000845 & #0700000559). 
Sampling of the animals 
Animals were sampled prior to immunisation (all 9 animals) and then 20 weeks post 
immunisation (8 out of 9 animals). Plasma was separated from anti-coagulated 
bloods by centrifugation at 233xg for 5 min at 4◦C. Samples were then stored at -
80◦C for further analysis. 
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Screening for C. pecorum infections  
Ocular and urogenital tract swab samples from all animals, prior to immunisation 
were screened for the presence of C. pecorum infections by 16S rRNA species-
specific quantitative PCR [19] and for the presence of C. pecorum MOMP specific 
antibodies by immuno blotting [17]. 
Design of Biotinylated peptide library for screening MOMP antibodies from 
koala plasma 
A library of overlapping 15 amino acid peptides were designed by our group and 
constructed by Mimotopes (Melbourne, Australia). The full-length koala C. pecorum 
MOMP sequence for MOMP F (Fig. 1) was used to design the first 63 overlapping (9 
amino acid offset) 15 mer peptides. In addition to peptides representing the complete 
370 amino acids of C. pecorum MOMP F, the four variable domain regions of C. 
pecorum MOMPs A, G and H, and three peptides representing two major predicted B 
cell epitopes in conserved domains were also covered by the remaining 25 
overlapping 15mer peptides. Each peptide consisted of a biotin molecule linked to a 
spacer (-SGSG-) to prevent steric hindrance, followed by the 15mer sequence with 
an offset of 9 amino acids. 
Biotinylated Peptide Enzyme Linked Immuno Sorbent Assay 
The wells of 96 well streptavidin coated plates pre-blocked with BSA (Thermo 
Fisher Scientific, Melbourne, Australia) were coated individually with each of the 88 
biotinylated peptides at a concentration of 2 µg/well in 1X Phosphate Buffered 
Saline Tween-20 and incubated for 2 hrs at room temperature (22◦C). Post 
incubation, the wells were washed 3X with PBS-T and the individual plasma samples 
(diluted to 1/1000) were added to the wells (100 µl/well), respectively. The plates 
were incubated overnight at 4˚C followed by washing 4X with PBS-T. The plates 
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were then incubated with sheep anti-koala IgG (1:4000 in PBS-T) (100 µl/well) and 
incubated for 1 hr at room temperature. Finally, after four washes, HRP-labelled 
rabbit anti-sheep IgG (1:1000 Southern Biotech/Invitro Technologies, Cleveland, 
Australia) was added (100 µl/well) to the wells and incubated for 1 hr at room 
temperature. After five washes with 1X PBS, 100 µl/well of ABTS  
[2, 2’-azino-bis (3-ethylbenzothiazoline-6-sulphonic acid), Southern Biotech, 
Alabama, USA] substrate solution was added and incubated for 10 min at room 
temperature. The optical density was then read at 405 nm (Bio-Rad, North Ryde, 
Australia). Background for each sample was calculated from the mean plus twice the 
standard deviation of the negative wells (no sera added). In an attempt to minimise 
the inter-assay variability and truly reflect the differences in antibody response 
profiles between samples, (a) the assay was performed on both pre- and post-
immunised samples of each animal alongside on the same day, and (b) the 
background absorbance (green line) used for comparing the response profiles from 
pre- and post-immunisations was a result of the mean plus two times the standard 
deviation of the negative controls of both samples.  
Western blot 
Western blots to assess the specificity of the koala plasma to different C. pecorum 
MOMP proteins was performed as previously described [17]. In brief, 5 µg aliquots 
of each of the MOMP’s A, F, G and H was loaded onto 12% SDS-PAGE gels and 
run at 110V for 1hr. Following blotting onto a nitrocellulose membrane at 90V for 
1hr, membranes were blocked in skim milk solution for 1hr. Plasma samples from 4 
weeks prior to immunization and 20 weeks post immunization (1:1000) were then 
analysed by incubating onto respective blots overnight at 4◦C. Membranes were then 
washed and sheep anti koala IgG was added at 1:1000 dilution and left for an hour. 
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After incubation, membranes were further washed with TBST and incubated with 
HRP-labelled rabbit anti-sheep IgG (1:1000) for 1hr. Blots were then washed 
thoroughly with TBS and visualised for bands by adding chemiluminescence 
substrate. 
6.5 RESULTS 
 
Response profile of plasma from Chlamydia negative koalas 
Plasma from four healthy, pre-immunised, Chlamydia negative koalas (Amity, 
Nessie, Jaffa and Guppy) were evaluated against the 88 peptides in the MOMP 
peptide library. Figure 4 shows each individual animal’s response (indicated by the 
blue lines; A, B, C and D). There were weak absorbance levels to all 88 peptides 
(except for peptide 22 in the conserved domain) in all four healthy, Chlamydia-free 
animals. The response profiles for each pre-immunisation sample was used to 
establish a background response profile for analysis of post-immunisation samples. 
Response profiles of plasma antibodies in koalas with natural Chlamydia 
infections  
Figure 2 shows the specificity of plasma antibodies produced in two animals [Popeye 
(Fig. 2A) and Mars Bar (Fig. 2B)] naturally infected with C. pecorum genotype G 
when compared to the response of four Chlamydia negative animals. Both animals 
had a similar response profile to the Chlamydia free animals for 84 out of 88 
peptides, however, plasma from these two diseased animals reacted strongly with 
epitopes from variable domain four of MOMP G (298’-
TLLGEATQVDNSNKF;peptide 79) and the equivalent epitope in MOMP H (298’-
TLLGQATQVDNSNKF;peptide 85), respectively. Interestingly, when this epitope 
of 15 amino acid length was aligned with all four MOMPs (Fig. 2C), there are nine 
 Chapter 6: Vaccination of koalas with a recombinant Chlamydia pecorum Major Outer Membrane Protein 
induces antibodies of different specificity compared to those following a natural live infection. 186 
amino acid differences between MOMP G and MOMP A, eight amino acid 
differences between MOMP G and MOMP F but only one amino acid difference 
between MOMP G and MOMP H, which presumably explains the cross reactivity of 
plasma antibodies to MOMP G and MOMP H. Apart from the epitopes in the 
variable domains, plasma antibodies from Mars Bar also recognised two unique B 
cell epitopes in the conserved regions of MOMP (peptides 16 and 27), consistent 
with differences in immune responses in out-bred animals. 
Figure 3 shows the specificity of the plasma antibodies in two animals [Nixon (Fig. 
3A), and Felix Pitt (Fig. 3B)] naturally infected with C. pecorum genotype F, again 
compared to the response of the four Chlamydia negative animals. Although both 
these wild koalas were infected with C. pecorum F, they had different responses to 
the MOMP peptides. Nixon (Fig. 3A) produced antibodies to the three epitopes in the 
variable domains, SMGQAPSTNSPADSV (variable domain one; peptide 11), 
GLIGISGSDLNSKVP (variable domain two; peptide 23) and 
LNMTTWNPTLLGEAT (variable domain four; peptide 49) whereas Felix Pitt (Fig. 
3B) produced antibodies to epitopes GLIGISGSDLNSKVP (variable domain two; 
peptide 23) and EATSVNAGNKYADVL (variable domain four; peptide 51). For the 
epitope recognized by both animals in variable domain two (Fig. 3C), we found four 
amino acid differences between MOMP F and the other three MOMPs. Interestingly, 
within the MOMP variable domain four (Fig. 3D), both animals recognised two 
different epitopes VD4 (1) and VD4 (3), respectively, although the epitopes shared 
three amino acids between them. At VD4 (1) there are 3-5 amino acid differences 
between the various MOMPs and 5-8 amino acid differences between various 
MOMPs at VD4 (3). Another animal (Kathy), naturally infected with C. pecorum F 
also produced antibodies to epitopes DSVSLQERENPAYGK (variable domain one; 
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peptide 13) and NQTLPLPITAGTATD (variable domain three; peptide 37) of 
MOMP F (Fig. 5A). 
Vaccination elicits cross-reactive MOMP antibodies in Chlamydia free animals 
immunized with recombinant MOMP proteins A, F and G 
Figure 4A shows the specificity of the antibodies produced by a Chlamydia negative 
koala (Amity) following immunization with recombinant MOMP A. Interestingly, 
when compared to animals immunised with other MOMPs (Figure 4), Amity’s post 
immunised sample had a better (but not extremely high) response profile against the 
majority of the same peptides recognized by her own pre-immunised sample. 
Immunization also induced cross-reactive antibody against three other MOMPs, as 
shown in the immuno blots of Figure 4A. Another Chlamydia negative koala 
(Nessie) was immunized with recombinant MOMP F protein and by 20 weeks post 
vaccination produced plasma antibodies (Fig. 4B) that reacted strongly against 
epitopes in (a) the conserved domains (peptides 16 and 27), (b) variable domains of 
MOMP F (peptides 13, 14 and 38) and; (c) variable domain two of MOMP H 
(peptide 84) (Table 2). Immunisation of a Chlamydia negative animal (Jaffa) with 
MOMP G protein resulted in antibodies that primarily recognise various linear 
epitopes in the conserved domains of MOMP (peptides 35, 44, 55 and 87) (Figure 
4C). Finally, when a Chlamydia negative animal was immunised with a combination 
of two MOMP proteins (A plus F) it produced antibodies that recognised the epitopes 
in conserved domains (peptides 2 and 19) as well as the variable domain one of 
MOMP F (peptides 13 and 14) (Fig. 4D) (Table 2). Both the animals immunised with 
MOMP F (one in combination with MOMP A) gave the strongest reaction to peptide 
13 (DSVSLQERENPAYGK) and its overlapping peptide 14 
(ERENPAYGKHMHDAE). Additionally, to corroborate the Pepscan data, we 
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performed immuno-blot assays on both pre- and post-immunised plasma at the same 
time points, using similar concentrations of plasma (1:1000) used in Pepscan assay 
for each animal. Although the pre-immunised samples were negative against four 
MOMP variants, the samples collected 20 weeks after immunisation developed 
cross-reacting antibodies to various MOMPs (Figure 4)  
Evaluation of MOMP antibody responses in a Chlamydia infected animal 
administered with placebo (adjuvant only) 
A C. pecorum F infected koala when vaccinated with a placebo (ISC) did not 
produce any antibodies to conserved domains, but retained a similar reactivity 
pattern to the pre-immunization sample (Figure 5A) by producing antibodies 
predominantly to the variable domains one and three of MOMP F. 
Enhancement of a broader repertoire of MOMP antibodies in naturally 
diseased animals following immunization with recombinant MOMP protein 
Figure 5B illustrates the vaccine induced production of antibodies to various epitopes 
in a koala that was previously naturally infected with C. pecorum G. Interestingly, 
after immunization with recombinant MOMP G protein there was a significant 
production of antibodies against previously recognized epitopes (induced by natural 
infection) in variable domain four of MOMP G and H and additionally to the 
conserved domains (Table 2). Figure 5C shows the enhancement of antibodies in a C. 
pecorum F infected koala after immunization with MOMP G protein. The major 
epitopes recognized fall in the conserved domains as well as the variable domain four 
of MOMP F and variable domain one of MOMP H (Table 2).  
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6.6 DISCUSSION 
Studies in various animal models (mice, guinea pigs and non-human primates) of 
Chlamydia infection, have suggested a significant requirement for antibody-mediated 
immune responses (neutralising antibodies) along with cellular immune responses 
(Th1) for an effective vaccine. Morrison et al. [20] demonstrated a significant role 
for B cells and CD4+ T cells but not CD8+ T cells, in resistance to C. trachomatis 
genital tract reinfection. In a follow up study, Morrison et al. [21] subsequently 
showed that antibody-mediated immune responses were critical in the resolution of 
secondary genital tract infection in mice but this resolution was independent of both 
CD4+ and CD8+ T cells.  Hence, optimising the antibody response is essential for 
effective chlamydial vaccine development.  
Our previous koala Chlamydia vaccine trials [17,18] have demonstrated strong 
vaccine induced humoral immune responses in healthy koalas as well as vaccine 
enhanced immune responses in naturally infected koalas, at both systemic and 
mucosal sites. One particularly encouraging aspect of these studies was the 
observation of cross-reactive antibodies in vaccinated healthy and diseased animals 
[17] that recognized MOMP from different C. pecorum strains. The functionality of 
these antibodies was demonstrated by their ability to cross-neutralize heterologous C. 
pecorum infections, in vitro [18].   
In our current study, we used Pepscan methodology to investigate linear epitopes 
along the entire MOMP protein to determine the specificity of the antibody responses 
produced following, (a) natural live infection, (b) recombinant MOMP vaccination, 
(c) recombinant MOMP vaccination on top of natural live infection. The 15mer 
peptides (overlapping by 9 amino acids) covered the full length of koala C. pecorum 
MOMP F protein, as well as the variable domain regions for koala C. pecorum 
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MOMPs A, G and H. When we evaluated immune sera from four naturally infected 
koalas, interestingly, only six linear epitopes were recognised.  Five of these epitopes 
(peptides 23, 49, 51, 79 and 85) were located in the variable domains, while the other 
epitope (peptide 53) was in a conserved domain. These naturally recognised epitopes 
presumably represent the surface-exposed regions on intact chlamydial EBs/RBs that 
are recognised during a natural live infection. Of these six naturally recognised 
MOMP epitopes, none were recognised by all four koalas. One possible explanation 
for this could be due to major histocompatibility complex restriction in these out bred 
koalas [22]. We found that different epitopes were recognised in koalas infected with 
different C. pecorum genotypes (peptides 79 and 85 were recognised by C. pecorum 
G infected koalas only; peptides 23, 49 and 51 were recognised by C. pecorum F 
infected koalas only).  
The in silico B cell prediction algorithm has predicted major epitopes in all four 
variable domains across C. pecorum MOMPs [18], however koalas naturally infected 
with C. pecorum G genotype produced antibodies only to the linear epitopes of 
variable domain four of MOMP G and MOMP H. This cross reactivity to MOMP G 
and MOMP H was similar to the immunoblot data we observed (Fig. 2D). 
Interestingly, an alignment of the amino acids at this epitope, revealed only one 
amino acid difference between them i.e. Glutamic acid (E) in MOMP G and 
Glutamine (Q) in MOMP H (Fig. 2C). Amino acids at variable domain four between 
MOMP G and H were more similar (93.3% consensus) when compared to the 
variable domain three (73.3% consensus), variable domain two (69.2% consensus) 
and variable domain one (62.5% consensus) regions, which explains the cross-
reactivity of antibodies to MOMP G and H. Among the koalas infected naturally 
with C. pecorum F, one animal (Nixon) produced plasma antibodies to three epitopes 
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at the variable domains of MOMP F (VD1, VD2 and VD4) whereas the other animal 
(Felix Pitt) produced antibodies to epitopes in two variable domains of MOMP F 
(VD2 and VD4). Both the animals (Nixon and Felix Pitt) shared a common epitope 
located in variable domain two. Even though there was 73.3% similarity between 
MOMP F and MOMP A at this linear epitope, and 66.6% between MOMP F and 
MOMP G/H, both koalas specifically produced antibodies only to MOMP F (Fig. 
3C). Surprisingly, although both targeting variable domain four of MOMP F, 
antibodies from each animal recognised two different overlapping epitopes within 
this domain (Fig. 3D). 
Pre-immunised plasma samples from four Chlamydia negative koalas, with the 
exception of Amity, did not recognise any of the epitopes except for peptide 22 
(Figure 4). When we evaluated sera from four Chlamydia negative koalas that were 
immunised either with individual recombinant MOMP proteins (A, F and G) or a 
combination of two recombinant MOMP proteins (A and F), we observed an epitope 
response that was different to the response seen with naturally infected koalas (Fig. 
4) (Table 2). In these four immunised koalas, a total of 15 epitopes were recognised 
and eight of these epitopes were different to the epitopes recognised during a natural 
live infection. Only five of these vaccine induced epitope antibodies were in the 
variable domains of MOMP F and MOMP H, while 10 were in conserved domains. 
Furthermore, a koala immunised with both recombinant MOMPs (A and F) did not 
show any extra boosting effect to the conserved domains in particular, when 
compared to animals immunized with a single MOMP. This data strongly correlates 
with the observation of no significant difference in the cross-reactivity of antibodies 
post-vaccination between the individual and dual MOMP groups, as shown in Figure 
4 and previously observed [18]. None of the in silico predicted B cell epitopes in the 
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conserved domain [18] were recognized by the koalas; however antibodies to various 
other epitopes in conserved domains were elicited. 
Early studies by Girjes et al. [23] reported in vitro neutralisation with sera from 
naturally infected koalas. However, in their study, less than 50% of the sera showed 
in vitro neutralisation activity and this varied between koalas. By comparison, the 
four koalas that were given a recombinant MOMP vaccine in our current study were 
all previously shown by Kollipara et al. [17] to produce in vitro neutralising 
antibodies. Although animals were immunized with single recombinant C. pecorum 
MOMPs, they still effectively cross neutralized the heterologous infections. 
Interestingly, there was no significant difference between individual and combined 
MOMP groups (MOMP A and MOMP F) in cross neutralization of C. pecorum 
infections. This is very encouraging from a vaccine development perspective, for the 
fact that seven of the recognised epitopes were in conserved domains and therefore 
conserved across all 13 C. pecorum MOMP genotypes (data not shown) that we 
currently have sequence information for, bodes well for wider cross neutralisation. It 
has also become evident from studies in naturally infected koalas that strong, long 
lasting protection from the neutralising antibodies does not result in natural 
infections [18]. Hence, an effective vaccine will need to improve on the existing 
natural immune response.   
In the final aspect of our study, we evaluated the specificity of the response of koalas 
naturally infected with C. pecorum and then administered the recombinant MOMP 
vaccine. This is critical because, if the vaccine has to be delivered to wild 
populations, which already have 20-50% C. pecorum infections levels (Kollipara et 
al., 2013; unpublished data), it has to be effective in these groups. In the naturally 
infected vaccinated animals, a total of eight vaccine induced epitopes were 
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recognised (Table 2). Out of eight epitopes, six were recognised in conserved 
domains and the remaining two in the variable domains (peptides 50 and 83).  
In conclusion, although this study has dealt with the specificity of the polyclonal 
antibodies against MOMP in wild (outbred) koalas, known to have highly variable 
MHC Class II genes [22]. We have primarily focussed on expanding the findings 
(highly specific as well as cross-recognising humoral immune responses) from our 
previous studies [17, 18].  In this study, we have shown, (a) specific MOMP B cell 
linear epitopes recognised in C. pecorum G and F genotype infected wild koalas and 
(b) MOMP linear epitopes responsible for the production of cross recognition 
antibodies in post-vaccinated healthy and diseased koalas. The findings from this 
study provides further insights into (a) screening various potential B cell epitopes 
using the Pepscan methodology in other chlamydial antigens, such as chlamydial 
heat shock protein (hsp60) [24] and thereby (b) developing diagnostic assays which 
aid in screening various healthy as well as diseased koalas. Using such findings as a 
proof of concept, a recent study [25] has identified new peptide antigens from C. 
trachomatis infected women and demonstrated the potential to develop an epitope-
based serological diagnostic assay. Since both humoral and cell mediated responses 
are critical for a protective immune response against persistent chlamydial infections, 
our next step is to apply this screening assay to identify several potential T cell 
epitopes in healthy and diseased koalas. 
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6.9 FIGURES 
 
 
 
Figure 1. Layout of C. pecorum MOMP peptide library. Peptides 1 to 63 
represent five conserved domains (straight lines) interspersed by four variable 
domains (boxes) of MOMP F. Peptides 64 to 88 represent four variable domains of 
MOMP A, MOMP G and MOMP H, respectively. 
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Figure 2. B cell epitope mapping across four MOMPs in naturally, C. pecorum genotype G infected koalas. Response profiles of two wild koalas 
naturally infected with C. pecorum G, Popeye (A) and Mars Bar (B) across MOMP peptide library and amino acid alignment of four MOMPs at VD4 epitope 
(C) (dots represent the consensus). Representative blot of plasma from the koalas infected with C. pecorum G against four recombinant full length MOMP 
proteins (D). The blue line indicates the mean of absorbance of four Chlamydia free animals. The red line indicates the Chlamydia infected animal. The green 
line indicates the background (Mean and two times standard deviation of negative controls). 
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Figure 3. B cell epitope mapping across four MOMPs in naturally, C. pecorum genotype F infected koalas. Response profiles of two wild koalas 
naturally infected with C. pecorum F, Nixon (A) and Felix Pitt (B) across MOMP peptide library. Alignment of four MOMPs at an epitope at variable domain 
two (C), and two overlapping epitopes at variable domain four (D) (dots represent the consensus). The blue line indicates the mean of absorbance of four 
Chlamydia free animals. The red line indicates the Chlamydia infected animal. The green line indicates the background (Mean and two times standard 
deviation of negative controls).
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Figure 4. B cell epitope mapping across four MOMPs in Chlamydia free koalas 
after vaccination.  Response profiles and immuno blots of four Chlamydia free 
koalas vaccinated with MOMP A (A), MOMP F (B), MOMP G (C) and MOMP A as 
well as MOMP F (D), respectively. The blue line indicates the absorbance of pre 
immunized samples collected from individual Chlamydia-negative animals. The red 
line indicates the 20 weeks post immunized sample. The green line indicates the 
background (Mean and two times standard deviation of negative controls). 
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Figure 5. B cell epitope mapping across four MOMPs in Chlamydia infected 
koalas after administration with placebo or vaccine. Response profile of a C. 
pecorum F infected koala administered with a placebo (adjuvant only) across our 
MOMP peptide library (A). Response profiles of a naturally infected C. pecorum G 
koala immunized with recombinant MOMP G (B), and a naturally infected C. 
pecorum F koala immunized with recombinant MOMP G (C) across our MOMP 
peptide library. The blue line represents the absorbance of the pre-immunized 
sample. The red line represents the 20 weeks post-immunized sample. The green line 
indicates the background (Mean and two times standard deviation of negative 
controls).   
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6.10 TABLES 
Table 1. List of diseased as well as healthy koalas in this study with their qPCR status, infecting strain 
and clinical disease observed during the study.  References are listed in the brackets. 
Koala 
Identifier 
Chlamydia  
PCR status 
Naturally 
infected with C. 
pecorum (strain) 
Clinical 
disease 
status 
Immunization 
Mars Bar + C. pecorum G Cystitis Not Immunised 
Popeye [19] + C. pecorum G Conjunctivitis MOMP G 
Nixon [19] + C. pecorum F Conjunctivitis MOMP G 
Felix Pitt [19] + C. pecorum F Conjunctivitis MOMP G 
Kathy [19] + C. pecorum F Cystitis Placebo only 
Amity [20] - - - MOMP A 
Nessie [20] - - - MOMP F 
Jaffa [20] - - - MOMP G 
Guppy [20] - - - MOMP A + MOMP F 
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Peptide 
No. 
MOMP region Peptide Sequence 
C. pecorum negative 
koalas 
C. pecorum G infected 
koalas 
C. pecorum F infected 
koalas 
C. pecorum free vaccinated koalas C. pecorum infected vaccinated koalas 
Mean of four C. 
pecorum free pre-
immunised animals 
Mars Bar*  Popeye* # Nixon* Felix Pitt* $ 
MOMP 
A 
immuni
sed@  
MOMP F 
immunised
@ 
MOMP G 
immunised@ 
MOMP A plus MOMP 
F immunised@ 
Kathy prior to placebo 
administration ^ 
Kathy 20 weeks post 
placebo administration ^  
Popeye vaccinated 
with MOMP G # 
Felix Pitt vaccinated 
with MOMP G $ 
1 
Conserved domain 
LPVGNPAEPSLLIDG                           
2 AEPSLLIDGTIWEGM                           
3 IDGTIWEGMSGDPCD                           
4 EGMSGDPCDPCATWC                           
5 PCDPCATWCDAISLR                           
6 TWCDAISLRVGFYGD                           
7 SLRVGFYGDYVFDRV                           
8 YGDYVFDRVLKTDVP                           
9 DRVLKTDVPQKFSMG                           
10 DVPQKFSMGQAPSTN                           
11 
C.pecorum MOMP F 
Variable Domain 1 
SMGQAPSTNSPADSV                           
12 STNSPADSVSLQERE                           
13 DSVSLQERENPAYGK                           
14 ERENPAYGKHMHDAE                           
15 
Conserved domain 
YGKHMHDAEWFTNAG                           
16 DAEWFTNAGYIALNI                           
17 NAGYIALNIWDRFDV                           
18 LNIWDRFDVFCTLGA                           
19 FDVFCTLGATSGYFK                           
20 LGATSGYFKGNSSSF                           
21 YFKGNSSSFNLIGLI                           
22 SSFNLIGLIGISGSD                           
23 C. pecorum MOMP F 
Variable domain 2 
GLIGISGSDLNSKVP                           
24 GSDLNSKVPNASISN                           
25 
Conserved domain 
KVPNASISNGVVELY                           
26 ISNGVVELYTDTTFS                           
27 ELYTDTTFSWSVGAR                           
28 TFSWSVGARGALWEC                           
29 GARGALWECGCATLG                           
30 WECGCATLGAEFQYA                           
31 TLGAEFQYAQSKPRV                           
32 QYAQSKPRVQELNVL                           
33 PRVQELNVLSNVAQF                           
34 NVLSNVAQFTVHRPK                           
35 AQFTVHRPKGYVNQT                           
36 RPKGYVNQTLPLPIT                           
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Peptide 
No. 
MOMP region Peptide Sequence 
C. pecorum negative 
koalas 
C. pecorum G infected 
koalas 
C. pecorum F infected 
koalas 
C. pecorum free vaccinated koalas C. pecorum infected vaccinated koalas 
Mean of four C. 
pecorum free pre-
immunised animals 
Mars Bar*  Popeye* # Nixon* Felix Pitt* $ 
MOMP 
A 
immuni
sed@  
MOMP F 
immunised
@ 
MOMP G 
immunised@ 
MOMP A plus MOMP 
F immunised@ 
Kathy prior to placebo 
administration ^ 
Kathy 20 weeks post 
placebo administration ^  
Popeye vaccinated 
with MOMP G # 
Felix Pitt vaccinated 
with MOMP G $ 
37 
C. pecorum MOMP F 
Variable Domain 3 
NQTLPLPITAGTATD                            
38 PITAGTATDSNEKLK                           
39 ATDSNEKLKNATINY                           
40 
Conserved domain 
KLKNATINYHEWQVG                           
41 INYHEWQVGAALSYR                           
42 QVGAALSYRLNMLIP                           
43 SYRLNMLIPYIGVQW                           
44 LIPYIGVQWSRASFD                           
45 VQWSRASFDADTIQI                           
46 SFDADTIQIAQPKLA                           
47 
C. pecorum MOMP F 
Variable Domain 4 
IQIAQPKLASPVLNM                           
48 KLASPVLNMTTWNPT                           
49 LNMTTWNPTLLGEAT                           
50 NPTLLGEATSVNAGN                           
51 EATSVNAGNKYADVL                           
52 
Conserved domain 
AGNKYADVLQIVSLQ                           
53 DVLQIVSLQINKLKS                           
54 SLQINKLKSRKACGV                           
55 LKSRKACGVSMGATL                           
56 CGVSMGATLLDADKW                           
57 ATLLDADKWAINGEL                           
58 DKWAINGELRLINER                           
59 GELRLINERAAHLSA                           
60 NERAAHLSAQCRF                           
61 LINERAAHLSAQCRF                           
62 HALPVGNPAEPSLLI                           
63 VWEGMSGDPCDPCAT                           
64 
C. pecorum MOMP 
A Variable Domains 
1,2,3 and 4 
DVPKQFTMGPIPTSS 
(VD1) 
                          
65 
TMGPIPTSSTSAADS 
(VD1) 
                          
66 
TSSTSAADSATPTER 
(VD1) 
                          
67 
ADSATPTERNNAAY 
(VD1) 
                          
68 
TPTERNNAAYGKHMH 
(VD1) 
                          
69 
GSSLEGKYPNANISN 
(VD2) 
                          
70 
LPLPTNAGTSNATDL 
(VD3) 
                          
71 WNPTLLGERTSGTTF                           
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Peptide 
No. 
MOMP region Peptide Sequence 
C. pecorum negative 
koalas 
C. pecorum G infected 
koalas 
C. pecorum F infected 
koalas 
C. pecorum free vaccinated koalas C. pecorum infected vaccinated koalas 
Mean of four C. 
pecorum free pre-
immunised animals 
Mars Bar*  Popeye* # Nixon* Felix Pitt* $ 
MOMP 
A 
immuni
sed@  
MOMP F 
immunised
@ 
MOMP G 
immunised@ 
MOMP A plus MOMP 
F immunised@ 
Kathy prior to placebo 
administration ^ 
Kathy 20 weeks post 
placebo administration ^  
Popeye vaccinated 
with MOMP G # 
Felix Pitt vaccinated 
with MOMP G $ 
(VD4) 
72 
C. pecorum MOMP 
G Variable Domains 
1,2,3 and 4 
KTDVPKQFTMGTTPT 
(VD1) 
                          
73 
GTTMGTTPTSAGAAA 
(VD1) 
                          
74 
TPTSAGAAATSNTSE 
(VD1) 
                          
75 
AAATSNTSEQRNNPA 
(VD1) 
                          
76 
TSEQRNNPAYGKHMH 
(VD1) 
                          
77 
GSTLNDMYPNANISN 
(VD2) 
                          
78 
LPLPTDAGTDAATGL 
(VD3) 
                          
79 
TLLGEATQVDNSNKF 
(VD4) 
                          
80 
C. pecorum MOMP 
H Variable Domains 
1,2,3 and 4 
KTDVPKQFTMGPIPT 
(VD1) 
                          
81 
QFTMGPIPTSSTSAE 
(VD1) 
                          
82 
IPTSSTSAEDSATPT 
(VD1) 
                          
83 
SAEDSATPTERNNAA 
(VD1) 
                          
84 
TPTERNNAAYHDAEW 
(VD1) 
                          
85 
TLLGQATQVDNSNKF 
(VD4) 
                          
86 
Conserved domain 
MKKTLKSAFLSAAFF                           
87 FLSAAFFAGDASLHA                           
88 DASLHALPVGNPAEP                           
 
Table 2. List of all major epitopes recognised by Chlamydia free, healthy animals; C. pecorum infected koalas; Chlamydia free, healthy koalas upon vaccination and C. pecorum infected koalas upon vaccination. 
Legend: Shaded boxes indicate epitopes already identified by the pre-immunised samples; Diagonal striped boxes indicate uniquely identified epitopes upon natural infection; Crosshatch boxes indicate new epitopes 
recognised post-vaccination in Chlamydia-free and infected koalas. * All the animals were compared to the mean of four pre-immunised samples; # $ @ Animal compared to its pre-immunised sample
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7.1 DISCUSSION 
Koalas (Phascolarctos cinereus) are native Australian tree-dwelling marsupials and 
the last surviving member of the family Phascolarctidae. Recently, the Australian 
Federal Government (April 2012) listed koala populations in Queensland, New South 
Wales and the Australian Capital Territory as “vulnerable”. The decline across 
various populations in Australia, particularly in previously densely populated koala 
populations, has been attributed to several factors, including, habitat loss due to land 
clearing [1], chlamydial disease [2], motor vehicle trauma [3] and dog attacks [4]. A 
recent modelling study suggested that addressing disease could be a key factor in 
enabling populations that are in sharp decline to recover [5]. Several studies [6-10] 
have described chlamydial infections in koalas and often suggested that koalas are 
more prone to diseases than other marsupials.  
Chlamydial infections in koalas have been associated with a spectrum of diseases 
ranging from keratoconjunctivitis (ocular disease) leading to blindness, rhinitis and 
pneumonia, as well as urinary and genital tract disease, resulting in inflammation and 
fibrosis of the bladder and the upper female genital tract [11]. A recent study by 
Griffith et al. [12] found that koalas with clinical signs of chlamydiosis made up the 
second most frequent admission group to a koala rehabilitation facility over the 30 
year period that they analysed. Although systemic antimicrobial drugs are used for 
treating chlamydial infections, several studies [13,14] have shown that the current 
treatment regimes are not efficient in controlling the spread of infections in wild 
koalas. As observed in humans, the majority of the chlamydiosis symptoms in the 
wild koalas are asymptomatic. For all these reasons, a vaccine is needed to control 
these infections effectively.  
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To develop an effective vaccine for chlamydial infections in koalas several key 
aspects needs to be addressed, including, (a) an understanding of the epizootiology of 
chlamydial infections, including the diversity of strains of C. pecorum infecting 
koalas, (b) the choice of a suitable vaccine candidate antigen and evaluation of its 
safety in koalas and its ability to generate an immune response, (c) detailed analysis 
of the immune response of koalas to a vaccine, including antibody and cell mediated 
immune responses, and (d) an evaluation of the safety and immune response to the 
vaccine in koalas that are already infected / diseased. This thesis has addressed all of 
these key questions by, (a) evaluating the epizootiology and diversity of C. pecorum 
strains infecting several wild koala populations across the koala’s habitat (Chapter 
Three) (b) demonstrating the safety and immunogenicity of a prototype recombinant 
Major Outer Membrane Protein (MOMP) based C. pecorum vaccine in healthy 
koalas as well as koalas with active disease (Chapter Four), (c) demonstrating the 
antigenic specificity of a monovalent versus polyvalent MOMP based C. pecorum 
vaccine in healthy koalas (Chapter Five), and (d) characterisation of antibody 
responses in healthy as well as naturally infected koalas, prior to and after 
vaccination (Chapter Six). 
Initially in this study, I investigated the prevalence as well as the genetic diversity of 
C. pecorum infections in several wild koala populations (Chapter Three). While 
screening 403 koalas from 11 populations (wild and captive/hospitalised) using a 
diagnostic 16S rRNA quantitative real-time PCR, I found 181 koalas (45%) to be 
positive for C. pecorum infections (Figure 1, Chapter Three). Among three 
anatomical sites tested, the urogenital tract was found to be the site most often 
infected. Within the six wild koala populations (244 koalas) in South East 
Queensland, C. pecorum infections were detected in 96 koalas (39.3%). In the 
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remaining five populations across Australia, after screening 159 koalas, I found 85 
koalas (53.4%) positive for C. pecorum infections. Among the three hospitalised 
koala populations, 74 of the 118 animals (62.7%) and 107 of the 285 animals 
(37.5%) in the eight wild koala locations, were positive for C. pecorum. 
Previously, Jackson et al. [15] used a fragment of the outer membrane protein gene 
(ompA VD4) typing scheme and identified five C. pecorum ompA genotypes 
(designated A, B, C, D and E) from various positive isolates across Australia. In the 
current study, I identified 10 new full length C. pecorum ompA genotypes (A, B, E’, 
F, F’, G, H, I, J and K) from various koala populations in Australia. If a newly 
identified, full length ompA genotype sequence was 100% identical to a previously 
identified genotype at the variable domain four, then both of them were designated 
with the same alphabet. For example, full length C. pecorum ompA genotype ‘A’ is 
identical to previously identified genotype A [15] at the variable domain four. The 
phylogenetic tree representing all the MOMP amino types has two main clades at the 
base. The smaller, basal/ancestral clade consists of three amino types (E’, F, and F’) 
which are widespread across the majority of the koala populations, except for the 
South Australian koalas. The more recently diverged amino types (A, B, G, H, I, J 
and K) cluster to form a large clade with several branches and are restricted to a 
lesser number of koala locations. The highest number of amino acid polymorphisms 
(55 amino acids) among the two clades was found between amino types A and F. 
Although these wild populations are spread out with no affiliations (animal 
interactions) between them, surprisingly I found very high levels of genetic diversity 
in C. pecorum strains when compared to the diversity of infections caused by various 
species of Chlamydiaceae in other densely populated hosts confined to a 
geographical location. As shown in Figure 1 of Chapter Three, the C. pecorum ompA 
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genotype F was widespread across 9 out of 11 screened populations, while genotype 
G was present in 4 of the 11 screened populations. Interestingly, 6 out of 11 
populations were infected with two or more C. pecorum genotype infections. Tanilba 
bay (A, F, G, I, J and K) was the only population to be infected with more than four 
different genotypes. The considerable genetic diversity of multiple C. pecorum 
ompA types that I have observed in the koala is reminiscent of that of the ompA 
sequence diversity of human serovars of C. trachomatis. A molecular epidemiology 
study on C. trachomatis infections in 2534 patients, identified eight VD2 ompA 
genotypes [16], whereas, in this study I have identified six VD2 C. pecorum ompA 
genotypes after screening only 403 koalas.  
Among the two species of Chlamydia infecting wild koala populations, C. pecorum 
is the dominant species (averaging 57%), with C. pneumoniae present at low levels 
(averaging 18%) [2]. Current efforts to control these chlamydial infections in koalas 
involve using systemic antimicrobial drugs such as enrofloxacin (Baycox® Bayer 
Healthcare AG, Lerverkusen, Germany) and chloramphenicol (Chloramphenicol 150 
Ceva Delvet, Seven Hill, Australia) [17]. Despite prevention and control efforts 
(includes Chlamydia screening and treatment with antibiotics) in the koalas either 
presenting to various wildlife hospitals or during longitudinal screening of several 
wild koala populations, this has had no significant impact on the prevalence rates 
[14]. The failure of these control efforts may indicate that C. pecorum interaction 
with the host immune system determines its epidemiology in koalas. This strongly 
suggests that vaccine development is the next essential step for control. The 
prerequisite of a successful Chlamydia vaccine is to prevent the acquisition and 
transmission of infection and to prevent the development of disease sequelae.  
 Chapter 7: GENERAL DISCUSSION 211 
The surface of the chlamydial elementary body is responsible for (a) protection 
against the environment outside of the host, (b) defense against the host’s immune 
response, and (c) attachment to host cells. The MOMP is an approximately 40 kDa 
highly disulphide cross-linked surface exposed protein that comprises about 60% of 
the outer membrane of Chlamydiae [18] and is presumed to play a key role in most if 
not all of the above mentioned features of the chlamydial EB. MOMP is an 
immunodominant antigen in both humans and other animals and contains several B 
and T cell epitopes, eliciting both neutralising antibodies as well as T-cell immunity 
[19,20]. MOMP is comprised of four variable domains interspersed with five 
constant domains [21,22]. The high non-synonymous substitution rate in the variable 
domains of ompA gene in concert with gene conversion and positive selection is 
responsible for a high degree of variability that promotes host immune evasion [23]. 
Using an in silico prediction algorithm, six of the predicted, high affinity T cell 
epitopes are highly conserved across all 10 MOMP amino types, four epitopes are 
located in the variable domain four with 2 – 6 amino acid changes between them. 
High levels of diversity ranging from 53% - 71.4% exist among four B cell epitopes 
located in the variable domains of various C. pecorum amino types. (Chapter Three). 
Although MOMP has been shown to be highly variable, it has been the major target 
antigen for vaccine development over the last 20 years in various animal models and 
continues to be in use [24-27].  
Some of the potential limitations of MOMP based vaccines [28,29] include (a) the 
inability to produce cross-serovar/strain protection or that the protection may be 
restricted to the homologous serovar, and (b) the requirement of appropriate tertiary 
confirmation and tedious refolding to preserve the immunogenicity of the protein 
[19]. However, to our knowledge, the rationale behind the inability of the MOMP 
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based vaccines to provide cross-serovar protection has not been experimentally 
justified/proved because of the following reasons, (a) none of the vaccine studies 
using the C. muridarum mouse model have evaluated a recombinant C. muridarum 
MOMP vaccine to elicit protection to several C. trachomatis human serovars or a 
recombinant MOMP vaccine involving several C. trachomatis human serovars to 
elicit cross-serovar protection to the C. muridarum isolate, and (b) studies performed 
in non-human primates using the native trimeric structure of MOMP as a vaccine 
were shown to produce highly serovar specific protective immune responses [24,30]. 
Hence, in the current study I have focussed on evaluating, (a) the ability of 
recombinant MOMP protein from a particular C. pecorum isolate to induce cross-
amino type immune responses in healthy as well as diseased koalas naturally infected 
with a different amino type (Chapter Four), and (b) to evaluate a monovalent versus 
polyvalent recombinant MOMP vaccine preparation from three highly diverse C. 
pecorum amino types (Chapter Five), identified as part of this study (Chapter Three).  
During the early trachoma immunisation trials in humans, upon re-infection with live 
natural Chlamydia, a sub-set of vaccinated individuals developed hypersensitivity 
reactions resulting in lesions that were more severe than the primary infection [31-
34]. Since these early, unsuccessful whole organism vaccine trials, all vaccine 
research has focussed on using purified recombinant proteins. Although Chlamydia 
triggers the host immune system, the immunity to natural infection is incomplete and 
apparently takes a significant length of time to acquire due to many immune evasion 
mechanisms [35]. Some of these mechanisms include antigenic variation of the 
MOMP, phase variation of Polymorphic Membrane Proteins (Pmps) and cytokine 
dependent modulation of developmental cycle responses, enabling the establishment 
of persistent forms and thereby reduced expression of the major protective antigens 
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[36]. Studies have focused on using highly conserved recombinant antigens such as 
chlamydial heat shock protein (chsp60) as a vaccine candidate [37,38] because of its 
significant role in inducing immune responses during natural human C. trachomatis 
persistent infections [39]. However, several vaccine trials in mouse or guinea pig 
models have shown worsening of clinical signs of disease and induction of 
autoimmune responses to host hsp60, due to amino acid similarity between the two 
proteins [40-42]. Hence, the current study is the first of its kind in the field of 
chlamydial vaccine development to evaluate a recombinant Chlamydia multi-subunit 
vaccine consisting of a highly variable MOMP and species conserved NrdB 
(ribonucleotide-diphosphate reductase beta subunit) in an animal species (koala in 
this study) adversely affected by naturally occurring ocular and genital tract 
chlamydial infections (Chapter Four). 
I vaccinated 22 wild koalas assigned into two groups, (a) healthy (n=10) and (b) 
naturally infected wild koalas (n=12). Healthy animals were divided into three sub 
groups which received either three doses of vaccine (n=4) or two doses of vaccine 
(n=4) or placebo (n=2). Diseased koalas were divided into two groups and were 
immunised with either three doses of vaccine (n=8) or placebo (n=4). Each of the 
subcutaneously immunised koalas were thoroughly examined and sampled (blood 
and swab collection) every four weeks until 20 weeks. Importantly, four of the eight 
animals in the diseased vaccine group demonstrated better disease scores 
(improvement in pre-existing lesions) at the end of 20 weeks, and no worsening of 
the lesions (no change in disease score) was observed for the remaining animals in 
the group. Two of the four animals in the diseased placebo group had a worsening of 
clinical signs during the course of trial. This strongly supports the safety of the 
vaccine tested. This confirms that our multi-subunit vaccine does not contain any 
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immune potentiating epitopes to induce autoimmune responses or aggravated 
pathology, at least up to 20 weeks following vaccination.  
A few studies utilising native MOMP formulations in non-human primates have 
looked at the vaccine induced immune responses and found specific responses either, 
to homologous serovars [24] or cross-reacting to the closely related heterologous 
serovars [30]. Recombinant preparations of MOMP have been extensively used in 
rodent models to protect against the homologous serovar but there have only been a 
few studies to elicit limited heterotypic protection using rMOMP. For example, 
Tuffrey et al. [43] immunised C3H mice with a truncated C. trachomatis serovar L1 
rMOMP by the subcutaneous, intramuscular or intraperitoneal routes and challenged 
intrabursally with C. trachomatis serovar F. Limited protection was observed against 
vaginal shedding and salpingitis in the vaccinated animals and no protection against 
infertility was observed. Similarly, Li et al. [44] have immunised BALB/c mice with 
C. trachomatis D rMOMP and challenged the animals intravaginally with C. 
muridarum. They did not observe any significant differences in vaginal shedding or 
tubal pathology when compared to a group of mice immunised with an unrelated 
antigen (CPAF).  These apparent discrepancies between the results could be due to 
the confirmation of the MOMP used, species of the animal model used and 
differences in the virulence of particular serovar/ amino type. Hence, as part of this 
study (Chapter Five) I recruited 12 healthy female koalas and divided them into four 
groups of three koalas per group. The four groups were (a) subcutaneously 
immunised either with rMOMP A or (b) rMOMP F or (c) rMOMP G or (d) rMOMP 
A plus rMOMP F. All the animals in this study have shown no adverse signs of 
swelling or abscess formation around the vaccination site when monitored up to 44 
weeks.  
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The responses central to chlamydial immunity have been identified through a variety 
of experimental approaches in several animal models. CD4+ T cell responses have 
been clearly demonstrated to be responsible for protective immunity against 
chlamydial infections in several animal models [24,45,46]. Cytokines of Th1 lineage 
such as IFN-γ and IL-12 are essential for protection [47-49], while the Th2 cytokine 
IL-10 has been associated with a pathological response [50]. At this stage, I was 
unable to determine the cytokine profile of proliferating cells, nor their phenotype 
(CD4 or CD8) due to lack of reagents available for the koala. However, in the current 
study (Chapter Four), I showed that a significant percentage of systemic lymphocytes 
(10-20%) from the vaccinated animals in both healthy as well as naturally infected 
groups underwent two or more rounds of cell division when challenged with the 
vaccine antigens in vitro demonstrating a strong cell-mediated response. In Chapter 
Five, I further investigated a MOMP based vaccine formulated with either one or two 
C. pecorum amino type rMOMPs to produce cross-recognising lymphocyte 
responses. Most promisingly, I found no significant differences in proliferating 
lymphocytes between the individual and dual MOMP groups when stimulated in 
vitro with homologous or heterologous C. pecorum EBs. This data, along with 
several T cell epitope predictions, suggests that the majority of the immunodominant 
T-cell epitopes of MOMP are in the conserved domains and cross-react with all C. 
pecorum amino types.  
The obligatory intracellular lifestyle of Chlamydiae suggests that cellular immunity 
will be more important than antibody in protection. However, there is considerable 
published evidence supporting the role of antibody in protective immunity. 
Resistance to natural chlamydial infections in humans [51] and experimental 
infections in primates [52] correlates with the presence of local Chlamydia-specific 
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IgG and IgA antibodies. Preclinical models of infection using B cell [53] or Fc 
receptor [54] deficient mice support a role for B cells or antibodies in protective 
immunity. In another study [55], immune serum was shown to confer a marked level 
of resistance against murine chlamydial genital tract reinfection but not against 
primary infection. Antibody mediated protection is dependent on a CD4 + T cell 
immune response that apparently regulates adaptive changes in the local genital tract 
tissues and thereby is responsible for the protective role of Ab. These studies have 
discovered an unrecognised role of B cells in recall immunity, an important aspect of 
adaptive immunity relevant in designing effective chlamydial vaccines.  
Surface exposed antigens such as MOMP on the infectious elementary body (EB) are 
the major targets for protective antibody responses. One of the major criteria in 
analysing the humoral immune response induced by an effective vaccine is to 
demonstrate functional antibodies which can neutralise the in vitro infectivity of 
chlamydial infections by blocking the EB attachment [56]. Recently, several studies 
have demonstrated that eliciting broadly neutralising antibodies to HIV could deliver 
a successful AIDS vaccine in humans [57,58]. In the current study (Chapter Four), I 
am the first to report significant vaccine enhanced production of C. pecorum 
neutralising antibodies in healthy as well as naturally infected koalas, when 
compared to their respective placebo groups. Although the majority of the diseased 
koalas were infected with C. pecorum F amino type and subsequently immunised 
with a heterologous rMOMP of C. pecorum G, they still were able to neutralise the 
C. pecorum G infection in vitro. Non human primate studies with C. trachomatis 
have demonstrated that neutralising antibodies produced as a result of immunisation 
with native MOMP of either an ocular serovar [24] or genital serovar [30] were 
highly serovar-specific, even though there were only two amino acid differences 
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between the homologous and heterologous serovars. In Chapter Five of the current 
study, for the first time using recombinant MOMP vaccine formulation, I have 
demonstrated that the vaccine induced plasma antibodies neutralised several C. 
pecorum infections in vitro. Even though animals in individual MOMP groups were 
immunised with a single C. pecorum rMOMP, they effectively neutralised 
homologous as well as heterologous C. pecorum infections in vitro. By comparison 
to the non-human primate vaccine studies mentioned above, although there was 35 – 
54 amino acid differences between the various C. pecorum MOMP sequences used in 
this study, interestingly I did not find any significant differences in neutralisation of 
various C. pecorum infections between individual and combined MOMP groups. 
This strongly suggests the presence of major functional B-cell epitopes located in 
both variable and conserved domains. Several MOMP based vaccine studies have 
used native MOMP, arguing that this ideally represents the conformation on EBs, 
and should result in the production of more effective antibodies. In our study, I was 
able to demonstrate the production of cross-neutralising antibodies after immunising 
with a non-conformational recombinant MOMP. 
Interestingly, unlike the intestinal tract, which has mucosal priming sites such as 
Peyer’s patches, the induction of immune responses for the genital tract are located at 
distant sites, such as spleen and iliac lymph nodes, resulting in delayed systemic 
response relative to other sites [59]. The dominant immunoglobulin class in the 
genital tract is IgG, while IgA is the dominant class at other mucosal sites [59]. Its 
dominating presence in the genital tract accounts for the translocation from the serum 
to secretions, rather than an increase in local IgG-secreting cells [60]. This 
uniqueness of the immune system in the genital tract and Chlamydia targeting 
mucosal epithelial cells, emphasises the prerequisite for a C. trachomatis vaccine to 
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induce both systemic and mucosal immune responses. In the current study (Chapters 
Four and Five), I have demonstrated vaccine induced systemic and mucosal humoral 
responses against the vaccine antigens in immunised koalas. Prior to vaccination, 
although koalas naturally infected with C. pecorum infections had pre-existing 
immune responses, this did not prevent the development of robust vaccine-induced 
responses. However, antibody responses produced to MOMP were significantly 
greater than to the highly conserved protein, NrdB. Several studies have used native 
and recombinant MOMP as a vaccine candidate in various animal models [28], 
although none of them have so far reported the cross-recognising humoral immune 
responses to heterologous serovars/amino types. To my knowledge, this is the first 
time in the field of chlamydial vaccine development that a natural animal model (i.e. 
not mice) has been used to demonstrate that immunisation can induce antibodies at 
systemic and mucosal sites in healthy as well as diseased animals. Most promisingly, 
the vaccine induced antibodies were also able to recognise multiple amino 
type/serovar MOMPs, apart from the immunising amino type or pre-existing MOMP 
amino type infections. This study suggests that (a) when koalas naturally infected 
with C. pecorum MOMP amino type F (in this study), developed antibodies to the 
surface exposed conformational and/or linear amino type-specific epitopes, these 
were not adequately protective (same as reported with C. trachomatis in humans), 
and (b) reveals the presence of major functional B-cell epitopes at both variable and 
conserved domains. Although conformational or linear serovar specific epitopes 
present in the native MOMP (nMOMP) may be predominant and more effective at 
inducing protection against the homologous serovar, they may not elicit the adaptive 
immune response to hidden/conserved epitopes that may be cross-reactive. Even with 
the use of limited surrogate parameters for evaluating this vaccine, I did not find any 
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difference in the vaccine induced cell-mediated and humoral immune responses 
between the koalas of individual and combined MOMP groups. 
Injectable vaccination of wild koalas will likely involve capture and release of 
animals, which is tedious, costly and stressful for the animals. These risks can be 
minimised by fewer booster immunisations in a wildlife setting. Hence, I compared 
the immune responses in animals administered three shots of vaccine versus two 
shots of vaccine (Chapter Four).  Interestingly, at the end of 20 weeks, I could not 
find any significant differences in humoral and cell-mediated immune responses 
between the two groups. This comparison strongly suggests that a two shot multi-
subunit vaccine when administered subcutaneously could be sufficient to induce 
immunity lasting at least 20 weeks.   
A promising aspect of my studies performed so far was the cross-reactivity of 
MOMP antibody responses from vaccinated healthy and diseased koalas. In this 
study (Chapter Six) I further investigated the B cell epitopes responsible for the 
cross-reactivity of the vaccine induced plasma antibodies by using biotinylated 
peptide assay representing four full length variable MOMP amino types (MOMP A, 
F, G and H). Here, I had characterised, (a) the specific MOMP epitopes recognised 
by koalas naturally infected with various C. pecorum amino types, (b) epitopes 
recognised by healthy animals immunised with either MOMP A or MOMP F or 
MOMP A plus MOMP F, and (c) epitopes recognised by the diseased animals 
immunised with MOMP G. Animals naturally infected with C. pecorum G produced 
antibodies only to the variable domain four of MOMP G and MOMP H. Interestingly 
when this epitope was aligned there was only one amino acid difference between 
MOMP G and MOMP H, which suggests the possibility of cross-reacting antibodies 
between them. Animals naturally infected with C. pecorum F produced plasma 
 Chapter 7: GENERAL DISCUSSION 220 
antibodies to epitopes in three of the four variable domains of MOMP F (VD1, VD2 
and VD4). By comparison to the responses in the naturally infected animals, 
vaccinated animals produced a different spectrum of antibodies. Chlamydia-free 
animals, when immunised with either MOMP A or MOMP F or MOMP G or MOMP 
A plus F, produced antibodies to the variable domains of the homologous MOMP as 
well as also producing antibodies to epitopes within the conserved domains. 
Similarly, when koalas previously naturally infected with C. pecorum G and F strains 
were then immunised with rMOMP G vaccine, they produced plasma antibodies that 
recognised several epitopes located within the variable as well as the conserved 
domains of MOMP. This study for the first time has characterised the specific B cell 
epitopes recognised in the koalas naturally infected with C. pecorum G and F amino 
types, healthy koalas immunised with a rMOMP variant and naturally infected koalas 
when immunised with a homologous or heterologous recombinant MOMP. 
Identification of common, non-immunodominant, and/or hidden antigens which aid 
in designing vaccines that induce cross-serovar/isolate protection pose a major 
challenge for several human pathogens such as Neisseria meningitides, hepatitis C 
virus, human immunodeficiency virus and influenza virus [61-64]. The findings in 
this study strongly suggest that the conserved, hidden B-cell epitopes are poorly 
presented to the immune system in the natural infection as well on the antigen in its 
native conformation. Following up on my study presented here, recently, vaccination 
with rMOMP in a C. muridarum mouse model was shown to elicit protection against 
homologous as well as heterologous Chlamydia serovars [65]. They have shown that 
immunisation with rMOMP from the C. trachomatis human serovars D, E or F, and 
the C. muridarum isolate, can protect mice against an intranasal challenge with C. 
muridarum. 
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Although the results from several studies as part of this project are very promising, 
several challenges still remain to deliver the vaccine to wild koala populations. 
Several areas that need to be addressed are, (a) to develop a single dose, long acting 
vaccine, (b) to vaccinate C. pecorum infected animals without any symptoms of 
chlamydiosis, (c) to vaccinate several wild koala populations to evaluate the vaccine 
under true field conditions, (d) to vaccinate the Chlamydia infected wild koalas and 
evaluate the protective efficacy by challenging them with live C. pecorum infections, 
and (e) to make the vaccine available to several koala sanctuaries and zoos, koala 
hospitals and care centres and wild koalas undergoing longer-term monitoring 
programs. 
In summary, my data in this project has demonstrated, (a) several C. pecorum amino 
types infecting various wild koala populations, (b) a multi-subunit chlamydial 
vaccine that can be safely administered to both healthy koalas as well as koalas that 
have a previous or current chlamydial infection, (c) the ability of the koalas to 
produce cross-reacting cell-mediated and humoral immune responses to various C. 
pecorum MOMPs and infections and (d) characterise the B cell epitopes, specifically 
recognised by the plasma antibodies in koalas naturally infected with various C. 
pecorum infections and cross-reactive epitopes recognised in healthy as well as 
diseased vaccinated koalas. 
7.2 Recommendations for Developing an Ideal Vaccine for Koalas 
Based on several significant findings reported in this study, I would suggest the 
following criteria for developing an effective Chlamydia vaccine in koalas. An ideal 
vaccine for koalas should (a) be formulated with recombinant proteins such as 
MOMP which consists of several immunodominant common and variable epitopes, 
and (b) design a MOMP-based vaccine based on the following criteria, (i) the 
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MOMP antigen in the vaccine should represent the most widespread amino type 
infection across several koala populations, and (ii) the MOMP antigen should 
represent the ancestral clade of the MOMP phylogenetic tree (e.g. MOMP “F” as 
shown in this study), (c) enhance a strong and broader/cross reactive cell mediated 
immune responses, and (d) produce a broader repertoire of systemic and mucosal 
humoral immune responses in healthy as well as animals with existing infections, 
against a range of C. pecorum isolates. 
7.3 Future Directions 
The studies performed in this thesis are novel in that I have evaluated our 
recombinant MOMP-based vaccine in a natural host, the koala, in which there are a 
range of infecting strains. While significant progress has been made, there are still 
several knowledge gaps that need to be addressed before delivering the vaccine to 
wild or captive koala populations across Australia.  
The differential immune pathways (mainly Th1, Th2, Th17 and Tc) that regulate the 
development of either humoral (antibody mediated) or cell mediated (T-cell) 
immunity or both are mediated through distinct immunoregulatory cytokines 
produced by two types of regulatory T-cells (CD4 and CD8 T-cells). In the process 
of developing a therapeutic vaccine in koalas, it is critical to identify the relevant 
immunological pathways of protection in koalas naturally infected with C. pecorum 
and then design a vaccine that will activate the appropriate pathway. In koalas, to 
date, the measurement of the immune responses has been severely hampered by the 
lack of immunological reagents. Hence, it is essential to develop a complete set of 
immunological reagents to measure Th1 and Th2 cytokine expression profile in 
koalas. These species specific immunological reagents would help us in 
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understanding the disease pathology caused by C. pecorum in koalas and aid in 
developing an effective vaccine [66,67].  
During the course of this study, at least in one trial, I was able to measure the degree 
of pathology at ocular and urogenital tract sites caused by C. pecorum natural 
infections in wild koalas. Although this is an ideal measure of the pathology caused 
by chlamydial infections, however there still needs to be an appropriate measure of 
the C. pecorum infections. The number of organisms recovered at fixed time points 
following infection could be used to define the severity of infection. This is critically 
important in testing vaccine efficacy to determine whether a vaccine administered 
can protect against either infection or disease, or both. 
The studies presented in this thesis have successfully evaluated a MOMP based 
vaccine in wildkoalas under captive conditions. In addition, it would be ideal to test 
the efficacy of the vaccine at several wild koala populations in their natural niche 
(i.e. wild life setting). However, use of an injectable vaccine in wild koala 
populations would require the capture and restraint of animals, which is both 
traumatic for the animals, expensive, and requires skilled animal handlers. For this 
reason, evaluating a MOMP-based vaccine formulated with novel, long acting 
adjuvants would represent a major advantage in a wildlife setting. Novel, long acting 
adjuvants such as VIDO adjuvant, co-formulated with pertussis toxoid (PTd), 
filamentous hemagglutinin (FHA) in soluble microparticles which has been reported 
to induce strong, long lasting Th1 immune responses in mice and pigs [68] could be 
potentially trialled in immunising wild koalas. 
As part of this study, I have evaluated the safety of our vaccine in healthy (termed 
group 1) as well as naturally infected koalas showing signs of chlamydiosis (termed 
group 3). To test the protective efficacy of the vaccine, group 3 animals represents an 
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ideal cohort and has several advantages over group 1 animals. However, a recent 
study by Geisler et al. [69] over a 2.5 yrs period have reported that 20% of women 
who were positive for C. trachomatis cervical infections (but no evidence of 
pathology) at the time of treatment will have subsequent re-infection within a year of 
treatment for infection. This relatively high rate of chlamydial re-
infection/persistence after antibiotic treatment may indicate that some infected 
individuals did not develop protective immunity. Similar to humans, a significant 
number of koalas in the wild are also positive for C. pecorum infections but with no 
signs of pathology/chlamydiosis (termed group 2 animals). Although it is difficult to 
screen and recruit these animals into the vaccine studies, it is very important to 
evaluate the vaccine in these animals since they represent a major demographic 
group in the wild. Furthermore, an ideal therapeutic chlamydial vaccine in koalas 
should be evaluated for protective immune responses in group 3 immunised koalas 
when challenged with live C. pecorum infection. 
The findings from the two vaccine trials reported in this thesis have shown the 
potential of our recombinant MOMP-based vaccine to induce long lasting, humoral 
as well as cell mediated immune responses (until 140 days) against multiple C. 
pecorum infections in healthy as well as diseased koalas. However, it is essential to 
address the above mentioned knowledge gaps to develop a successful therapeutic 
vaccine in koalas.  
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8.1 ABSTRACT 
 
Background 
Chlamydia pecorum is an obligate intracellular bacterium and the causative agent of 
reproductive and ocular disease in several animal hosts including koalas, sheep, 
cattle and goats.  C. pecorum strains detected in koalas are genetically diverse, 
raising interesting questions about the origin and transmission of this species within 
koala hosts.  While the ompA gene remains the most widely-used target in C. 
pecorum typing studies, it is generally recognised that surface protein encoding 
genes are not suited for phylogenetic analysis and it is becoming increasingly 
apparent that the ompA gene locus is not congruent with the phylogeny of the C. 
pecorum genome. Using the recently sequenced C. pecorum genome sequence (E58), 
we analysed 10 genes, including ompA, to evaluate the use of ompA as a molecular 
marker in the study of koala C. pecorum genetic diversity.    
Results 
Three genes (incA, ORF663, tarP) were found to contain sufficient nucleotide 
diversity and discriminatory power for detailed analysis and were used, with ompA,  
to genotype 24 C. pecorum PCR-positive koala samples  from four populations. The 
most robust representation of the phylogeny of these samples was achieved through 
concatenation of all four gene sequences, enabling the recreation of a “true” 
phylogenetic signal.  OmpA and incA were of limited value as fine-detailed genetic 
markers as they were unable to confer accurate phylogenetic distinctions between 
samples. On the other hand, the tarP and ORF663 genes were identified as useful 
“neutral” and “contingency” markers respectively, to represent the broad 
evolutionary history and intra-species genetic diversity of koala C. pecorum. 
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Furthermore, the concatenation of ompA, incA and ORF663 sequences highlighted 
the monophyletic nature of koala C. pecorum infections by demonstrating a single 
evolutionary trajectory for koala hosts that is distinct from that seen in non-koala 
hosts. 
Conclusions 
While the continued use of ompA as a fine-detailed molecular marker for 
epidemiological analysis appears justified, the tarP and ORF663 genes also appear to 
be valuable markers of phylogenetic or biogeographic divisions at the C. pecorum 
intra-species level.   This research has significant implications for future typing 
studies to understand the phylogeny, genetic diversity, and epidemiology of C. 
pecorum infections in the koala and other animal species. 
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8.2 BACKGROUND 
 
Chlamydia are obligate intracellular bacterial pathogens that are characterised by a 
biphasic development cycle, involving the inter-conversion between an extracellular, 
metabolically inert form (elementary body, EB) and an intracellular, metabolically 
active form (reticulate body, RB) [1]. With the advent of molecular analyses, the 
taxonomy of chlamydiae has undergone several revisions [2], with a recent proposal 
recognising nine species within the Chlamydia genus: C. trachomatis, C. muridarum, 
C. pneumoniae, C. abortus, C. suis, C. felis, C. psittaci, C. caviae, and C. pecorum 
[3, 4, 5]. For the purpose of this research paper, we will refer to koala C. pecorum 
strains using this proposed nomenclature. While each of these are responsible for a 
number of disease states in a wide range of animals (including humans), the 
prevalence and transmission of C. pneumoniae and C. pecorum throughout 
Australian koala populations has contributed to a significant decline in koala 
numbers and remain a critical threat to the koala’s continued survival [6, 7, 8]. 
C. pneumoniae and C. pecorum have been isolated from most koala populations 
investigated, with C. pecorum found to be the most widespread and pathogenic of the 
two species [7, 8, 9, 10].  Notably, C. pecorum is also recognised as a pathogen and 
causative agent of polyarthritis and abortion in sheep and cattle [11].  In the koala, 
clinical manifestations of C. pecorum include ocular infection leading to conjunctival 
scarring and blindness, respiratory tract infection, urinary tract infection causing 
incontinence, and genital tract infection potentially leading to infertility [6, 7, 12, 13, 
14].  The latter disease signs have been implicated in lowered reproductive rates in 
wild koala populations in several parts of Australia, highlighting the need to 
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understand this complex host-parasite relationship for the purpose of effective 
management and control strategies [8]. 
Questions remain about the evolutionary origin of C. pecorum in koalas, given its 
traditional role as a pathogen of sheep and cattle and the modes of transmission 
within and between geographically isolated koala populations.  In an attempt to 
understand these questions, Jackson et al., have previously performed fine-detailed 
epidemiological surveys of C. pecorum-infected populations, revealing that C. 
pecorum is genetically very diverse [7].  This analysis was performed on short 
variable domain IV (VDIV) sequence fragments of the ompA gene, encoding the 
surface-exposed major outer membrane protein (MOMP) which is common to all 
members of the Chlamydiaceae [15]. There are currently eight ompA VDIV 
genotypes that have been identified, following several studies of geographically 
isolated koala populations in Australia [7, 8, 14, 16, 17].  While the majority of these 
genotypes are apparently confined to the koala host, several identical or near-
identical sequences have been found in European sheep and cattle implying the 
possibility of cross-species transmission events between these hosts [7]. 
Questions, however, remain regarding the use of ompA as a single gene marker of 
chlamydial diversity.  From a phylogenetic perspective, previous studies have 
demonstrated that ompA phylogenies are not congruent with the phylogeny of other 
gene targets, including other membrane proteins [18, 19, 20].  Similar observations 
have also been made for non-koala strains of C. pecorum [11, 21], indicating that C. 
pecorum ompA gene phylogenies are not congruent with the phylogeny of other 
targets, nor are they compatible with groupings based on tissue tropisms or 
pathobiological profiles. Diversifying host immune pressure is postulated as the 
reason why the C. pecorum ompA gene evolves more rapidly than the rest of the 
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chlamydial genome, and hence, renders it incapable of reflecting the true 
evolutionary divergence of C. pecorum [11]. 
Until recently, the use of alternate molecular markers for the genetic analysis of 
koala C. pecorum has been limited due to the lack of DNA sequences for this 
species.  However, the recent completion of the currently unpublished C. pecorum 
genome sequence from the E58 type strain is allowing investigation into novel and 
alternative gene targets.  Most notably, Yousef Mohamad et al. recently identified 
several genes that were potentially useful as C. pecorum markers of virulence and 
pathogenicity [21].  In the current study, we have utilised the C. pecorum E58 strain 
genome sequence in the preliminary characterisation of 10 novel gene targets for the 
purpose of validating ompA as a fine-detailed genetic and phylogenetic marker for C. 
pecorum infections in the koala. 
The primary objectives of the present study were to apply our selected genes to (1) a 
determination of the number of major phylogenetic divisions within koala C. 
pecorum samples obtained from four distinct koala populations; (2) the identification 
of useful fine-detailed genetic markers to represent these phylogenetic divisions; and 
(3) a reconstruction of the evolutionary history of lineage divergence between koala 
and non-koala hosts of C. pecorum.  Overall, this study identifies useful alternative 
tools for the future characterisation of koala C. pecorum infections.  Additionally, we 
present a preliminary appreciation of the phylogenetic diversity of C. pecorum in 
koala and non-koala hosts, as a prelude to future in-depth multi-locus sequence 
typing (MLST) studies of the C. pecorum phylogeny. 
 
 Chapter 8: APPENDIX 237 
8.3 METHODS 
 
Chlamydial strains and clinical samples 
The ‘type strain’ (MC/MarsBar) utilised for C. pecorum gene sequencing and 
analysis was recently isolated and cultured in our laboratory from a female koala 
suffering severe genital tract and ocular disease with chronic cystitis.  The sample 
originated from Mount Cotton, in South-East Queensland.  Swab samples collected 
from wild koalas were stored at -80°C prior to DNA extraction. 
Selection of candidate molecular marker genes 
A total of 10 genes were selected as candidate marker genes, including two 
housekeeping genes to serve as a control for analysis, five membrane proteins and 
three potential virulence genes.  The gene candidates included: 16S rRNA: A 
housekeeping gene that forms the 16S ribosomal unit; 16S-23S intergenic spacer: A 
non-transcribed spacer between 16S and 23S ribosomal sequences [22]; ompA: 
Encodes the major outer membrane protein (MOMP) protein, a porin responsible for 
nutrient transfer, attachment and structural support [23]; omcB: A cysteine-rich outer 
membrane polypeptide with functional, structural, and antigenic properties [24]; 
pmpD: A polymorphic membrane protein and putative autotransporter peptide [25]; 
incA: Encodes an inclusion membrane protein engaged in the interactions between 
the chlamydial inclusion and cytosolic components [26]; copN: A virulence-related 
Type III secretion effector [27]; tarP: A translocated actin-recruiting phosphoprotein 
that recruits actin at the site of internalisation [28]; MACPF: The membrane attach 
complex/perforin protein and a predicted virulence gene [29]; and ORF663: A 
hypothetical protein gene whose function is currently unknown [21]. Overall these 
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genes are functionally diverse and are widely distributed around the C. pecorum 
chromosome (data not shown). 
Primers, PCR amplification and sequencing 
Primers were primarily based on C. pecorum E58 gene sequences. To assist in the 
design of primers to amplify regions of sufficient conservation in the unknown koala 
C. pecorum genes sequences, analysis of homologous gene sequences available from 
other published chlamydial genomes, including C. trachomatis, C. pneumoniae, C. 
caviae, C. felis, C. muridarum, and C. abortus (Table 1), was also performed.  
Amplification of novel gene sequences from our C. pecorum koala type strain began 
with the addition of 100 ng of semi-purified MC/MarsBar to a PCR mixture 
containing 1X ThermoPol reaction buffer, 0.2 mM deoxynucleotide triphosphates 
(Roche), 1 pmol/µL each primer (Sigma; Table 2), and 0.02 U/µL VentR® DNA 
polymerase (New England Biolabs).  PCR conditions were a single cycle of initial 
denaturation at 94°C for 2 minutes, 30 cycles of denaturation at 94°C for 1 minute, 
primer annealing for 1 minute (Table 2), primer extension at 72°C for 2 minutes 
followed by a final elongation step at 72°C for 10 minutes. 
Due to the low quality and quantity of template from the koala clinical samples, an 
alternate PCR protocol was adopted which was optimised for higher specificity and 
sensitivity.  This was achieved by the addition of 5 µL of DNA extracted from C. 
pecorum-positive swab samples to a PCR mixture containing 1X GeneAmp PCR 
Gold buffer, 0.2 mM deoxynucleotide triphosphates (Applied Biosystems), 1 
pmol/µL each primer (Sigma; Table 2), and 0.05 U/µL AmpliTaq Gold DNA 
polymerase (Applied Biosystems).  PCR conditions were a single cycle of initial 
denaturation at 95°C for 10 minutes, 45 cycles of denaturation at 95°C for 1 minute, 
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primer annealing for 1 minute (Table 2), primer extension at 72°C for 1 minute, 
followed by a final elongation step at 72°C for 7 minutes.   
PCR products for both assays were separated by gel electrophoresis and visualised 
using a UV transmilluminator.  Negative controls (dH2O) were included in each 
amplification round to control for PCR contamination. PCR products were purified 
with an Invitrogen PureLink™ PCR purification kit and sent to the Australian 
Genome Research Facility (AGRF) for sequencing using the Sanger dideoxy method 
[30]. Gene sequence names from each C. pecorum positive sample were derived 
from the population from which the koala originated and the ID name assigned by 
the veterinarians (i.e. ‘Bre/Ned’ = Brendale population; animal name ‘Ned’). 
Sequence and statistical analysis 
Alignments for each sequenced gene were produced using ClustalW [31] and 
RevTrans [32] was used to reverse-translate all alignments.  Non-coding genes were 
aligned based on their nucleotide sequence.   
The software package DnaSP 5.0 [33] was used to analyse the extent of sequence 
variation by calculating the number of polymorphic and parsimony-informative sites, 
the average nucleotide diversity (p-distance) and Tajima’s test for neutrality (D-
value).  The Molecular Evolutionary Genetics Analysis (MEGA) [34] software 
package was used to calculate the number of synonymous and non-synonymous sites 
and subsequent dN/dS ratio using the Nei-Gojobori method [35].  The discrimination 
index (D.I.), based on Simpson’s index of diversity [36], was calculated to determine 
the differentiating and discriminatory capacity of each gene: 
D = 1 - [{1/N (N - 1)} x ∑ni (ni - 1)] 
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where D = index of discrimination, N = number of strains in the sample, and ni = 
number of strains in group i.  The index ranges from 0 to 1, with a value close to 0 
indicating low genetic diversity and a value close to 1 indicating high genetic 
diversity [36].  Calculation of the D.I. requires at least three nucleotide sequences for 
analysis. 
Criteria for identifying genetic markers 
In order to select the most appropriate candidate genes for further investigation, a 
shortlist of three genes: ORF663, incA and tarP (in addition to ompA) were selected 
based on several empirical criterions, and their application in previous C. pecorum 
typing studies [21].  The average proportion of nucleotide distances (p-distance) 
should be ≥ 0.02 before intra-species differentiation may be attempted [37, 38], and 
can be calculated from an alignment containing two or more sequences [39, 40]. 
Furthermore, both highly constrained, slowly-changing molecular markers and 
highly variable genes under diversifying selection each have their advantages, 
disadvantages, and advocates [41], implying the importance of selecting genes under 
both positive and negative selection.  Finally, the discrimination index (D.I.) for 
candidate markers should be > 0.50, which is suggested to be sufficient 
discriminatory power for adequate differentiation of bacteria beyond the species 
level [42, 43, 44].   
Koala populations, swab collection and processing 
Four distinct Australian koala populations were studied: East Coomera, Brendale, 
Narangba, and Pine Creek. The East Coomera population is located in South-East 
Queensland, approximately 54 km south of Brisbane and is comprised of 
approximately 500 koalas located in a 1716 ha area of cleared lands with isolated 
trees and small patches of native vegetation.  The Brendale and Narangba 
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populations are located among residential developments on the outskirts of Brisbane 
and are separated by a busy highway.  The Pine Creek population is situated 20 km 
south of Coffs Harbour, New South Wales and consists of approximately 6400 ha of 
coastal eucalypt forest interspersed with pockets of rainforest, pasture and freehold 
incursions.  The Pine Creek population was previously surveyed and was found to 
have 52% C. pecorum PCR positivity amongst animals screened [9].  
A total of 295 ocular and urogenital swabs were collected from 80 koalas within the 
four populations.  Ethics approval for the collection of swab samples from koalas 
was considered and provided by the QUT Animal Research Ethics Committee 
(Approval number 0900000267).  
For each sample, vials containing swabs and sucrose phosphate glutamate (SPG) 
transport media were vortexed for 30 seconds to release chlamydial bodies from the 
swab.  1 mL was transferred to a 1.5 mL eppendorf tube and centrifuged at 13,000 x 
g for 30 minutes to pellet the sample.  Following removal of the supernatant, the 
pellet was resuspended in 50 µL of SPG transport media and heated to 100°C for 2 
minutes to release the DNA.  Chlamydial DNA was then extracted using the tissue 
protocol of the QIAamp DNA kit (Qiagen). 
C. pecorum-specific diagnostic quantitative real-time PCR 
A total of 82 swabs from urogenital and ocular sites of the Narangba, Brendale, Pine 
Creek, and East Coomera koalas (65 animals) were screened for the presence of C.  
pecorum using a diagnostic quantitative real-time PCR (RT-PCR) targeting a 204 bp 
fragment of the 16S rRNA gene.  
The RT-PCR assay involved the addition of  3 µL of chlamydial DNA to a PCR 
mixture containing 1 x Faststart Taq DNA polymerase reaction buffer (Roche), 0.2 
mM deoxynucleotide triphosphates (Roche), 10 µM primers (RT-Pec.sp-F: 5’-
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AGTCGAACGGAATAATGGCT-3’, RT-Pec.sp-R: 5’-
CCAACAAGCTGATATCCCAC-3’; Sigma), 0.25 U/µL Faststart Taq DNA 
polymerase (Roche), and 1X SensiMixPlus SYBR green (Quantace).  All samples 
were assayed in triplicate.  The MC/MarsBar type strain served as a positive control 
while dH2O was used as the negative control.  PCR conditions were an initial 
denaturation of 94°C for 3 minutes, 40 cycles of denaturation at 94°C for 15 seconds, 
primer annealing at 57°C for 30 seconds, and DNA elongation at 72°C for 25 
seconds.  This was followed by a melting step from 70-90°C.  Equal numbers of C. 
pecorum positive samples (n=6) were randomly selected  for further PCR 
amplification, sequencing, and analysis. 
While incA and ORF663 were amplified and sequenced as full-length genes, smaller 
fragments of ompA and tarP were used for analysis.  These included a 465 bp 
fragment of ompA that comprises the highly variable VD III and IV regions which 
were previously targeted in a range of phylogenetic and fine-detailed 
epidemiological studies [11, 21] and a 726 bp highly polymorphic fragment of the 
tarP gene.   
Phylogenetic analysis 
Phylogenetic reconstructions were performed under both distance and maximum-
parsimony frameworks.  Distance analyses were performed using the neighbour-
joining algorithm and the Tamura-Nei model of molecular evolution as implemented 
in MEGA.  Maximum parsimony analyses were conducted by using the tree-
bisection and reconnection method of branch swapping and the heuristic search 
algorithm of PAUP* version 4.0b.  Relative support for individual nodes was 
assessed by nonparametric bootstrapping, with 1000 replications of the data.  The 
pairwise-deletion option was chosen to remove all sites containing missing data or 
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alignment gaps from all distance estimations.  Optimisation of the branch lengths 
was done by using the maximum-likelihood method (using Modeltest to define the 
evolutionary parameters [45]), subject to the constraint that all sampled sequences 
were contemporary (i.e., molecular clock was enforced).  All rooted trees were 
constructed with mid-point rooting to facilitate genotypic comparisons of the outer 
topologies. 
Genotypic Analysis 
The ability of each of the shortlisted genes to define specific genotypes within the 
koala populations was assessed, based on the nucleotide dissimilarity of sequences.  
To facilitate comparisons with previous research on koala C. pecorum infections, a 
similar genotyping approach was adopted where nucleotide dissimilarity > 1% 
(based on multiple sequence alignments of all koala  strains for each gene) results in 
a new genotype [7, 8, 46] 
Recombination 
Recombination Detection Program (RDP) was used to test aligned sequences for 
recombination.  This package utilises six published methods found to be sensitive for 
the identification of recombination and to yield the fewest false-positive findings 
[19].  These six methods are: RDP [47], GENECONV [48], Bootscan [49], MaxChi 
[50], Chimaera [51], and SiScan [52].  Different tests are applied to aligned 
sequences by each method to detect potentially recombinant regions [19].  The null 
hypothesis is clonality, i.e., that the pattern of sequence variation among the aligned 
sequences shows no indication of recombination [19].  Recombination was deemed 
to occur in a locus if clonality was rejected by three or more tests at a significance 
level of P < 0.001 [19]. 
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GenBank accession numbers of novel sequences 
All novel C. pecorum sequences characterised in this study were submitted to 
GenBank and are available according to accession numbers HQ457440 to 
HQ457545. 
8.4 RESULTS 
PCR amplification and sequence analysis of 10 candidate molecular markers from 
the koala C. pecorum type strain (MC/MarsBar) 
Successful PCR amplification of each of the 10 gene loci was achieved using the 
primers and conditions outlined in Table 2.  Analysis of the gene sequences for the 
selected targets is summarised in Table 3.  The ompA, incA, copN, and ORF663 
gene sequences were analysed in conjunction with previously published C. pecorum 
data (Table 1), while the 16S rRNA, 16S/23S intergenic spacer, omcB, pmpD, tarP, 
and MACPF genes were compared with the E58 reference strain as no other data is 
currently available for these genes.   
In total, 16244 bp of data was analysed which represents 1.62% of the complete C. 
pecorum genome.   The two housekeeping and non-coding genes, 16S rRNA and 
16S/23S intergenic spacer, were sampled to provide a counterpoint to the coding 
sequence data and represent genes under stabilising selection.  Across a total of 3548 
bp of data from these two genes, only two SNPs were observed (0.13%).   
Analysis of ompA revealed a significantly higher level of polymorphisms (122), 
which equated to 10.43% of the 1170 bp gene and a mean diversity of 0.162.  Both 
incA and ORF663, while possessing fewer individual polymorphisms than ompA 
(116 and 66 respectively), exhibited a higher percentage of nucleotide diversity at 
11.79% and 11.96% respectively. This equated to a mean diversity of 0.656 for incA 
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and 0.741 for ORF663.  Together ompA, incA, and ORF663 were the most divergent 
genes out the 10 investigated. The remaining candidates were significantly more 
conserved with a five-fold reduction in nucleotide diversity.  TarP exhibited 56 
individual polymorphic sites out of 2604 bp (2.15%) for an average diversity score of 
0.029, while MACPF was the most conserved of the coding genes investigated with 
only seven polymorphic sites (0.30%), resulting in a mean diversity of 0.003. 
Within ompA, there were 72 mutations leading to a change in amino acid (non-
synonymous mutations), representing 59.02% of the total nucleotide diversity for this 
locus.  The dN/dS ratio for ompA was therefore 0.17, which correlates with the D-
value of 1.73 indicating ompA’s considerable deviation from neutrality and tendency 
for negative selection.  Interestingly, out of all eight coding genes investigated, 
ompA maintained the lowest percentage of non-synonymous mutations and therefore 
the lowest dN/dS ratio.  The omcB gene represented the opposite end of the scale 
with 87.5% of mutations leading to an amino acid replacement with a dN/dS ratio of 
2.15. 
The number of parsimony-informative sites and the discrimination index (D.I.) were 
calculated to enable each locus to be graded according to their discriminatory 
capacity, however, it is important to note that the estimates for both tests remain 
limited due to the mutual requirement for more than two sequences for analysis.  
Nevertheless, ompA had the most parsimony-informative sites (111 sites), 
approximately twice as many as incA (59 sites).  These results were slightly altered 
when considering the D.I. values as both incA and ORF663 scored the highest (both 
0.98), while ompA remained at 0.91 and copN at 0.88. 
The ompA, incA, tarP, and ORF663 genes are potentially useful intra-species 
molecular markers of koala C. pecorum infections 
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Based on the defined criteria for selecting fine-detailed molecular markers (see 
Materials and Methods), the omcB, pmpD, MACPF, and copN genes had insufficient 
mean diversity and were not selected for further analysis.  Conversely, the ompA, 
tarP, incA, and ORF663 genes were able to satisfy this criterion and in addition, 
represent loci under diverse selection processes.  Three of these four genes also 
offered useful D.I. values, while the unavailability of additional sequence data for 
tarP prevented its calculation.  Nevertheless, tarP’s adequate mean diversity and 
tendency for negative selection provided an important counterpoint to the highly 
divergent, positively-selected incA and ORF663 genes. 
Phylogenetic analysis of the ompA, incA, tarP, and ORF663 genes from clinical 
samples. 
The phylogenetic analysis of our four targeted genes was prefaced with an evaluation 
of the mean genetic diversity for each locus based solely on the koala populations, in 
comparison with the data generated for non-koala hosts (Table 3).  We observed a 
decreased level of mean diversity for ompA (p = 0.096), ORF663 (p = 0.065), and 
incA (p = 0.016), which is anticipated given the expected contrast between the 
genetic variation present in our koala populations and the global samples of C. 
pecorum from multiple animal hosts.  Interestingly, the tarP gene produced a 
comparable figure of p = 0.028.  These results are significant from a global C. 
pecorum genetic diversity perspective, but this remains outside the scope of this 
study.  However in the context of this study, this data importantly demonstrated that 
the incA value of p = 0.016 for the koala populations is below the p = 0.02 threshold 
required for intra-species differentiation.   
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Examination of the resulting phylogenetic trees revealed a level of resolution that 
was consistent with the corresponding gene’s mean nucleotide diversity within the 
koala strains (Figure 1).  Between each of the four trees there remained a consistent 
dissimilarity of branching orders, each with varying degrees of bootstrap support.  
Overall, there was a tendency for ompA and ORF663 to separate the Narangba and 
Brendale populations from the East Coomera and Pine Creek populations, while the 
tarP phylogenetic tree provided the most robust evidence for this distinction (Figure 
1). The incA tree revealed less resolution between C. pecorum positive samples, 
correlating with its low level of mean sequence diversity and discriminatory power 
(Table 3). 
To create a more comprehensive data set to permit more robust phylogenetic 
inferences, sequences for each of the four genes were concatenated and used in the 
construction of an additional phylogenetic tree (Figure 2).  This tree produced largely 
similar groupings to those described above with the separation of the Narangba and 
Brendale populations from the Pine Creek and East Coomera populations, as well as 
the isolation of the more divergent C. pecorum positive samples from their respective 
populations.  To test whether the phylogeny resulting from the concatenated 
sequence was biased by a single locus, a subset of trees was built using the 
concatenated data with each region omitted. This resulted in no perturbation of the 
tree topology (data not shown). 
In addition, a phylogenetic analysis was performed to examine the relationship 
between the koala C. pecorum samples analysed in this study, and other previously 
sequenced strains from non-koala hosts (Table 1).  Initially a tree was constructed 
using only ompA data (Figure 3) which clearly shows the koala C. pecorum 
sequences grouping with sheep and/or cattle strains rather than with each other.  
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Subsequently, the sequence data for ompA, incA, and ORF663 were concatenated 
and a single phylogenetic tree constructed.  While there was no visible relationship 
between geography or body site of infection, there was a clear separation between 
the koala and non-koala strains (Figure 4).  As ancestral relationships are not being 
inferred between the koala and non-koala hosts, unrooted phylogenetic trees were 
used to illustrate this data. 
Genotypic analysis of the ompA, incA, tarP, and ORF663 genes. 
To highlight the discriminatory power of ompA, incA, tarP, and ORF663, C. 
pecorum-specific genotypes were established based on their level of nucleotide 
dissimilarity and aligned with the phylogenetic gene trees outlined above (Figure 1).  
The ompA gene was able to separate the koala samples into four genotypes, the incA 
gene produced three genotypes, the tarP gene separated the clinical samples into two 
genotypes, while ORF663 was able to discriminate between seven distinct 
genotypes. 
Recombination 
Each of the four shortlisted genes (ompA, incA, ORF663, tarP) was tested for 
evidence of recombination by the RDP.  All sequences were found to deviate from 
clonality by all six recombination tests (P < 0.001), which is consistent with previous 
reports regarding ompA and ORF663 [19, 53]. 
8.5 DISCUSSION 
The current study revealed three novel and significant characteristics of the evolution 
and genetic diversity of C. pecorum infections in the koala: (1) the ompA gene has a 
phylogenetic history that is congruent with other gene targets in the C. pecorum 
genome, yet is phylogenetically-insufficient for use as a single gene marker; (2) the 
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tarP and ORF663 genes are potentially useful in representing C. pecorum genomic 
diversity and evolution, and (3) koala C. pecorum infections appear to be 
monophyletic, possibly suggesting a limited number of cross-host transmission 
events between koalas and non-koala hosts. 
The ompA gene is one of the most polymorphic genes across all Chlamydia species 
[23] and as a result, was previously selected as the molecular marker of choice in 
epidemiological and genotyping studies of C. pecorum infections of the koala.  This 
increased nucleotide diversity is reported to be due to the antigenicity of MOMP and 
the selective pressure of the host’s immune response [54].  Early C. trachomatis 
studies and more recent C. pecorum studies suggested that the phylogenetic 
categorisation of the ompA gene is not concordant with pathobiotypes, tissue 
tropisms, or the evolution of the genome as a whole [7, 11, 18, 20, 21] . Based on 
these findings, the use of ompA gene as a molecular marker of koala C. pecorum 
genetic diversity also required re-evaluation.   
Assumptions on the validity of ompA as a genetic marker for koala C. pecorum 
strains must be preceded by an appreciation of the  koala C. pecorum phylogeny.  
Without in-depth MLST studies to determine the true C. pecorum phylogeny, this 
study applies our four genes of interest: ompA, incA, ORF663 and tarP, to a multi-
locus approach to phylogeny in an effort to recreate the most accurate phylogenetic 
signal (Figure 2) using single gene targets.  Some level of phylogenetic discordance 
is expected between these genes given their diverse metabolic function, 
chromosomal location, possibility for evolutionary rate heterogeneity and the 
susceptibility of all four genes to recombination events.  However, this multi-locus 
method utilises a “majority rule” approach by allowing the amplification of 
congruous phylogenetic information while reducing the effects of phylogenetic 
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“noise”.  In addition, the equalisation of outer branch lengths serves to resolve minor 
phylogenetic inconsistencies.  Together, this results in a more accurate phylogeny 
than that inferred from a single gene [55, 56].  There was no perturbation of the tree 
topology when each gene was sequentially omitted from analysis, alleviating 
concerns that individual genes may dominate and sweep the phylogenetic signal.  It 
is expected that the systematic addition of further gene data will continue to produce 
a more refined and resolute phylogeny, however we suggest that the phylogenetic 
tree using concatenated sequences of ompA, incA, ORF663, and tarP provides a 
preliminary and useful indication of the true phylogenetic relationship between these 
koala C. pecorum samples and a prelude to future MLST and phylogenetic studies. 
The phylogenetic tree generated from concatenated data clearly defines two distinct 
lineages between the four populations investigated: (1) the Pine Creek and East 
Coomera populations (separated by ~500 kms), and (2) the Narangba and Brendale 
populations (separated by ~5 kms), while each lineage is further subdivided into two 
clades, each representing an individual population.  From an evolutionary standpoint, 
this phylogenetic reconstruction appears valid.  For example, it is clear that the 
Brendale and Narangba populations remain geographically (and genetically) similar, 
as do the East Coomera and Pine Creek populations, albeit to a lesser degree. The 
genetic diversity and uniqueness of geographically isolated C. pecorum strains is 
presumably the result of disturbances to koala population distribution and structure 
from land clearing and urban pressure over the last 200 years of European settlement, 
leading to the formation of isolated koala colonies in which C. pecorum strains 
continue to undergo local selection and adaptation. The question that remains is how 
effective are the four shortlisted genes in abbreviating this vast phylogenetic 
information for epidemiological study? 
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Beginning with ompA, previous C. pecorum studies suggest that this gene is 
reflective of the overall evolution of the C. pecorum genome [7, 23], however these 
studies are based on broad comparisons between chlamydial species and do not 
represent evolutionary lineages on an intra-species level.  Alternatively, intra-species 
C. trachomatis studies have indicated that the ompA locus differs from other regions 
of its genome [19].  The results of the present study illustrate a tendency for the 
phylogenetic topology of the ompA gene to separate the Narangba/Brendale 
populations from the Pine Creek/East Coomera populations while other, more 
divergent strains do not cluster according to their respective population.  This data 
would appear to correlate with ith previous C. pecorum fine-detailed epidemiological 
studies where it was concluded, using the ompA gene, that an association between 
the site of koala capture and the genotype of its resident C. pecorum strain usually 
exists, while some genotypes were distributed widely into different geographic areas 
[7].  The phylogenetic divisions offered by the tree using concatenated sequences, 
however, clearly show that regions of the ompA gene are actively contributing to a 
misinterpretation of the “true” phylogenetic signal.  This observation supports 
previous conclusions that ompA is ineffective as a genome-representative marker.  It 
is therefore suggested that while the ompA gene continues to be a useful fine-detailed 
comparative marker, it remains suboptimal for any phylogenetic, evolutionary and/or 
biogeographic analysis.  Both the tarP and ORF663 genes, conversely, are appealing 
alternatives to ompA. 
The tarP gene encodes the translocated actin-recruiting phosphoprotein [57] which 
has important virulent functions involved in the attachment of the chlamydial 
elementary body to the host cell [28]. The  tarP gene’s tendency for negative 
selection and relatively low mean nucleotide diversity reinforces its important 
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biological role in the chlamydial cell and typifies a gene that changes slowly enough 
to make it useful as an evolutionary chronometer [41].  Recent C. trachomatis studies 
have suggested that the full-length tarP gene, based on the inverse relationship 
between the number of tyrosine repeats and the number of actin-binding domains, 
can be correlated with clinical phenotype [58], highlighting its potential as a useful 
genetic marker.  
The koala C. pecorum tarP gene phylogenetic tree produced two distinct clades 
which, interestingly, revealed a clear separation between the Brendale and Narangba 
isolates and the Pine Creek and East Coomera isolates. Initially, there appeared to be 
no distinction between ocular and urogenital sites of infection, however upon further 
inspection, it was clear that (with the exception of Nar/Dion (Left Eye)), all the 
ocular isolates remained confined to one phylogenetic clade (among seven urogenital 
isolates) which are distinct from the remaining urogenital isolates. Importantly, this 
ocular “outlier” (Nar/Dion (Left Eye)) retains 100% nucleotide similarity with the 
remaining isolates within the Narangba population, all of which were isolated from 
urogenital sites of infection.  Coupled with the fact that isolate ‘Ned’ from the East 
Coomera population harbours genetically distinct ocular and urogenital isolates of C. 
pecorum, this suggests that high rates of transmission within these confined koala 
populations may contribute to the transfer of C. pecorum from one body site to 
another and that the site of detection may not be the original niche of the strain [58].  
It appears that the tarP gene has potential as a phenotypic-dependent marker, 
however, importantly, further investigation is required that utilises the full-length 
tarP gene (in conjunction with wider geographic sampling) to properly determine its 
true potential. 
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From a full genome evolutionary standpoint, the separation of the 
Brendale/Narangba populations from the Pine Creek/East Coomera populations is a 
distinction that is clearly mirrored in the overall phylogenetic analysis using 
concatenated data.  This suggests that tarP, although having a relatively low rate of 
substitution, is capable of more accurately and specifically differentiating koala 
strains according to geography than ompA and ORF663, albeit with reduced 
resolution.  For these reasons, tarP also appears promising as an evolutionary 
indicator and may be classified as a “neutral marker”, characterised by its selective 
constraints yet ability to reflect sequence diversity between koala populations that are 
geographically separate [59].  However, as a “neutral marker”, the tarP gene remains 
less useful when estimating a population’s adaptive potential or local population 
divergence.  
ORF663 encodes a hypothetical protein and includes a 15 nucleotide variant coding 
tandem repeat (CTR) region that putatively associates it with a virulence-related role.  
Interestingly, this gene has not been identified in any other chlamydial species and 
BLAST search reveals no similarities to any other sequences in the database.  The C. 
pecorum ORF663 gene was the most polymorphic gene among all investigated and 
represents a locus under considerable positive selection.  Using this gene, we were 
able to observe the most distinctions between strains by identifying seven separate 
genotypes.  These genotypes highlight the considerable discriminatory capacity of 
ORF663 which correlates with (while extending) the divisions made by ompA and 
tarP, by isolating the Narangba and Brendale populations into their own genotypes 
while separating the more heterogeneous Pine Creek and East Coomera populations 
into multiple genotypes. Where the tarP gene represents a neutral marker that 
assumes isolates within a population are equally related to each other, ORF663 can 
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be considered a “divergence-based” or “contingency” marker that is capable of 
characterising diversity both within and between populations for fine-detailed 
epidemiological study. 
The value of the marker genes identified in this study was extended to consider the 
genetic diversity between C. pecorum infections in koalas and non-koala hosts.  
Previous research has suggested that, supported by ompA VD3/4 sequence data, C. 
pecorum is a polyphyletic organism in Australian koala populations.  This hypothesis 
originated from the similarity of one or two koala ompA genotypes to European 
bovine isolates of C. pecorum [7, 11] and based on this data, a model was proposed 
whereby koalas obtained C. pecorum infections as a result of a series of cross-species 
transmission events from sheep and/or cattle [7, 8, 11, 60].  While similar results 
were obtained using ompA data in this study (Figure 3), the phylogenetic analysis 
has already suggested in inadequacy of the ompA gene alone in representing C. 
pecorum’s true evolutionary course within koala populations.  Indeed, both this and 
previous studies utilised a 465 bp fragment of the ompA locus (VD 3/4) which, while 
containing the majority of ompA’s nucleotide variation, would remain largely 
insufficient to describe the extensive genetic diversity that has accumulated in global 
isolates of C. pecorum. 
Consequently, we prepared an unrooted phylogenetic tree from the concatenation of 
incA, ompA, and ORF663 sequences, revealing a surprising alternative picture that 
clearly distinguishes koala C. pecorum strains from non-koala hosts (Figure 4). This 
distinction is further supported by the noticeable difference in branch lengths 
between koala C. pecorum sequences and non-koala hosts, suggesting that as a 
whole, koala strains are much more closely related to each other than to other non-
koala host strains. This result is significant as it may be an example of  an alternate 
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evolutionary model in which koalas obtained C. pecorum as a result of a limited 
number of cross-host transmission events in the past and have subsequently evolved 
along an evolutionary trajectory that is distinct from that seen in sheep and cattle 
isolates.  This result also reinforces the benefit and efficacy of applying more 
phylogenetically-robust data (the concatenation of three congruent genes) to the 
epidemiological study of C. pecorum infections, both in koala and non-koala hosts.  
It must be noted however, that this remains a cautionary finding.  Without ompA, 
incA, and ORF663 nucleotide sequences from Australian sheep and cattle isolates it 
remains impossible to truly establish a compelling cross-host transmission hypothesis 
for koala isolates.  Nevertheless, this data cannot be completely discounted and 
functions as preliminary insight into the genetic diversity of koala isolates of C. 
pecorum. 
8.6 CONCLUSIONS 
The findings of this study have highlighted the opportunities and drawbacks of 
estimating phylogenetic relationships from multiple independent datasets [61].  A 
concatenation approach to phylogenetic inference appears promising, however a true 
evolutionary reconstruction of the C. pecorum lineage may require a rigorous MLST 
approach that incorporates genetic data from several more independent loci and 
extensive geographic sampling. 
It is clear that the ompA gene is distorted by technical and biological interference 
rendering it incapable of representing true phylogenetic divisions as a molecular 
marker, yet it remains useful as a fine-detailed, cost-effective, comparative marker 
for fine-detailed epidemiological investigation of large numbers of koala C. pecorum 
positive samples. Alternatively, the tarP gene’s ability as a “neutral marker” to 
provide a “bird’s-eye-view” on higher levels of evolutionary divergence between 
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koala populations and ORF663’s opportunities as a contingency marker are 
promising for future phylogenetic studies in the koala.   
While three out of our four shortlisted genes (including ompA) proved to be effective 
gene markers, incA was ultimately deemed to be the least effective and was 
discarded from further analysis.  However, the significant discrepancy noted between 
the mean diversity of incA from koala and non-koala hosts (as well as ORF663) 
invites intriguing questions regarding the genetic diversity of C. pecorum beyond the 
koala host which, while outside the scope of this study, will be important in 
subsequent research in this area. 
Although this study focussed on a mere 10 genes in the C. pecorum genome, it 
successfully challenged ompA as a molecular marker and provided an important 
opportunity to review previous knowledge on the genetic diversity of C. pecorum in 
Australian koala populations. The availability of the complete E58 C. pecorum 
genome sequence and, eventually, a koala C. pecorum genome, will facilitate the 
characterisation of additional genes and promote further analyses of genomic 
variation to support comprehensive surveys of lineage prevalence within and 
between koala populations.  Until then, the data described here provides a solid 
foundation for this subsequent research by highlighting a robust measurement tool 
for koala C. pecorum infections and presents a compelling depiction of their 
phylogenetic relationships. This application will have importance for our ability to 
successfully map, control and manage diseased populations of this dwindling native 
icon.  
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8.9 FIGURES 
 
Figure 1.  Mid-point rooted phylogenetic trees based on each of the four 
candidate genes.  Inferred by the neighbour-joining method with bootstrapping 
support (1000 replicates).  a) ompA; b) incA; c) tarP; d) ORF663. 
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Figure 2.  Phylogenetic tree from concatenated sequences of ompA, incA, ORF663, 
and tarP from all koala populations.  Mid-point rooted and inferred by the 
neighbour-joining method with bootstrapping support (1000 replicates). 
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Figure 3.  Phylogenetic tree of ompA sequences from koala C. pecorum isolates, 
with previously published sequence information.  Unrooted; inferred by the 
neighbour-joining method with bootstrapping support (1000 replicates). 
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Figure 4.  Phylogenetic tree of the koala C. pecorum isolates sequenced, with 
previously published sequence information.  Unrooted; constructed using 
concatenated sequences of ompA, incA, and ORF663 using the neighbour-joining 
method with bootstrapping support (1000 replicates). 
 Chapter 8: APPENDIX 267 
8.10 TABLES 
Table 1.  Chlamydial sequences analysed in this study 
  
Species Strain Origin Host Pathology 
Sequence 
reference 
C. abortus S26/3 Scotland Sheep Abortion [62] 
C. caviae GPIC USA Guinea Pig Conjunctivitis [63] 
C. felis Fe/C-56 Japan Cat Pneumonia [64] 
C. 
muridarum Nigg USA Mouse Pneumonia 
[65] 
C. pecorum 824 Scotland Sheep Conjunctivitis [21] 
C. pecorum AB10 France Sheep Abortion [21] 
C. pecorum AKT Tunis Sheep Abortion [21] 
C. pecorum BE53 England Cattle Encephalymylitis [21] 
C. pecorum E58 USA Cattle Encephalomylitis [21] 
C. pecorum iB1 France Sheep Healthy (faeces) [21] 
C. pecorum iB2 France Sheep Healthy (faeces) [21] 
C. pecorum iB3 France Sheep Healthy (faeces) [21] 
C. pecorum iB4 France Sheep Healthy (faeces) [21] 
C. pecorum iB5 France Sheep Healthy (faeces) [21] 
C. pecorum iC2 France Goat Healthy (faeces) [21] 
C. pecorum iC3 France Goat Healthy (faeces) [21] 
C. pecorum iC4 France Goat Healthy (faeces) [21] 
C. pecorum LW679 USA Sheep Arthritis [21] 
C. pecorum M14 Morocco Goat Abortion [21] 
C. pecorum MC/MarsBar Australia Koala Genital tract infection (this work) 
C. pecorum R69 Ireland Sheep Healthy (faeces) [21] 
C. pecorum SBE England Cattle Encephalomylitis [21] 
C. pecorum VB2 France Sheep Orchitis  [21] 
C. pecorum W73 Ireland Sheep Healthy (faeces) [21] 
C. 
pneumoniae CWL029 USA Human Pneumonia [62] 
C. 
trachomatis A/HAR-13 Saudi Arabia Human Conjunctivitis [63] 
C. 
trachomatis B/Jali20/OT The Gambia Human Conjunctivitis [62] 
C. 
trachomatis B/TZ1A828/OT Tanzania Human Conjunctivitis [64] 
C. 
trachomatis D/UW-3/CX USA Human Genital tract infection [65] 
C. 
trachomatis L2/434/Bu USA Human Bubo [66] 
C. 
trachomatis L2b/UCH-1/proctitis England Human Proctitis [66] 
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Gene Annotation Primer Sequence (5’ – 3’) Ta Size 
Housekeeping Genes   
16S 
rRNA 
16S ribosomal 
subunit  16S-For CTGAGAATTTGATCTTGG 52°C 
1549 
bp 
   16S-Rev AAAGGAGGTGATCCAGC   
16S/23S  
16S-23S 
intergenic 
spacer 
 Spacer-For AAGGATAAGGAAAGCTATCA 54°C 225 bp 
intergen
ic 
spacer 
  Spacer-Rev AATTTTTGATCCATGCAAGA   
Membrane Proteins   
ompA 
Outer 
membrane 
protein A 
1 ompA-For ATGAAAAAACTCTTAAAATCGG 56°C 
1170 
bp 
   ompA-Rev TTAGAATCTGCATTGAGCAG   
  2 MJFvd3a GGITG(CT)GCAACTTTAGGIGC 50°C 457 bp 
   MJRvd4a CACAAGCTTTTCTGGACTTC   
  3 CpeNTVD3
b GTTCTTTCTAACGTAGC 46°C 359 bp 
  CpeNTVD4b TGAAGAGAAACAATTTG   
omcB Cysteine-rich outer  omcB-For ATGACCAAACTCATCAGAC 54°C 
1675 
bp 
 membrane protein B  omcB-Rev TTAATACACGTGGGTGTTTT   
pmpD Polymorphic membrane  pmpD-For ATGATCAGTCATATACGGAC 56°C 
4145 
bp 
 protein D  pmpD-Rev TTAGAAAATCACGCGTACG   
incA Inclusion membrane   incA-S-F
c TATCGTAATACCAAACCACT 52°C 984 bp 
 protein A  incA-S-Rc GTGTGAGATGGCTCTTTATG   
copN Chlamydia outer protein N  copN-For ATGGCAGCTGGAGGGAC 56°C 
1191 
bp 
   copN-Rev TTATGACCAGGGATAAGGTT   
Potential Virulence Genes   
tarP Translocated actin- 1 tarP-For ATGACCTCTCCTATTAATGG 56°C 
2604 
bp 
 
recruiting 
phosphoprotei
n 
 tarP-Rev CTAGTTAAAATTATCTAAGGTTT   
  2 tarP-2-For AAGAACCAACTCTGCATTATGAAGAGG 54°C 768 bp 
   tarP-2-Rev AAGAGGTATTCACGCGACTTCCG   
MACPF Membrane-attack   MAC-For TTGGCGATTCCTTTTGAAGC 58°C 
2346 
bp 
 complex/perforin protein  MAC-Rev TTATAAGCACACACTAGGTCT   
ORF663 Hypothetical protein  663-F
c AAACAACTGCACCGCTCTCT 55°C 1167 bp 
   663-Rc GAAGGACTTTCTGGGGGAAG   
Table 2.  Genomic region, primers, and melting temperatures for all genes investigated.   
1primers used for initial sequencing of full-length gene from MC/MarsBar/UGT type strain; 2/3 
primers used for second-stage sequencing from koala populations for further analysis; aprimers 
designed by [7]; bprimers designed by [10]; cprimers designed by [26]. 
